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SUMMARY  
 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease in which 
low levels of survival of motor neuron (SMN) protein lead to the degeneration of alpha 
motor neurons (MNs) in the spinal cord. The pathological mechanism of SMA is highly 
controversial and until recently it was not possible to obtain human MNs to study the 
disease. The development of induced pluripotent stem cell (iPSC) technology has made it 
possible to bypass this obstacle and iPSC-based models of SMA type I have already been 
validated by two separate groups. Encouraged by these pioneering findings I have produced 
and characterized iPSCs from several members of a discordant consanguineous family in 
which four haploidentical siblings share the same homozygous SMN1 mutation, but 
nonetheless show different phenotypes of the disease. I have differentiated iPSC clones 
from three of the siblings and the carrier unaffected mother, as well as a control unaffected 
clone and a clone derived from a patient with SMA type I, into ISL1+/ChAT+ MNs. No 
obvious phenotypic difference was observed between the MN cultures of the siblings 
during the period of study, but cells from the SMA type I patient did show an impaired 
ability to form rosettes. The study of SMN and PLS3 levels during the differentiation from 
iPSCs to ChAT+ MNs showed a gradual decay of these proteins during MN development 
in all clones. Furthermore, SMN protein levels did not correlate with the pattern of mRNA 
expression, suggesting the existence of post-transcriptional and/or post-translational 
regulation of full-length SMN (FL-SMN) transcripts and protein. The FL/Δ7-SMN mRNA 
ratio and total SMN (tSMN) mRNA levels were found to be possible biomarkers to 
distinguish unaffected individuals from SMA patients and the severity of SMA pathology, 
respectively. PLS3 protein level was higher in the SMA type IV/asymptomatic sibling than 
in two of the type III SMA siblings, but it could not be confirmed as a modifier factor in the 
family. These results suggest that SMN levels are regulated during MN development, and 
that low levels may impair the generation of rosettes but not necessarily of MNs. SMN 
levels in MNs only show minor differences between patients, suggesting that there may be 
a threshold after which reduced levels of SMN within a narrow range become suddenly and 
increasingly detrimental unless modifier factors can compensate for the cellular function(s) 
lost. 
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 SPINAL MUSCULAR ATROPHY  
1.1.1 SMA PATHOLOGY AND MOLECULAR BASIS 
Spinal muscular atrophy (SMA) is an autosomal, recessive, neurodegenerative disease that 
affects the functionality and survival of lower alpha motor neurons (MNs), resulting in 
atrophy of skeletal muscles and generalized weakness (Figure 1.1). MN cell loss leads to 
weakness of proximal muscles responsible for crawling, walking, head/neck control, 
swallowing as well as the involuntary muscles that control breathing and coughing 
(Buchthal & Olsen 1970; Emery et al. 1976; Passini et al. 2010). MNs are borne in specific 
areas of the central nervous system (CNS): in the brain cortex (upper MNs), the brain stem, 
and in the spinal cord (lower MNs) (Nizzardo et al. 2010). Only the functionality and 
survival of lower alpha MNs is affected in the SMA pathology. SMA is one of the most 
common genetic cause of infant mortality, affecting approximately 1/10,000 births, with a 
carrier frequency of approximately 1/50 (Pearn 1980).  
 
 
Figure 1.1: Histopathology of SMA. 
SMA patients show absence of motor neurons in the spinal 
cord (B2) and hypertrophic and atrophic fibres in the 
skeletal muscle (B4). Sections from healthy unaffected 
patients are shown for comparison (B1 and B3). Taken and 
modified from (Lunn & Wang 2008). 
 
 
SMA was first mapped to chromosome 5 
(specifically 5q13) in 1990 (Brzustowicz et al. 
1990). Nevertheless, given that the SMA locus is 
located in a very unstable region susceptible to intra-chromosomal rearrangements, it was 
not until 1995 that the exact disease causing-gene was identified: Survival motor neuron 1 
(SMN1) (Lefebvre et al. 1995). SMN is present in multiple copies in the human genome: 
one SMN1 (telomeric copy) and several SMN2 (centromeric copies).  The genes differ only 
by five nucleotides and only one of them is in a coding region, on exon 7. Even though the 
later nucleotide change does not alter the amino acid sequence, the transition (C to T) is 
responsible for the alternatively spliced isoform with no exon seven in SMN2. Indeed, the 
transition is localized in an exonic splicing enhancer and the substitution blocks the binding 
of the U2 class of small nuclear ribonuclear protein (U2 snRNP) (Cartegni & Krainer 
2002). This short version of the protein (Δ7-SMN) is thought to be non functional and 
rapidly degraded (Lorson & Androphy 2000). However, about 10% of the SMN2 pre-
??? ???
??? ???
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mRNA is properly spliced and produces functional SMN, which is indiscernible from the 
one produced from the SMN1 gene (Lefebvre et al. 1995) (Figure 1.2). 
 
Figure 1.2: SMN genes in human chromosome 5.  
There are two SMN genes in the human genome. SMN1 produces mainly FL-SMN, but SMN2 only produces 
10% of the full length protein due to the presence of a C-to T mutation that causes exon 7 skipping. Taken 
from (Sendtner 2010). 
 
The molecular cause of SMA is the homozygous disruption of the SMN1 gene by several 
possible mechanisms (Lefebvre et al. 1995; Lunn & Wang 2008). Over 95% of 5q-linked 
SMA patients have homozygous deletions for the whole SMN1 gene or have gene 
conversion at exons 7 or 8, whereas the remaining subjects have missense, nonsense or 
splice site mutations (Alias et al. 2009). The severity of the disease is associated with the 
amount of total SMN protein available and is clinically divided in 4 types mainly grouped 
by the age of onset and highest motor function achieved (Munsat 1992; Russman 2007). In 
SMA type I (Werdnig-Hoffman disease), the onset of the disease occurs before the 6 
months of age and patients usually die within the first two years of life. SMA type I 
children present profound and severe hypotonia which prevents them from controlling the 
movements of the head and generates problems for breathing, swallowing and sucking, as 
well as a impaired airway protection (which makes them more prompt to infections). In 
SMA type II patients the onset of the disease is between 6-18 months of age and patients 
usually die within 10-40 years. SMA2 patients can sit but not stand or walk independently. 
They also present respiratory insufficiency and weak swallowing. In SMA type III the onset 
of the disease is after the 18 months of life, but the phenotype is very heterogeneous: some 
patients walk, some are in wheelchairs and some develop an abnormal shape of the column 
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(scoliosis). The respiratory function in these patients is not compromised. Finally in SMA 
type IV, the onset of SMA is during the second or third decade of life and patients only 
present mild motor impairment (Munsat 1992; Russman 2007). 
1.1.2 SMA PROTEIN AND INTERACTIONS WITHIN THE CELLULAR CONTEXT 
The full length SMN (FL-SMN) has nine exons (eight of which are coding exons), and it 
encodes a protein of 38 KDa with 294 aminoacids. The protein is present in the cytoplasm 
and nucleus of all somatic tissues with particular high amount in the MNs of the spinal cord 
(Lefebvre et al. 1997). In the nucleus of the cell, SMN associates with gemins proteins 
(through direct interaction with gemin2, gemin3, gemin5, gemin7 and gemin8, and 
indirectly with gemin4 and gemin6) and forms nuclear bodies termed gems which are very 
similar and often found associated with Cajal bodies, another nuclear structure (Liu & 
Dreyfuss 1996; Carissimi et al. 2006a; Carissimi et al. 2006b). Gemin-SMA associations 
are also found in granules located in growth cones and neural processes of MNs (Fallini et 
al. 2010; Fallini et al. 2011).  
SMA is a multifunctional protein that has been implicated in a variety of cellular processes, 
mostly involved in RNA metabolism. The first and most described function of SMN is its 
ubiquitous role in the splisosome machinery of cells (Meister et al. 2002). SMN together 
with gemins2-8 and unrip proteins forms a macromolecular complex (SMN complex) that 
functions in the assembly of small nuclear ribonucleoproteins (snRNPs) of both the major 
and the minor splicing pathways through their interaction with Sm proteins (Pellizzoni 
2007).  snRNPs are the principal components of spliceosomes, the system in charge of the 
proper splicing of the pre-mRNAs (Otter et al. 2007).  There are two splicesomes in the 
eukaryotic cells, a major one that processes most of the introns in pre-mRNAs and a minor 
one that processes a small fraction (Brow 2002). SMN complex seems to be particularly 
necessary for a subset of snRNPs and the lack of SMN preferentially affects the 
accumulation of U11 snRNP—a component of the minor spliceosome—in tissues of severe 
SMA mice (Gabanella et al. 2007). 
The assembly of the snRNPs takes place in the cytoplasm, where Sm proteins (which 
interact with the SMN complex) combine with snRNAs that are exported from the nucleus. 
The assembled snRNPs are further modified and then translocated back to the nucleus 
where they function in pre mRNA splicing (Figure 1.3) (Chari et al. 2009) . The specific 
role of SMN, along with gemin 2-6 and unrip (SMN complex) is to recruit Sm proteins and 
small nuclear ribonucleic acids (snRNAs) and mediate the formation of the Sm core 
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domain. All this process occurs in the cytoplasm, before the import of the assembled 
snRNPs into the nucleus (Figure 1.4) (Chari et al. 2009).  
 
Figure 1.3: snRNPs Biogenesis and pre-mRNA splicing.  
Within the nucleus, mRNA is transcribed (A1) and spliced (A2) before it is further exported into the 
cytoplasm (A3) where it is translated into protein (A4). Meanwhile, snRNA is also transcribed (B1) and 
exported to the cytoplasm (B2) where it assembles with the Sm proteins to form the snRNP (B3). The 
complex is then hypermethylated (B4) and imported back into the nucleus (B5) where other proteins are 
added to the snRNP before its incorporation in the spliceosome (B6). SMN complex specifically modulates 
the step B3. Taken from (Chari et al. 2009). 
 
 
 
 
Figure 1.4: SMN role in the snRNPs assembly.  
The assembly chaperone pICln binds the Sm proteins D1-D2 (1), D3-B (2), and E-F-G (3). These proteins are 
further transferred to the SMN-complex (4) which then recruits snRNA, catalyses Sm ring closure, and 
releases the assembled RNP (5). Taken from: (Chari et al. 2009). 
 
The influence of the lack of SMN in the mRNA processing has been studied in vitro and in 
tissues of mouse models of SMA. The in vitro study of Dreyfuss’s group (University of 
Pennsylvania, USA) showed that a dominant-negative mutant SMN inhibited pre mRNA 
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splicing (and thus mRNA biogenesis), as opposed to wild type SMN (Pellizzoni et al. 
1998). Furthermore, Pellizoni’s group (Dulbecco Telethon Institute, Italy) found that a 
subset of gemin proteins, as well as the snRNP assembly activity were dramatically reduced 
in the spinal cord of severe SMA mice and that these reductions were proportional to the 
severity of the disease (Gabanella et al. 2007).  Interestingly, this impairment was also 
found in brain and kidney tissues, although the defects were less pronounced in non-neural 
tissue. 
Even though the results seems to point out that the SMA phenotype is strongly correlated 
with the snRNP assembly efficacy, it is not really known if the same is true in vivo and if 
so, if there is indeed a defective processing of specific mRNAs that contributes to the 
preferential vulnerability of MNs to reduced levels of SMN (Rossoll et al. 2003; Gabanella 
et al. 2007). 
It has been hypothesised than SMN might serve additional functions in the axons of MNs 
by forming different complexes as the ones traditionally and consistently studied in the 
cytoplasm for the snRNP assembly (Rossoll et al. 2003). Sendtner’s group (University of 
Wuerzburg, Germany) has shown in MNs of SMA mouse models and in differentiated 
PC12 cells, that SMN associates with heterogeneous nuclear ribonucleoprotein (hnRNP) R 
and promotes the binding of the later to the 3’ untranslated region (UTR) of the β-actin 
mRNA, influencing by an unknown mechanism the localisation of beta-actin in the growth 
cones. β-actin plays a major role in growth cone movement and neurite growth.  
Furthermore, lack of SMN protein or hnRNP causes a significant decrease in neurite length 
of mouse MNs, which is reversed by their exogenous restoration (Rossoll et al. 2003). 
SMN-hnRNP complex might be involved in the axonal transport of the mRNA, its stability 
or its translation. Given the length MNs develop in order to accomplish their function in the 
organism, SMN’s influence in β-actin metabolism could explain the cell specificity of this 
disease. 
Apart from SMN localisation in the nucleus, the cytoplasm and the neural processes, SMN 
has also been localized in the leading edge of neurite outgrowths (growth cones) and in the 
neuromuscular junctions (NMJs) (Broccolini et al. 1999; Fan & Simard 2002). SMN active 
transport through the axon has also been reported (Fallini et al. 2010).  
Supporting the idea that SMN forms other complexes that are not related to the splicing 
machinery, but to the transport of mRNAs along the axon, Bassell’s group (Emory 
University School of Medicine) has demonstrated that SMN interacts with the neuronal-
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specific mRNA-binding protein HuD, a protein that binds to AU-rich elements in the 3’ 
UTR of target mRNAs and controls their stability and translation (Tiruchinapalli et al. 
2008; Fallini et al. 2011). Furthermore, SMN and HuD co-localized in actively transported 
axonal granules and low SMN levels impaired the localisation of HuD and of poly(A)-
positive mRNAs specifically in the axons of primary motor neurons, supporting a role for 
SMN in mRNA trafficking. 
It seems logical to think that impaired mRNA trafficking will affect the more distal parts of 
the cells. In this regard Monani’s group (Columbia University) has demonstrated in mouse 
models of SMA and in human tissues of SMA patients that MNs nerve terminals have pre-
synaptic defects (they appeared thick and swollen with abnormal neurofilament (NF) 
aggregates, poor terminal arborisation, dispersed synaptic vesicles and smaller 
mitochondria) and that these are correlated with post-synaptic defects in the motor end 
plate as well  (persistence of immature plaque-like acetylcholine receptor [AChR] clusters 
and presence of its embryonic γ subunit, which is supposed to switch to the ε subunit in the 
adult) (usaKariya et al. 2008). Indeed, electrophysiological recordings showed synapse 
defects. Surprisingly, there was not an increase of unoccupied endplates as compared to 
wild type mice. Furthermore, all the defects were found only in α-MNs (which terminate in 
NMJs) and not in γ-MNs (which terminate in muscle spindles). NF accumulation in the 
terminal axons of NMJs seems to be a key characteristic of SMA phenotype, but the 
molecular mechanism has not been properly studied yet. It is important to consider that this 
feature could very well be a symptom rather than a cause for MN dysfunction, which could 
also be the case for the absence of β-actin in the growth cones (Cifuentes-Diaz et al. 2002). 
Another observation that have been highlighted in mouse SMA MNs is that there are 
defects in the clustering of Cav2.2 channels in axonal growth cones, which are directly 
associated with a reduced frequency of local Ca2+ transients. Furthermore, stimulation of 
mSmn production from the transgenic SMN2 gene by cyclic adenosine monophosphate 
(cAMP) restores Cav2.2 accumulation and excitability (Jablonka et al. 2007). It is 
reasonable to think that these defects could lead to disturbances of active zones in the 
presynapse, causing reduced transmitter release at the motor endplate. Monani’s group has 
also proposed that reduced levels of calcium in SMA terminals fails to activate calcium 
proteases at the synapse, eventually causing a build-up of NF protein, which would 
consequently aggravate the presynaptic function (usaKariya et al. 2008).  
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If we set the facts in order, we could think that by a splicing/stability/transport defect of the 
β-actin mRNA, as well as other cytoskeletal proteins, the lack of β-actin protein in SMN-
deficient MNs interferes with axonal elongation and voltage-gated calcium channels 
(VGCC) translocalisation to membrane clusters. The alteration in the VGCC could in turn 
cause NF accumulation by improper activation of proteases and impair transmitter release 
from the axon terminals finally affecting the global functionally of NMJs and causing the 
death of MNs.  
Taken together, these results suggest that SMN may indeed fulfil neuronal- and muscle-
specific functions, providing a more plausible mechanism explaining MN degeneration and 
associated denervation atrophy of skeletal muscles in SMA (Fan & Simard 2002).  
1.1.3 KNOWN MODIFIERS OF SMA PHENOTYPE 
As previously mentioned (Section 1.1.1), SMN2 produces ~10% of FL-SMN protein and 
consequently the SMN2 gene copy number determines the final amount of this protein 
when SMN1 is absent or not functional, constituting the most important clinical prognostic 
indicator in SMA patients (Wirth et al. 2006). In accordance to this, Wirth’s group 
(University of Bonn, Germany) quantified the copy number of SMN2 in 375 patients with 
type I, type II, and type III SMA showing a significant correlation between SMN2 copy 
number and type of SMA, as well as duration of survival (Feldkotter et al. 2002). Their 
results show that 80% of patients with SMA type I carry one or two SMN2 copies, 82% of 
patients with type II SMA carry three SMN2 copies and 96% of patients with type III SMA 
carry three or four SMN2 copies.  
The number of SMN2 copies is indeed variable within the population, which is thought to 
be derived from the fact that the gene is part of a 500 kb inverted duplication on 
chromosome 5q13 (involving also SMN1), which is susceptible to rearrangements 
(Lefebvre et al. 1995). SMN gene duplication is thought to have occurred more than 5 
million years ago, but the appearance of SMN2, which so far is unique to Homo sapiens, 
seems to have occurred later during evolution (Rochette et al. 2001). 
Interestingly, the SMN2 copy number-SMA phenotype correlation has been found not to be 
as strong as initially thought, suggesting that there must be other proteins apart from SMN 
involved in the pathology.  Several cases have been published supporting this idea. 
Asymptomatic carriers with bi-allelic deletions of the SMN1 gene have been found within 
families where the rest of the siblings are indeed affected, in many cases with different 
degrees of severity. All the members within each family posses the same copy number of 
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SMN2 and the same haplotype (Cobben et al. 1995; Hahnen et al. 1995; Capon et al. 1996; 
Wang et al. 1996; Bussaglia et al. 1997; Cusco et al. 2003; Cusco et al. 2006; Jedrzejowska 
et al. 2008). It is important to mention however, that a variant of the SMN2 gene has been 
found to produce higher amount of FL-SMN transcripts than the amount expressed by the 
wild type SMN2 gene, showing that not all SMN2 genes are the same (Prior et al. 2009). 
Indeed, it has also been shown that SMN2 alleles are functionally not equivalent due to 
differences in DNA methylation and that the latter correlates with SMA severity, but a 
functional basis has not been found (Hauke et al. 2009). 
Another factor that has been reported as a modifier of the SMA phenotype severity is the 
levels of plastin 3 (PLS3). Wirth’s group (University of Bonn, Germany) found in several 
discordant families of SMA, that the unaffected siblings showed high levels of PLS3 in 
immortalized lymphoblasts, whereas only a small percentage of the affected members and 
healthy individuals expressed it in these particular cells (Figure 1.5). This co-relation was 
only found in females, and not in males (Oprea et al. 2008). It is important to mention 
nevertheless that PLS3 is highly expressed in the human foetal and adult spinal cord, even 
though it is rare in blood cells.  Further studies trying to identify the function of PLS3 
showed that it promoted axonogenesis by increasing F-actin levels. Actin cytoskeleton 
dynamics (G-actin/F-actin(G/F-actin) ratio]  is know to play a major role in axon growth, 
path finding, and branching, three vital processes MN  function and survival (Dent & 
Gertler 2003). Indeed, overexpression of PLS3 rescued the axon length and outgrowth 
defects associated with Smn down-regulation in MNs of SMA mouse and zebrafish 
embryos. Even though PLS3 and Smn co-localized in axons and growth cones, they did not 
interact directly, and PLS3 overexpression alone overcame the SMA phenotype induced by 
the lack of Smn (Figure 1.6) (Oprea et al. 2008).  
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Figure 1.5: PLS3 expression in blood samples and lymphoblats.  
PLS3 expression was measured by qRT-PCR and compared between healthy control individuals, type I-III 
SMA patients and six SMA discordant families. PLS3 expression values were empirically defined as high 
(more than 0.9), low (0.5-0.9) and no expression (less than 0.5). Taken from (Oprea et al. 2008). 
 
 
 
Figure 1.6: Overexpression of PLS3 rescues SMA phenotype. 
 (A) Zebrafish embryos were treated with control morpholinos (MO), smn MO, PLS3 RNA, and smn MO + 
PLS3 RNA. Pictures taken 36 hours post fertilisation show a severely truncated motor axon in an smn 
morphant (arrow), and a mild ventral branch in a PLS3 injected embryo (arrowhead). (B) Classification of the 
defects found in embryos. Taken from (Oprea et al. 2008). 
 
1.1.4 CURRENT TREATMENT IN SMA 
There is no current curative therapy for SMA, nevertheless current treatment is focused in 
increasing by several methods the amount of functional SMN in the MNs of the affected 
patients. The main limitations of these approaches are the heterogeneous responses between 
?? ??
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patients in drug-derived therapies and the specific targeting and long lasting SMN 
expression in MNs for viral-based gene therapies.  
Several drugs have been found to increase the expression of the SMN2 gene and/or to 
promote the inclusion of exon 7 during SMN2 pre-mRNA splicing with the subsequent 
increased translation of the FL-SMN transcript into a functional protein (Van Meerbeke & 
Sumner 2011). The most popular group of drugs are the histone deacetylase (HDAC) 
inhibitors sodium butyrate (SB) (Chang et al. 2001), phenylbutyrate (PB) (Andreassi et al. 
2004), valproic acid (VPA) (Brichta et al. 2003; Sumner et al. 2003), suberoylanilide 
hydroxamic acid (SAHA) (Hahnen et al. 2006) and trichostatin A (TSA) (Avila et al. 2007) 
all which have shown to increase FL-SMN protein in vitro and in animal models of SMA.  
VPA and PB were taken to clinical trials without much success (Mercuri et al. 2004; 
Swoboda et al. 2010; Kissel et al. 2011), but other clinical trials with related drugs are 
currently in progress. 
It is worth mentioning within this category (drug therapy) the use of antisense 
oligonucleotides (ASOs), modified oligonucleotides that target specific sequences in the 
SMN2 pre-mRNA in order to promote the inclusion of exon 7 by blocking the binding of 
splicing repressors. This potential therapy has shown promising results in SMA mouse 
models, although repetitive administrations are required (Passini et al. 2011). A different 
drug-derived mechanism to the ones described previously is the one employed by 
aminoglycosides. These molecules have been shown to induce translational read-through of 
stop codons in the SMN2 transcripts giving a longer C terminal to the truncated SMN 
protein, which is more stable and functional than the shorter Δ7 counterpart (Mattis et al. 
2009). 
The second approach that has been showing very positive results in the past few years is the 
adeno-associated viral vector (rAAV)-mediated introduction of the complementary DNA 
(cDNA) of the SMN1 gene directly into the affected MNs in order to promote the 
continuous expression of the functional protein. rAAV-mediated SMN gene augmentation 
studies have been performed in SMA mouse models through intravascular injections (Foust 
et al. 2010; Valori et al. 2010; Dominguez et al. 2011) and 
intracerebroventricular/intraparenchymal injections (Passini et al. 2010). The most 
successful results have been obtained thought the systemic injection of self complementary 
AAV serotype 9 (scAAV9s) encoding the therapeutic gene, where complete rescue was 
achieved (Foust et al. 2010). It is important to mention nonetheless that there seems to be a 
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unique time frame in which viral gene delivery of this vector through this route is effective, 
which is associated with the maturation state of the blood brain barrier (BBB) (Foust et al. 
2009). Moreover, it seems that there is a different transduction pattern in the intravascular 
delivery method in non-human primates, as well as pre-exiting neutralizing antibodies 
(Gray et al. 2011). New routes of delivery are currently being tested and compared 
(Glascock et al. 2012; Barkats Unpublished data), including the use of new SMA animal 
models (Duque Unpublished data) . 
A third approach for SMA therapy has been proposed by Comi’s group (University of 
Milan, Italy) within a different category: cellular therapy. Comi’s group have shown that 
transplantation of neural stem cells can ameliorate SMA phenotype in mouse models (Corti 
et al. 2008; Corti et al. 2010). The mechanism behind the recovery of the animal is not 
understood, but it seems to come from the support (neuroprotection) of the grafted cells 
more than from their differentiation into new MNs. 
Even though we have gained important insights into the pathology and into the potential 
reach of various therapies for SMA through the use of animal models, we require 
alternative systems in which we could systematically study the initiation and progress of 
the disease in the human context, something that until recently could only be achieved with 
limited post mortem samples.  Several studies have now shown than human MNs can be 
efficiently obtained from stem cells. Furthermore, the use of a new type of stem cells called 
“induced pluripotent stem cells or iPSCs” has shown that aspects of several human 
pathologies can be modelled in vitro. As such, iPSCs provide a new and promising 
platform for the modelling, drug screening and therapeutic designs for SMA. 
 1.2 INDUCED PLURIPOTENT STEM CELLS (iPSC)  
1.2.1 INDUCTION OF PLURIPOTENT STATE 
The study of human disease mechanisms, the determination of suitable targets for reversing 
disease phenotypes and the approaches to effectively reconstitute a cellular function, a 
defective tissue or even an organ are all issues encountering new possibilities in the last 
decade. For many years, the most accessible way to study diseases and general mechanisms 
in the human being was through the use animal models, preferentially mice and rats. During 
the course of the experiments, scientists have found critical differences between these 
models and the real situation in the human; either because the cause of the disease is not 
clearly known and single transgenic modifications do not recreate the pathology, because 
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the genetic background differs or simply because even by introducing the same genetic 
defect, the development of the disease is not comparable, frequently presenting a very 
different physiopathology (Miranda et al. 2004; Nelson & Gibbs 2004; Olson et al. 2004; 
Coppola et al. 2006; Roep 2007; Dambrot et al. 2011; Yazawa et al. 2011) In vitro models, 
where the target human cells affected by a disease are cultured in the laboratory, have then 
come into play to bypass these limitations. Unfortunately cells do not grow in culture as 
they do inside the organism and many of the primary cells affected by human diseases have 
a very restricted access due to their nature and localisation, in particular in the case of 
neurodegenerative diseases (Dimos et al. 2008; Ebert et al. 2009; Soldner et al. 2009). 
Furthermore, most of cells that can be easily and ethically obtained from a human patient 
are somatic cells and these are known by their incapability to renew themselves (and thus to 
be cultured in vitro) and for their compromised developmental potential (lineage 
restriction). Even after immortalisation with genetic/epigenetic modification (which 
introduces questionable additional variables), many human cell types have never properly 
been adapted for growth in vitro. Over the past few years it has been discovered that 
somatic cells can be converted into a pluripotent state, very similar to the one observed in 
embryonic stem cells (ESCs) derived from the blastocyst, using several mechanisms 
(Figure 1.7) (Amabile & Meissner 2009):  
ü Exposure to factors in the enucleated oocyte through somatic nuclear transfer (NT) in 
order to generate NT-ESCs. This technique besides being highly inefficient also 
requires the donation of a very large number of oocytes and it has not been achievable 
in human cells so far (Wilmut et al. 1997; Byrne et al. 2007; Amabile & Meissner 
2009). 
ü Exposure to factors expressed in an ESC (or any other pluripotent cell) through 
fusion and generation of a tetraploid cell. This technique usually requires the use of 
ESCs obtained from human embryos (with the concomitant ethical and moral issues) 
and gives rise to a pluripotent hybrid cells with an abnormal karyotype (Tada et al. 
2001; Cowan et al. 2005). 
ü Direct reprogramming through over-expression of defined reprogramming 
transcription factors (RTFs). This recent technique allows the generation of the so-
called “induced pluripotent stem cells” (iPSCs), which will be the focus in this 
project (Takahashi et al. 2007; Yu et al. 2007). 
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ü Culture induced reprogramming using specific culture conditions for isolated cells 
from the germ line. This technique has been performed with some success through 
the use of primordial germ cells  (PGC) from human embryos in order to generate 
embryonic germline cells (EGCs). Unfortunately, the maintained culture has been 
shown to be prone to spontaneous differentiation (Turnpenny et al. 2003). It was later 
also shown that adult germline stem cells (GSCs) can also be obtained from culture 
induced reprogramming of spermatogonial 
cells from adult human testis, bypassing the 
need to manipulate human embryos (Conrad et 
al. 2008). Recent reports suggest nonetheless, 
that the later cells are not pluripotent, but only 
multipotent and very similar to mesenchymal 
stem cells (MSC) (Chikhovskaya et al. 2012). 
 
 
 
 
Figure 1.7: Strategies to induce a pluripotent state.   
Pluripotent cells can be obtained by nuclear transfer from 
a somatic cell into an enucleated oocyte (i); somatic cell 
fusion with a pluripotent stem cell, such as an ESC (ii); 
ectopic expression of RTFs associated with pluripotency 
(iii) and culture induced reprogramming of cells of the 
germline. Taken from: (Amabile & Meissner 2009).  
 
 
1.2.1.1 DISCOVERY OF iPSCS 
Of the four previously described techniques, the generation of iPSCs is the most recent and 
outstanding technology developed in the molecular and cell biology field and its potential 
has drawn an immense attention from the scientific and medical worlds.  In 2006, 
Kazutoshi Takahashi and Shinya Yamanaka (Kyoto University, Japan) demonstrated that 
mouse embryonic and adult fibroblast could be reprogrammed into a pluripotent state, very 
similar to that of the embryonic stem cell (ESC) through the ectopic expression of four 
RTFs: OCT4, SOX2, C-MYC and KFL4 (Takahashi & Yamanaka 2006). A year later these 
authors published similar results, but this time using the four factors to reprogram adult 
human fibroblast (Takahashi et al. 2007).  Each factor was expressed from a different 
retroviral vector and even though there was a different pattern of integration in each cell, in 
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all the cases the four retroviruses were strongly down-regulated once the human iPSCs 
were established. These authors stated in consequence, that ectopic expression was only 
necessary at the beginning and that once the reprogramming occurred there was an 
activation and further maintenance of the endogenous expression. The process of 
reprogramming nevertheless was not understood (Takahashi et al., 2007).   
In the same year Thomson's group (University of Wisconsin-Madison, USA) also 
demonstrated the capacity to reprogram human somatic cells, (IMR90 primary foetal 
fibroblasts and human newborn foreskin fibroblasts), but using a different combination of 
lentiviral-delivered factors. While OCT4 and SOX2 were still included, c-MYC and KFL4 
were replaced by NANOG and LIN28 (Yu et al., 2007). Even though both groups 
(Yamanaka’s and Thompson’s) acknowledge the critical role of OCT4 and SOX2 on the 
reprogramming of the cells, the rest of the cocktail seemed to be potentially dispensable. 
Indeed, it has now been shown that somatic cells can be reprogrammed with as little as one 
RTF, namely OCT4, and that reprogramming efficiency and timing can be modulated by 
other parameters such as the type of somatic cell to be reprogrammed, the delivery method 
of the RTFs and the use of small molecules (Kim et al. 2009b; Kim et al. 2009c). 
Initially the selection of factors from both research groups came from the screening of 
optimal combinations of genes with known enriched expression in human ES cells. OCT4 
also known as POU class 5 homeobox 1 (Entrez gene ID 5460) and SOX2 also known as 
SRY (sex determining region Y)-box 2 (Entrez gene ID 6657) are key RTFs that up-regulate 
genes involved in pluripotency while suppressing differentiation associated genes. It seems 
that these RTFs are unable to bind to their target genes in differentiated cells because of 
other inhibitory mechanisms, including DNA methylation and histone modification and 
here is where the other factors play their role (Takahashi et al. 2007). c-MYC also known as 
v-myc myelocytomatosis viral oncogene homolog (Entrez ID 4609) is an RTF with many 
downstream targets (more than 25000 potential binding sites) that enhance proliferation and 
transformation and it also associates with acetyltransferase complexes which could help 
OCT4 and SOX2 to bind to their specific target loci (Takahashi & Yamanaka 2006). 
Nevertheless, c-MYC is extremely oncogenic and mutations, overexpression, rearrangement 
and translocation of this gene have been associated with a variety of hematopoietic 
tumours, leukemias and lymphomas (NCBI, Entrez ID 4609). KFL4 also known as 
Kruppel-like factor 4 (Entrez ID 9314) is a RTF that seems to contribute to the activation of 
NANOG and other ESC specific genes through the repression of the tumour protein p53, a 
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growth inhibitor (Entrez ID 7157). NANOG (Entrez ID 79923) is one the highest expressed 
genes in ESCs, since its activity is directly involve in embryonic development, a feature 
that makes it the preferable marker for the assessment of pluripotency. Finally LIN28 
(Entrez ID 79727) is a RTF involved in developmental timing more than in self-renewal. 
Indeed, it has been found that even though LIN28 is highly expressed in undifferentiated 
cells, its overexpression increases differentiation and a slow cell cycle (Darr & Benvenisty 
2009). The role of most these RTFs is still poorly understood, a situation that explains why 
there has been more than one combination of factors able to reprogram somatic cells.  
1.2.1.2 METHODS OF REPROGRAMMING  
Several methods have been employed for the generation of iPSCs since the first retroviral-
based reprogramming; including other integrative approaches with the same 
retroviral/lentiviral vectors (polycistronic constructs, inducible promoters) (Brambrink et 
al. 2008; Somers et al. 2010) and many other non-integrative/excisable methods. The latter 
category includes: transient plasmid transfection (Okita et al. 2008; Yu et al. 2009), 
adenoviruses (Stadtfeld et al. 2008), Sendai viruses (Seki et al. 2010), and episomal vectors 
with excisable cassettes containing loxP sites (Kaji et al. 2009) or the piggyBac transposon 
(Woltjen et al. 2009). iPSC reprogramming using only proteins and a combination of 
subsets of RTFs  and small molecules has also been achieved, although with less success 
(Huangfu et al. 2008a; Kim et al. 2009a; Zhou et al. 2009). The most successful method 
developed so far to reprogram iPSCs free of genetic integrations (which was quickly 
commercialized by Stemgent) is the mRNA transfection method designed by Rossi’s group 
(Children’s Hospital Boston, USA) (Warren et al. 2010). This method is as efficient as the 
retroviral reprogramming and is also 100% free of transgenes and vectors, bypassing the 
need to screen colonies as in the case of excisable methods (Gonzalez et al. 2011). 
Recently, a very different approach has been reported: mouse and human cells were 
reprogrammed to a pluripotent state by using microRNAs (post-transcriptional regulators) 
delivered either with lentiviral vectors or by direct transfection, and without the addition of 
any of the previously described RTFs (Anokye-Danso et al. 2011; Miyoshi et al. 2011). 
Each reprogramming method has its advantages and its disadvantages, but the common 
perspective in the field is the improvement of these methods should aim to fulfil three main 
criteria: high reprogramming efficiency, absence of integration or genetic modification and 
simplicity in the methodology. As it can be anticipated some criteria are more or less 
 35 
important than others, depending on the downstream application: study of reprogramming 
or differentiation mechanisms, disease modelling or cell therapy (Gonzalez et al. 2011). A 
diagram of the different reprogramming methods is shown in Figure 1.8. 
 
Figure 1.8: Methods for the delivery of reprogramming factors.  
Diagram showing current integrating, excisable and non-integrating methods for the delivery of 
reprogramming factors/microRNAs during the generation of iPSCs. Taken and modified from (De Souza 
2010) 
 
Independently of the method used for reprogramming, established iPSCs clones should 
behave like ESCs including aspects such as: morphology, proliferation, surface antigen and 
RTF expression, methylation status of the promoters of pluripotency genes, telomerase 
activity and ability to differentiate into representative cells/tissues of the three embryonic 
layers in vitro (through embryoid body) and in vivo (through teratoma formation) 
(Takahashi et al., 2007; De Sousa, 2009). Mouse iPSCs, should also be able to form 
chimaeric mice with subsequent germline transmission and to produce adult mice by 
tetraploid complementation assays (Maherali et al. 2007; Boland et al. 2009; Kang et al. 
2009). 
1.2.2 STEM CELL DIFFERENTIATION   
During in vitro differentiation of pluripotent stem cells as well as during mammalian 
development, cells go through a process of differentiation, in which pluripotency pathways 
are repressed and lineage specific pathways are activated (Boyer et al. 2005). The early 
studies in embryology provide the first knowledge on cell developmental potential and 
differentiation, and in this regard Waddington´s epigenetic landscape idea, published in his 
book ¨The Strategy of the Genes¨ in 1957 set the stage for the subsequent studies. The 
epigenetic landscape is a visual depiction of a set of developmental choices that is faced by 
a cell in the embryo and according to it, the cells are under the influence of inducing signals 
that will ultimately lead them to different pathways down the “valley¨, pathways that are 
!"#$
%&'()!"#$
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associated with different states of terminal differentiation (Waddington 1957; Slack 2002). 
A modern version of this idea is depicted in Figure 9, where it is also shown how the 
process of differentiation is accompanied by changes in the epigenetic status of the cell. In 
a totipotent cell, which is able to give rise to all the cells of an organism, including 
embryonic and extra-embryonic tissues, there is a global DNA demethylation which is 
similar to the one observed in pluripotent cells (ESCs from the inner cell mass of the 
blastocist, EGCs derived from explanted PGCs and iPSC), nevertheless, pluripotent cells 
are not able to give rise to extra embryonic tissues and can only form a whole organism by 
tetraploid complementation (Howlett & Reik 1991; Boland et al. 2009; Hochedlinger & 
Plath 2009; Zhao et al. 2009). Further along the process of differentiation cells become 
multipotent, pluripotency genes become methylated and the X chromosome inactivation 
takes place (Gardner & Lyon 1971; Santos et al. 2002). These multipotent or somatic stem 
cells reside in various organs such as bone narrow, brain, liver, skeletal muscle and dermal 
tissue (Yoshida & Yamanaka 2010). When the repression of lineage-specific genes starts to 
get lost, cells acquire a unipotent state in which their developmental potential is 
compromised to a specific lineage (cell determination and subsequent commitment), such 
as muscle cells, B cells, macrophages and fibroblast (Hochedlinger & Plath 2009) (Figure 
1.9). 
 
Figure 1.9: Developmental potential and epigenetic states of cells at different stages of development. 
According to Waddington’s model cell differentiation occurs as a ball going down a valley subjected to 
different forces that influence its course.  ICM: inner cell mass. ES cells: embryonic stem cells. EG cells: 
Embryonic germline cells. EC cells: embryonic carcinoma cells. mGS cells: multipotent germline cells. iPSC 
cells: induced pluripotent stem cells. Take from: (Hochedlinger & Plath 2009)who took and modified a 
previous version from (Waddington 1957). 
* human mGS cells are not considered pluripotent  
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Cell differentiation is governed by co expression of cross-antagonist regulatory factors that 
drive alternative lineage specific programs of gene expression leading to lineage priming (a 
promiscuous expression in progenitors of transcriptional programs associated with an 
specific lineage) (Graf & Enver 2009). As cells continue to specialize, there is a different 
set of cross-antagonist regulatory factors coming into action and the temporal expression of 
each set has been shown to be important (Iwasaki & Akashi 2007). Figure 1.10 shows the 
main differentiation pathways that a pluripotent cell can follow, describing the main cell 
types derived from the three germ layers: ectoderm, mesoderm and endoderm. As we know 
by the process of embryogenesis, cells derived from the ectoderm form the outer layer of 
the skin and the nervous system; cells derived form the mesoderm form the muscles, bones, 
some organs, the hematopoietic system and the endothelium lining the blood vessels; and 
cells derived from the endoderm form the lining of the digestive, respiratory and urinary 
tracts and a number of other organs and glands. 
 
Figure 1.10: Differentiation pathways of a pluripotent cell.  
Pluripotent cells differentiate into multiple cellular lineages (and their associated mature cells) of the three 
germ layers: ectoderm, mesoderm and endoderm. Taken from: BD Stem Cell Resource. Markers of Self-
Renewal and differentiation. bdbiosciences.com/stemcell.  
 
A distinct type of situation of that previously described, is the so called “trans-
differentiation process”, in which there is a conversion of one differentiated cell type into 
another without any gain in differentiation potential. Such is the case of differentiated B 
cells reprogrammed to macrophages and embryonic fibroblasts reprogrammed to myoblasts 
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in the mouse context (Davis et al. 1987; Xie et al. 2004; Hochedlinger & Plath 2009). 
These first studies provided the insights that gave birth to a limited list of publications with 
human cells were lineage-specific RTFs introduced into fibroblasts created cardiomyocyte-
like cells (Ieda et al. 2010) neurons (Pang et al. 2011), and dopaminergic neurons (Caiazzo 
et al. 2011; Pfisterer et al. 2011). Other types of “lineage switches” have also been 
reported. 
1.2.2.1 iPSC DIFFERENTIATION AND THEIR USE IN DISEASE MODELLING 
In the previously described context, iPSCs have defied all the rules, since they have, taking 
the previously described Waddington’s model as reference, found a way to roll up the 
valley to then be coaxed to roll down in many different pathways (as opposed to the trans-
differentiation process). Many cells have already been repeatedly differentiated from 
human iPSCs, including, but not limited to: motor neurons (Dimos et al. 2008), 
dopaminergic neurons (Soldner et al. 2009; Cooper et al. 2010), retinal pigment epithelium 
cells (Carr et al. 2009), astrocytes and oligodendrocytes (Krencik & Zhang 2011; Song et 
al. 2012), mature pancreatic insulin-producing cells (Zhang et al. 2009a), hematopoietic 
progenitors of the myeloid and erythroid lineages (Raya et al. 2009), functional osteoclasts 
(Raya et al. 2009), smooth muscle cells (Lee et al. 2010), functional cardiomyocytes 
(Zhang et al. 2009b), neuroepithelial, neural crest, endothelial and endodermal cells (Lee et 
al. 2009) and hepatocytes (Song et al. 2009). 
Furthermore, several diseases have now been modelled through the differentiation of iPSCs 
generated directly from cells of the patients suffering the pathology. In these studies, iPSCs 
were differentiated to the cell type affected in the disease, which then showed an expected 
cellular phenotype or molecular mechanism already seen in vivo and not present in a 
control unafected iPSC line.   These studies include: Familial dysautonomia  (Lee et al. 
2009), Parkinson’s disease (Soldner et al. 2009; Devine et al. 2011; Nguyen et al. 2011; 
Seibler et al. 2011), Type 1 diabetes (Maehr et al. 2009), LEOPARD syndrome (Carvajal-
Vergara et al. 2010), Friedreich Ataxia (Liu et al. 2010), Dyskeratosis congenital (Agarwal 
et al. 2010), Rett’s syndrome (Marchetto et al. 2010; Cheung et al. 2011), Long QT 
syndrome (Moretti et al. 2010; Itzhaki et al. 2011; Matsa et al. 2011), Schizophrenia 
(Brennand et al. 2011), Hutchinson-Gilford progeria syndrome (Liu et al. 2011; Zhang et 
al. 2011), Timothy syndrome (Yazawa et al. 2011), Multiple sclerosis (Song et al. 2012), 
Alzheimer’s disease (Yahata et al. 2011; Israel et al. 2012) and of course Spinal muscular 
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atrophy (Ebert et al. 2009; Chang et al. 2011; Sareen et al. 2012). Table 1.1 summarizes 
the methods and findings of several of these disease-modelling studies, as example of what 
can be achieved with iPSC models.  
 
Table 1.1:  iPSC-based human disease modelling and drug screening studies.  
Taken from(Tiscornia et al. 2011). 
 
 
ALS, amyotrophic lateral sclerosis; FD, familial dysautonomia; SMA, spinal muscular atrophy; DC, 
dyskeratosis congenita; LQTS, long QT syndrome; RS, Rett’s syndrome; SCH, schizophrenia; PD, 
Parkinson’s disease; HGPS, Hutchinson-Gilford progeria syndrome; TS, Timothy syndrome; VSMC, 
vascular smooth muscle cell; MSC, smooth muscle cell.  
 
As described previously, in SMA, the main cell type affected is the MN, more specifically 
the lower alpha MNs. The differentiation of iPSCs to MNs, which is an extrapolation of the 
differentiation protocols from hESC to MNs, is based in the same developmental process 
that these cells go through in vivo during embryogenesis and which will be summarized in 
the following section,  
1.2.2.2 MN DIFFERENTIATION  
MNs are the postmitotic neurons borne in the CNS and projecting out to the peripheral 
nervous system (PNS) to control the movement of all the muscles in the body (Ericson et 
al. 1997). They are divided in somatic and visceral MNs (depending on the type of tissue 
they innervate, skeletal or visceral respectively). Within the somatic MN classification, they 
are further divided into upper and lower MNs (depending on whether they are located in the 
brain stem or the spinal cord) as well as in alpha, beta and gamma MNs (depending of the 
type of fibre they innervate).  Alpha MNs are somatic MNs that specifically project their 
axons toward the skeletal muscle forming a synapse, which is always cholinergic in nature, 
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called neuro-muscular junction (NMJ) (Bear et al. 2007). The study of the generation and 
degeneration of this cell type in humans has always been hampered by its inaccessibility 
from human tissues. As a result, most of what is known about MNs in humans is based on 
studies performed in other organisms, particularly in chicken, and in some limited studies 
in human embryos (Jessell 2000; Muhr et al. 2001; Jakovcevski & Zecevic 2005). After the 
formation of the three germ layers in the developing embryo, the neuroectoderm gives rise 
to the neural tube, which makes up the CNS. In general, the specification of different cell 
types in the neural tube is regulated by the precise spatiotemporal expression of particular 
genes, which results in a sequential generation of neurons, oligodendrocytes, and 
astrocytes. Thus, regionalisation along the rostro-caudal and dorso-ventral axes through 
gradients of signalling molecules (morphogens) is key for defining the identity of the cells 
in the nervous system (Jessell 2000; Lee & Pfaff 2001). In the rostro-caudal axis, retinoid 
acid (RA) switches the default anterior state of the cells in the neural tube to a caudal fate, 
whereas in the dorso-ventral axe sonic hedgehog (SHH) determinates the fate of different 
domains (Durston et al. 1998; Briscoe et al. 2000). Indeed, a gradient of SHH generates the 
organisation of five different progenitor cell domains in the ventral neural tube through the 
repression and induction of a set of homedomain proteins (class I and II respectively). MNs 
are generated in the pMN domain (Briscoe et al. 2000). The subtype specification of MNs 
progenitors within the pMN domain, as well as the generic neural differentiation and cell 
cycle exit is given by the co-expression of the helix–loop–helix transcription factors 
oligodendrocyte 2 (OLIG2) and neurogenin 2 (NGN2) (Mizuguchi et al. 2001; Novitch et 
al. 2001). Once MN progenitors exit the cell cycle, post mitotic MNs are established. Post-
mitotic MNs express specific transcription factors such as homeobox gene HB9 and the 
LIM homeodomain transcription factor insulin gene enhancer protein Islet-1 (ISL-1) (Pfaff 
et al. 1996; Arber et al. 1999). As they mature, post-mitotic MNs also express choline 
acetyltransferase (ChAT), an enzyme catalysing the synthesis acetylcholine (identifying 
cholinergic neurons, which in the ventral spinal cord are exclusively MNs) for signal 
conduction through the NMJs (Wichterle et al. 2002; Hu & Zhang 2009). 
In vitro, functional maturity of MNs can be evaluated though the assessment of 
electrophysiological properties, specifically through the presence of fast inactivating 
sodium currents and the ability to fire action potentials. Functional maturity can also be 
assessed through MN co-culture with muscle in order to evaluate the formation of NMJs 
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with features such as the presence of synaptic markers and the induction of the clustering of 
acetylcholine receptors in the myotubes (Li et al. 2005; Li et al. 2008; Hester et al. 2011). 
Since there is a temporal pattern in the expression of the transcription factors, gene transfer 
techniques have provided a very useful approach for the study and follow up of MN 
differentiation. Furthermore, in the context of disease modelling, many diseases, including 
SMA are of monogenic, and as such, gene therapy strategies directed towards the affected 
gene have proven to be successful in the restoration of the normal phenotype in cells 
differentiated from iPSCs derived from patients (Chang et al. 2011). Given the extensive 
use of gene transfer techniques in the iPSC field, the next section will summarize the 
current methods for gene transfer, emphasizing the viral systems. 
 1.3 GENE TRANSFER AND GENE THERAPY 
Gene transfer is the exogenous delivery of genetic material (DNA, RNA or a molecule 
containing both or parts of them) to a cell. This technique has been widely used as a 
reporter tool by the transference of fluorescent proteins whose transgenic expression is 
controlled by a cell-type specific promoter (Marchetto et al. 2008). When effective reporter 
expression is the only parameter considered, the selection of the most adequate delivery 
system will depend mainly in its transfection/transduction efficiency and its sustained 
expression within the target cell. Likewise, gene transfer is the basis for iPSC 
reprogramming and coaxed differentiation, but as described previously the method of 
choice is highly dependable in these cases in the absence of integration or genetic 
modification if therapeutic approaches are desired (Gonzalez et al. 2011; Hester et al. 
2011). 
Gene transfer also constitutes the basis of gene therapy. In gene therapy, the transfer of 
genetic material aims at the correction of a cellular dysfunction, which has a proven genetic 
cause or at the provision of a novel cellular function, which can ameliorate or counteract 
the existing dysfunction (Friedmann & Roblin 1972; Nonnenmacher & Weber 2012). 
Different gene transfer/ gene therapy delivery systems have been developed so far, 
including viral vectors (Nanou & Azzouz 2009), naked DNA (Herweijer & Wolff 2003), 
cationic lipid/DNA complexes (Abe et al. 1998) and cell encapsulation (Orive et al. 2003).  
Particularly, viral vectors have received a lot of attention because of their natural ability to 
infect human cells. Up to date, there are 1843 clinical trials using gene therapy, 1218 of 
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which are based on viral vectors, particularly on adenovirus and retrovirus (Wiley Last 
updated June 2012).  
For clarity, all the names of wild type viruses and recombinant viral vectors will be 
preceded by a “wt” and a “r” respectively. When referring to both types, no letter will be 
used. 
Several viral vectors have been studied for the treatment of numerous diseases, especially 
cancer, but viral-based gene therapy studies for neurological diseases evolving to clinical 
trials, currently account for a much smaller percentage, with Parkinson’s being the most 
studied so far (Feigin et al. 2007; Kaplitt et al. 2007; Eberling et al. 2008; Marks et al. 
2008; Herzog et al. 2009; Marks et al. 2010). Unfortunately, viral vectors have encountered 
important obstacles that have raised doubts about the safety of their use over the past few 
years (Deakin et al. 2009). One of the most well known cases was the human gene transfer 
study conducted by Alain Fischer in France to correct X linked severe combined 
inmunodeficiency (SCID X1) (Hacein-Bey-Abina et al. 2003). In this study, autologous 
CD34+ cells were transduced with a replication-incompetent Moloney murine leukemia 
viral vector (rMMLV) carrying the common gamma chain transmembrane protein subunit 
gene shared by the receptors of six different interleukins. Even though this has been until 
recently one the most successful trials in gene therapy, showing an impressive 
improvement in most of the children treated, there were four unfortunate cases in which 
insertional mutagenesis at or near oncogenes occurred, causing T cell leukemia 31–68 
months after gene therapy (Hacein-Bey-Abina et al. 2003; Hacein-Bey-Abina et al. 2008). 
rAAV, nonetheless, has recently shown very positive results in several clinical trial for the 
treatment of Leber congenital amaurosis, an inherited eye disease leading to retinal 
degeneration. So far no significant secondary effects have been found (Jacobson et al. 
2012; NIH). 
Ever since the observation of the first adverse events, much of the gene therapy research in 
viral vectors has been focused in finding a way to bypass the safety issues, related mainly 
to integration of the viral DNA in the host genome and the immunotoxicity, without 
compromising the activity and efficiency of the encoded transcript/protein. One of the 
major discussions about the safety of viral vectors is strongly related to the features and 
properties of each of them and their original source. Each viral vector studied so far, has 
shown relevant advantages and disadvantages, and the selection depends mainly on the 
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target cell, whether or not integration occurs, the cloning capacity, the elicited 
immunogenicity and the transduction efficiency (Table 1.2) (Nanou & Azzouz 2009).  
Table 1.2:  Characteristics of the most common vectors used in gene therapy.  
Taken and modified from: (Nanou & Azzouz 2009).  
 
* Wild type AAV integrates, but recombinant AAV rarely does 
 
Adenoviral vectors (rAd) and retroviral vectors (rRVs) have been the most commonly used 
vectors so far in gene therapy, but their high immunogenicity and high integration 
frequency respectively, have motivated the research and development of other type of viral 
vectors. In this regard, and specifically considering the context of neurodegenerative 
diseases, even though adeno-associated viral vectors (rAAV) have only been used in 4.9% 
of the clinical trials in gene therapy (Gene Therapy Clinical Trials Wordwide, updated in 
June 2012), the findings from Kaspar´s group where an rAAV9 is able to bypass the BBB 
after intravenous injection in a mouse model, has drawn an increased attention to these viral 
vectors, particularly to serotype 9 (Foust et al. 2009). In fact, as described before, in vivo 
rAAV9 transfer of hSMN1 has already been shown to rescue SMA in mouse models (Foust 
et al. 2010; Valori et al. 2010; Dominguez et al. 2011). In the current study I employed 
three different viral vectors for gene transfer including rAAV9. The other vectors used 
belong to the Retroviridae family and they were used for iPSC reprogramming and iPSC-
derived MN identification respectively: rMMLVs and HIV-1 based lentiviral vectors 
(rH1LVs). Their structure, cell cycle, recombinant production and transduction pattern are 
described in the following sections.  
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1.3.1 VIRAL VEHICLES FOR GENE TRANSFER 
1.3.1.1 AAVs 
1.3.1.1.1 wtAAV structure  
wtAAV is a small non-enveloped virus that belongs to the Dependovirus genus of the 
Parvovirus family. The single stranded DNA viral genome is approximately 4.7 Kb in 
length, and it is composed of two open reading frames (ORF) flanked by two inverted 
terminal repeats (ITR) (Ding et al. 2005) (Figure 1.11 A). The 5' ORF (rep) encodes 4 
replication proteins generated from two different promoters:  Rep 78 and Rep 68 which are 
translated from the p5 promoter and Rep52 and Rep40 which are translated from the p19 
promoter; each pair or proteins differ by alternative splicing (Virag et al. 2009). The 3' 
ORF (cap) encodes 3 capsid proteins VP1, VP2, and VP3, generated through alternative 
mRNA splicing and alternative start codon usage (Ding et al. 2005). VP1 is translated from 
an ATG codon on the 2.4 Kb mRNA, while VP2 and VP3 are translated from the 2.3 Kb 
mRNA, using a weaker ACG start codon for VP2 (amino acid T138) and a read through 
translation to the next ATG codon for VP3 (amino acid M203), the most abundant capsid 
protein (Warrington et al. 2004) (Figure 1.11B). 
The ITR 's at both ends of the genome contains 145 nucleotides organized in a T shape 
hairpin structure, a feature that allows the genome to replicate itself without the need to 
synthesize a primer (Figure 1.11C). ITRs are required in cis for gene expression, DNA 
synthesis, rescue from integrating genomes and packaging of the DNA into preformed 
capsids (Hermonat & Muzyczka 1984; Berns 2007). ITRs contain a terminal resolution site 
(trs), which is cleaved by rep proteins in order to replicate monomeric copies of the wtAAV 
genome (McCarty 2008). ITRs seem to be the only necessary viral component in 
recombinant vector genomes since they are the only requirement for packaging DNA into 
capsids (Ding et al. 2005; Schultz & Chamberlain 2008). 
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Figure 1.11: wtAAV structure. 
 (A) Complete wtAAV genome. (B) Proteins translated from the two open reading frames, REP and CAP: 
Rep78, Rep68, Rep52, Rep40, VP-1, VP-2 and VP-3. (C) Detailed map of the structure of the ITRs. 
RRE/RRE’: Rep binding element. Trs: terminal resolution site. Taken and modified from (Berns 2007; Virag 
et al. 2009). 
1.3.1.1.2 wtAAV cell cycle 
Most of the studies in wtAAV and have been performed in the serotype 2 (wtAAV2), 
comprising the understanding of events ranging from virus-cell attachment through vector 
genome conformation in the target cell and expression patterns (Schultz & Chamberlain 
2008). wtAAV enters the cell through attachment or binding to specific receptors and co-
receptors, and each serotype has its own, although some are shared between two or more 
serotypes (Table 1.3) (Schultz & Chamberlain 2008; Nonnenmacher & Weber 2012).  
Interestingly, the specific transduction behaviour of the serotype 9 after systemic 
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administration has shown that by some unknown mechanism, these viral vectors (like no 
other wtAAV serotype described so far) are able to enter the cells that form the BBB 
without un-coating, being then released on the other side of this barrier where they are able 
to infect the adjacent cells (Foust et al. 2009). Nevertheless, not obvious mechanism can be 
explained by the currently known wtAAV9 receptors/co-receptor: the 37/67-kDa laminin 
receptor and N-linked glycans with terminal galactosyl residues (Akache et al. 2006; Shen 
et al. 2011). After binding to the cell receptor, the most common entry mechanism for 
wtAAV is through receptor mediated endocytosis in clathrin coated vesicles, which is 
followed by intracellular trafficking of the virus through the endosomal compartment, 
endosomal escape, nuclear import, virion un-coating and viral genome conversion into 
double stranded DNA (dsDNA) (Ding et al. 2005).  The process of wtAAV trafficking 
before nuclear import is still controversial and it seems that the mechanism differs between 
and within serotypes (Ding et al. 2005; Schultz & Chamberlain 2008; Nonnenmacher & 
Weber 2012). After the conversion of the wtAAV genome into dsDNA, and in the absence 
adenoviruses or herpes viruses (helper viruses), wtAAV integrates into a specific site in 
chromosome 19 called AAVS1 through the interaction of the wtAAV ITR´s and the rep 
protein (lysogenic pathway) (Howarth et al. 2009).  In the presence of helper viruses, the 
wtAAV genome is excised from the host cell chromosome for replication and packaging. 
The further generation of new particles of wtAAVs, requires the assembly of 60 units of the 
three structural proteins (VP1 87 kDa, VP2 73 KDa and VP3 62 kDa) of the capsid in an 
approximate ratio of 1:1:18 (Warrington et al. 2004).  Nevertheless, It has been shown that 
AAV-like particles can also be formed with VP3 alone (Rabinowitz et al. 1999; Warrington 
et al. 2004). Since Rep proteins and wtAAV DNA co-localized with the capsids in intra-
nuclear area outside the nucleoli, it is now commonly accepted that wtAAV packaging and 
assembly occurs in the nucleus instead of the cytoplasm (Wistuba et al. 1997; Warrington 
et al. 2004). After packaging, the newly assembled particles are released through helper 
virus-induced cell lysis (Goncalves 2005). 
1.3.1.1.3 rAAV production  
Based on the knowledge of wtAAV, rAAV has been designed using a two or a three 
plasmids transfection method in HEK293T cells, which enhances the safety of the viral 
vectors produced through this technology (Xiao et al. 1998). Since the ITRs are the only 
structures necessary in cis for wtAAV rescue, replication and packaging, the wtAAV 
genome is split in two plasmids for recombinant production: one plasmid contains the 
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transfer/therapeutic gene (between 4.1 and 4.9 kb) flanked by the two ITRs, and the second 
plasmid contains the CAP and REP genes (Dong et al. 1996; Goncalves 2005). 
Given that wtAAV is a replication defective virus, a third element is required. In order to 
avoid the use of wild type adenovirus/herpes virus, current rAAV production requires co-
transfection with a helper plasmid (derived from the sequences of the wildtype helper virus) 
to supply the necessary genes to produce viable particles (Xiao et al. 1998). Between the 
helper plasmid and the producer cell, the following molecules should be provided: (i) early 
genes E1A, E1B, E2 and E4 for trans-activation of viral regions, modification of host 
cellular and immunological environment, enhancement of viral gene expression over host 
protein synthesis and initiation of viral replication, and (ii) untranslated RNAs (VA RNA´s) 
for combatting the cellular defence mechanisms by blocking activation of the interpheron 
response (Howarth et al. 2009) (Figure 1.12). 
 
 
Figure 1.12: General outline of rAAV production in vitro. 
For rAAV production, a transfer plasmid containing the gene of interest flanked by the wtAAV ITRs is co-
transfected with a packaging plasmid containing the open reading frames of REP and CAP and a helper 
plasmid containing the adenoviral genes into HEK293T cells. Taken and modified from: (White). 
 
In the absence of a helper virus/plasmid during transduction, AAV establishes a long 
lasting infection within the cell, which is predominantly characterised by persistent 
episomal forms in circular concatamers, and in rare cases by integration events (Wu et al. 
2006; Schultz & Chamberlain 2008). 
????????????????????? ??????????????????????????? ??????????????????????????????
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1.3.1.1.3.1 Self-complementary adeno-associated viral vectors (scAAV)  
Once inside the nucleus, one of the limiting steps regarding effective transduction with 
rAAV is the conversion of single stranded DNA (ssDNA) into double stranded DNA 
(dsDNA). Recently, this step has been bypassed by the development of scAAV (Wu et al. 
2006). In scAAV, the terminal resolution site of one of the ITR (Figure 1.13) is deleted so 
the resolution is inhibited and dimeric genomes are formed and packed into virions in the 
producer cell (Step 5d, Figure 1.13).  One important disadvantage of this technique 
however is that the coding capacity of the vector is reduced to 50% in order to 
accommodate the duplicated genome (McCarty 2008). The increase in efficiency gained by 
the scAAV varies from moderate to impressive depending on the tissue, cell type and route 
of administration. It is also important to consider that in the case of the CNS, higher 
transduction efficiency does not have an important impact if the virus does not reach 
widespread distribution, as it usually occurs due to the presence of the BBB. This means 
that even if the viral vectors have a very high probability of getting into target cells in a free 
environment (like an in vitro culture), the overall efficiency of the gene delivery will be 
mostly determined by the ability of the virus to reach all the cells in the target region (and 
not just a very restricted zone) from the site of injection, as it is the case in an in vivo 
scenario.  
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Figure 1.13: Formation of dimeric inverted repeats genomes during scAAV replication. 
 ssDNA virion enters the host-cell nucleus and the 3ʹ ITR acts as a primer for host DNA polymerase. The 3ʹ-
ITR primer is elongated, displacing and replicating the ITR at the 5ʹ end (1). The duplex ITR is re-folded into 
a double-hairpin configuration by host or viral DNA helicase, forming a new primer for DNA synthesis (2). 
While the 3ʹ-ITR is elongated and the complementary strand displaced, AAV Rep protein recognizes and 
binds to the ITR at the downstream end (3). To generate complete monomeric genomes, Rep endonuclease 
nicks the trs of the downstream ITR, initiating a second DNA replication complex, to copy the ITR before 
being reached by the complex initiated at the other end (4). The original replication complex displaces the 
daughter strand, including the newly synthesized ITR, and completes replication to the end of the genome, 
recreating the template for isomerisation in step 3 (5m). The displaced single-stranded genome is packaged 
into the AAV capsid (6m). Dimeric genomes are generated when Rep fails to nick the trs before being reached 
by the replication complex from the other end (7m). Replication continues through the ITR (5d), and the 
displaced strand, to generate a dimeric dsDNA template (6d) which can initiate a new round of DNA 
synthesis either by isomerizing the open end (as in step 4) or by terminal resolution of the hairpin end (7d). 
Further isomerisation after terminal resolution allows priming of DNA synthesis from the resolved end (8d), 
and replication of the dimeric template displaces a single-strand dimeric inverted repeat genome (9d), which 
can then be packaged into the AAV virion (10d). Taken from (McCarty 2008). 
   1.3.1.1.4 AAV transduction patterns  
 There are 12 known human serotypes of AAV, which are grouped according to their 
functional and immunological characteristics. The only exception to this rule are serotypes 
1 and 6, whose capsids differ only in six aminoacids and which have been found to be 
immunologically indistinguishable from each other (Gao et al. 2004; Schultz & 
Chamberlain 2008). AAV9 is the one of most recent serotypes discovered. This serotype 
 50 
was found in isolates from 3 humans in 2004 by James Wilson’s research group through the 
recovery and sequencing of full-length capsid genes by PCR in tissue samples (GenBank: 
AY530579.1). In this same study the transduction efficiency in vitro and in vivo of AAV2 
pseudotyped with different capsids were compared and it was found that even though 
AAV9 had the highest transduction efficiency in vivo in liver, lung and muscle tissues, its 
in vitro efficiency was low (less than 40%), contrary to what was seen for AAV2  (Gao et 
al. 2004) (Figure 1.14). 
  
  
  
  
 
 
 
Figure 1.14: Transduction 
efficiency of novel primate rAAV-
based infections in vitro and in 
vivo.  
For in vitro transductions, a 
construct encoding the green 
fluorescent protein (GFP) was used 
and the efficiency is expressed as 
percentage of GFP+ cells. For in 
vivo transductions a construct 
encoding Human α- antitrypsin 
(A1AT) was used and the efficiency 
is expressed as the concentration of 
this protein in serum samples. Taken 
from (Gao et al. 2004). 
  
 
 
 
 
 
 
 
 
 
 
The evaluation and comparison of transduction efficiencies have been looked at in several 
studies. In general AAV2 is known to transduce a wide range of tissues with moderate 
efficiency while the other serotypes have less tropism but higher efficiency of transduction 
(Wu et al. 2006; Schultz & Chamberlain 2008). For AAV9 a high transduction have been 
reported in striated muscle (heart), liver, pulmonary system, retinal pigmented ephitelium, 
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pancreas CNS and skeletal muscle (Inagaki et al. 2006; Allocca et al. 2007; 
Vandendriessche et al. 2007; Foust et al. 2009; Yu et al. 2011).  Table 1.3 presents an 
updated list of the preferential (not unique) tissue tropism of different serotypes along with 
their know receptors/co-receptors. 
Table 1.3: AAV receptors and preferential tissue tropism.  
Taken from (Nonnenmacher & Weber 2012). 
 
 
Abbreviations: AAV, adeno-associated virus; CNS, central nervous system; EGFR, epidermal growth factor 
receptor; FGFR1, fibroblast growth factor receptor 1; HGFR, hepatocyte growth factor receptor; HSPG, 
heparan sulfate proteoglycan; i.v., intravenous injection; PDGFR, platelet-derived growth factor receptor; 
SM, skeletal muscle; VSMC, vascular smooth muscle cell. 
 aPreferential tissue tropism following local delivery, unless otherwise indicated. 
  
It seems that the difference in the transduction efficiency of different serotypes is 
associated with differences in cellular uptake and intracellular trafficking and that this 
difference is associated with the structural architecture of the capsid (Wu et al. 2006).  
1.3.1.2 RETROVIRAL VECTORS  (RVs)     
1.3.1.2.1 wtRVs structure  
wtRVs are enveloped ssRNA viruses belonging to the Retroviridae family. Within this 
family, several genus and species have been vectorised and converted into efficient gene 
transfer tools. wMMLVs are part of the Gammaretrovirus genus and are considered simple 
wtRVs, whereas wtH1LVs belong to the Lentivirus family and are considered complex 
retroviruses (Vogt 1997). Structurally, lentiviruses (wtLVs) contain the same genes as 
simple wtRVs do, but six more genes are also present. The ssRNA of all wtRVs is 
approximately 7-13 Kb in length and it is composed of three genes, gag, pol, env, flanked 
by two long terminal repeats (LTRs) (Goff 2006) (Figure 1.15). The mRNA of wtRVs is 
translated in different ways for different species, but in general long polyproteins have to be 
cleaved by viral-encoded proteases to produce individual proteins (Kay et al. 2001). The 
gag gene encodes the matrix (MA), the capsid (CA) and the nucleocapsid (NC); the pol 
gene encodes the protease (PR), the retro-transcriptase (RT) and the integrase (IN); and the 
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env gene encodes the surface protein (SU) and the transmembrane protein (TM). wtH1LVs 
also encode the genes Vif, Vpr, Tat, Rev, Vpu and Nef, but only Tat, and Rev are essential 
for effective viral replication. (Goff 2006). 
The LTRs at both ends of the RNA genome are formed by the two unique sequences “U5” 
at the 5’ end and “U3” at the 3’ end. Both of these sequences are followed by a repeat 
sequence “R”. LTRs are necessary in cis during viral gene expression, packaging, retro-
transcription and integration of the genome (Kay et al. 2001). Other important retroviral 
elements are the primer binding site (pbs), the polypurine track (PPT), the rev response 
element (RRE) and the packaging signal (ψ) which are involved in viral replication, nuclear 
export and packaging (Goff 2006). 
 
Figure 1.15: Structure of RVs. 
 (A) Genetic organisation of wMMLVs and wHILVs. The fragments of the genome corresponding to different 
open reading frames are shown for each protein. A scale for genome sizes is shown at the bottom of the panel. 
Long terminal repeats (LTRs) are located at each end (gray boxes) (B) General schematic diagram of 
retroviruses. The viral envelope is formed by a cell-derived lipid bilayer in which the transmembrane (TM) 
and the surface (SU) components of the envelope are inserted. They matrix (MA) capsid (CA) and 
nucleocapsid (NC) proteins form the structural proteins of the virion. The particles are packaged along with 
their reverse transcriptase (RT), integrase (IN) and protease (PR). Taken and modified from (Vogt 1997). 
1.3.1.2.2 wtRV cell cycle 
wtRVs have a complex life cycle, which includes ssRNA-dsDNA conversion where many 
elements are involved. The general steps can be described as follow: (1) wtRVs enter the 
cell via receptor-mediated fusion with the cellular membrane. (2) Once inside the 
cytoplasm, the virus un-coats and reverse transcription occurs. (3) The dsDNA is trans-
located to the nucleus where it integrates into the host genome as a provirus. (4) Once 
integrated, the viral genome is transcribed and full length as well as spliced RNAs are 
produced and exported out of the nucleus. (5) Viral component are translated and (6) full-
length genomes are package, budding out the cellular membrane where the envelope 
?????
????
?? ??
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proteins are anchored. (7) Proteolytic process occurs within the assembled particle to give 
rise to the viral core proteins (Cepko & Pear 2001; Dornburg 2003).  
1.3.1.2.3 rRV production  
As in the case of rAAVs, rRVs require the splitting of the viral genome in several plasmids. 
Several strategies have been developed so far for this purpose, but in general, one plasmid 
contains the LTRs and other necessary sequences in cis (PBS, PPT, ψ, and RRE in the case 
of LVs) along with the gene of interest, whose expression is driven by its own promoter in 
modern vectors. The rest of the genes are usually split in two or more plasmids. In the case 
of simple RVs such as MMLVs for example, cell lines stably expressing the gag, pol and 
env genes can be used to produce rRVs by the unique transfection of the transfer plasmid 
(Cell Biolabs 2008). The most recent and safest system developed so far for a rRVs is the 
non integrating, self inactivating, third generation rLV production, which is a variant of 
standard LVs (Figure 1.16) (Dull et al. 1998; Zufferey et al. 1998; Philippe et al. 2006; 
Yanez-Munoz et al. 2006). For this: 
ü The viral genome is split in four plasmids: a packaging plasmid encoding the gag and 
pol genes under a CMV promoter, a rev plasmid encoding the rev protein for nuclear 
export; an envelope plasmid encoding the desired envelope protein; and a transfer 
plasmid with the gene of interest. 
ü The active site of the integrase gene has been mutated 
ü Wild-type copies of the HIV LTR are replaced: (i) the U3 in the 5’ LTR was replaced 
by an alternative enhancer/promoter, thus rendering the virus replication tat 
independent (ii) the U3 in the 3’ LTR has been partially deleted, which results in 
inactivation of both viral LTRs after transduction and reverse transcription. 
ü A splice donor site is added between the 5’ LTR and the internal promoter in order to 
splice out the ψ and RRE elements. 
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Figure 1.16: Third generation rLVs production.  
Four plasmids are necessary for rLV production. The pMDLg/pRRE plasmid (A) encodes the viral core 
proteins gag and pol. The RSV-Rev (B) and the pMD.G (D) plasmids encode the Rev protein and the 
envelope protein respectively. The pRRL.SIN-18 (C) constitutes the transfer plasmid with a chimeric 5 prime 
LTR containing the Rous Sacoma Virus (RSV) enhancer/promoter. SD: splice donor site; SA: splice acceptor 
site. In non-integrating rLVs, the integrase is mutated (pol gene) Taken from (Dull et al. 1998). 
  
 1.3.1.2.4 RV transduction patterns  
The main functional difference between LVs and simple RVs is that the former can 
efficiently infect dividing and not diving cells, whereas the latter can only infect dividing 
cells (Goff 2006). The molecular basis for this difference is a subject of controversy, but it 
is clear that in simple RVs the pre-integration complex (PIC), which mediates the nuclear 
import of the viral dsDNA, requires the disruption of the nuclear membrane during mitosis 
(Miller et al. 1990).  
The envelope of all rRVs can be substituted by another from a different virus in a process 
called pseudotyping (Kay et al. 2001). The most frequently used pseudotype is with the G 
glycoprotein of the vesicular stomatitis virus (VSV-G), which can infect most cells through 
an interaction with what it seems to be an ubiquitous cellular “receptor”, the identity of 
which is still a matter of debate (Akkina et al. 1996; Naldini et al. 1996; Reiser et al. 1996; 
Coil & Miller 2004). In fact, VSV-G pseudotyping has become the standard to which other 
pseudotypes are compared to (Cronin et al. 2005).  
Since LV can transduce non-dividing cells, many of the transduction efficiency studies 
using rRVs have been performed with them. rLVs pseudotyped with VSV-G are 
particularly good in transducing hematopoietics stem cells ex vivo (Guenechea et al. 2000; 
May et al. 2000)and CNS in vivo (Yanez-Munoz et al. 2006). Table 1.4 summarizes the 
preferences of the most common rLVs pseudotypes.  
 
A B 
C D 
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Table 1.4: Tropism of rLV pseudotypes. 
Taken from (Cronin et al. 2005) 
VSV-G: G glycoprotein of the vesicular stomatitis virus; LCMV: lymphocytic choriomeningitis virus; RRV: 
Ross River virus; SeV: Sendai virus; F: fusion protein; HN: hemagglutinin-neuramonidase; JSRV: Jaagsiekte 
sheep retrovirus; GALV: gibbon ape leukemia virus. 
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 1.4 AIMS OF THIS STUDY 
1.4.1 GENERAL AIM 
To establish human iPSC-derived models that allow the developmental and functional 
study of SMA, particularly in MNs from a discordant SMA family. 
1.4.2 SPECIFIC AIMS  
ü To generate iPSCs from human fibroblasts of five members of a discordant SMA 
family using rMMLVs as vehicles to deliver Yamanaka´s set of reprogramming 
factors. 
ü To assess the efficient reprogramming of selected iPSC clones from each family 
member through quality control tests and features such as hESC morphology, 
expression of hESC surface and nuclear markers, down-regulation of transgenic 
expression, in vitro differentiation potential, karyotype stability and genotype 
analysis.  
ü To differentiate selected iPSC clones from each family member, as well as one iPSC 
clone from a SMA type I patient and one iPSC clone from an unaffected control 
individual into MNs. 
ü To generate rH1LVs carrying a reporter gene under the control of the MN specific 
HB9 promoter in order to follow and quantify the generation of MNs during iPSC-
MN differentiation. 
ü To evaluate potential SMA phenotypes during iPSC-MN differentiation, as well as in 
the derived MNs through the assessment of the MN proportion within the culture, 
neurite length, and formation of the NMJ.  
ü To follow the expression of SMN isoforms and PLS3 at the transcriptional and 
translational levels during the iPSC-MN differentiation process in clones from 
unaffected individuals and SMA patients. 
ü To compare PLS3 mRNA and protein levels between iPSC-derived MNs in order to 
determine if PLS3 could be a modifier factor in the discordant SMA family.   
ü To generate scAAV9s carrying a human SMN1 transgene in order to study the SMN 
expression profile after the restoration of the gene in iPSC-derived MNs from the 
SMA type I patient. 
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 2.1 MATERIALS 
All reagents, chemicals, buffers, plasticware, cells, culture media, enzymes, DNA and 
protein size makers, kits, unmodified plasmids, primers, antibodies, instruments and 
software are listed in this section along with more detailed descriptions in the appendix 
section.  
2.1.1 REAGENTS AND MOLECULES  
All reagents whose characteristics are similar between manufacturers and formats are listed 
in “General reagents” Appendix 1. All reagents whose specific composition, activity and/or 
functionality are variable between manufacturers and/or between formats from the same 
manufacturer are shown in “Special reagents and media components” Appendix 1. The 
latter list includes all components and small molecules used for making up media (section 
2.1.9). All tissue culture related molecules were sterilized by filtration with a 0.22 µM pore 
filter in a class II biosafety cabinet class.  
2.1.2 BUFFERS AND SOLUTIONS  
2.1.2.1 BUFFERS FOR WESTERN BLOT (WB) 
ü 10X WB Migration buffer: 0.25 M Tris-HCl, 1% SDS, 1.92 M glycine, pH 8.3. Prior 
to use, the buffer was diluted 10 times in ddH20.  
ü  10X TBS buffer: 0.5 M Tris-HCl, 1.5 M NaCl, pH 7.5. Prior to use, the buffer was 
diluted 10 times in ddH20. For washing membranes, Tween-20 was added at a final 
concentration of 0.1% (TBS-T).  
ü 10X WB Transfer buffer: 0.48 M Tris-HCl, 0.37% SDS, 0.39 M glycine, pH 8.3. 
Prior to use, the buffer was diluted 10 times in ddH20 and methanol (the final 
concentration of methanol was 20%). 
ü WB Blocking buffer: 5% dry milk in TBS. 
ü WB 5X Loading buffer: 250 mM Tris-HCl, 50mM DTT, 10% SDS, 0.5% 
bromophenol blue, 50% Glycerol, pH 6.8. 
ü Lower buffer for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE): 1.5 M Tris-HCL, 0.4% SDS, pH 8.8. To prepare two 12% resolving gels the 
following solutions were mixed: 4 ml 30% Acrylamide/Bis-acrylamide, 2.5 ml lower 
buffer, 3.5 ml ddH20, 100 µl 10% APS, 10 µl TEMED. 
ü  Red Ponceau solution: 0.1% Ponceau S, 1% acetic acid. 
ü RIPA buffer: 50 mM Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 
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mM EDTA, pH 7.4. RIPA buffer was supplemented just before use with fresh 
protease inhibitor cocktail (cOmplete ULTRA Tablets, Mini, EDTA-free, Roche, Cat 
No. 05892791001). 
ü Upper buffer for SDS-PAGE: 1.0 M Tris-HCl, 0.8% SDS, pH 6.8.To prepare two 5% 
resolving gels the following solutions were mixed: 0.83 ml 30% Acrylamide/Bis-
acrylamide, 0.63 ml upper buffer, 3.6 ml ddH20, 50 µl 10% APS, 5 µl TEMED.  
2.1.2.2 BUFFERS FOR BACTERIAL WORK 
ü Competent cells-Buffer 1: 30 mM KOAc, 100 mM RbC12, 10 mM CaCl2, 50 mM 
MnC12, 15% glycerol, pH 5.8. 
ü Competent cells-Buffer 2: 10 mM MOPS/KOH, 75 M CaC12, 10 mM RbC12, 15% 
glycerol, pH 6.5. 
2.1.2.3 BUFFERS AND SOLUTIONS FOR IMMUNOFLUORESCENCE/ FLOW 
CYTOMETRY 
ü 10X Tris Buffered Saline (TBS) buffer: 0.5 M Tris-HCl, 1.5 M NaCl, pH 7.5. Prior to 
use, buffer was diluted 10 times in ddH20. For washing IF stainings in coverslips, 
Tween-20 was added at a final concentration of 0.1 % (TBS-T). 
ü  10X Phosphate buffered saline (PBS) buffer:  1.47 M NaCl, 26.8 mM KCl, 75.2 mM 
Na2HPO4, 17.64 mM KH2PO4, pH 7.4. Prior to use, buffer was diluted 10 times in 
ddH20. 
ü  IF Blocking buffer: 0.5% BSA in 1X PBS for cells culture in tissue culture plates 
and 10% BSA, 0.1% Tween-20 and 0.4% Triton X-100 in 1X TBS for cells cultured 
in coverslips. 
ü 4% Paraformaldehyde (PFA) fixative: 4% PFA in 1X TBS, pH 7.3.  
2.1.2.4 BUFFERS AND SOLUTIONS FOR rAAV PRODUCTION  
(All these solutions were sterilized either by filtration through a 0.22 µM pore filter or by 
autoclave at 15psi, 121◦C for 20 minutes [min]) 
ü AAV cell lysis buffer: 0.15M NaCl, 1M Tris-HCl, pH8.5. 
ü 2xHBS: 100 mM HEPES, 281 mM NaCl, 1.5 mM Na2HPO4, pH 7.12. 
ü AAV Precipitation buffer: 40% PEG8000, 2.5 M NaCl. 
ü 5X PBS-MK buffer: 5 mM MgCl2 and 12.5 mM  KCl in 1XPBS. 
ü Iodixanol gradient 15%: 25% Optiprep density gradient medium and 1M NaCl in 1X 
PBS-MK buffer.  
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ü Iodixanol gradient 25%: 41.6% Optiprep density gradient medium and 0.2% phenol 
red  in 1X PBS-MK buffer. 
ü Iodixanol gradient 40%: 66.6% Optiprep density gradient medium in 1X PBS-MK 
buffer.  
ü Iodixanol gradient 60%: Optiprep density gradient medium (neat), 0.2%  phenol red.   
ü Proteinase K buffer 2X: 20 mM Tris pH8, 20 mM EDTA, 1% SDS.  
ü Tris-EDTA (TE): 10 mM Tris-Cl, pH 7.5, 1 mM EDTA, pH 8.0. 
ü Dot blot re-suspension buffer: 0.4M NaOH,10 mM EDTA, pH 8.0. 
ü 20x saline-sodium citrate (SSC) buffer: 1.5 M NaCl, 0.3 M Na3 citrate. Prior to use, 
the buffer was diluted ten times in ddH20. 
ü Dot blot primary wash buffer: 6M urea, 0.4% SDS, 0.5x SSC. 
2.1.2.5 BUFFERS FOR iPSC-RELATED PROCEDURES  
ü Carnoy fixative: 3:1 methanol/acetic acid 
ü Hypotonic solution:  5.6 mg/ml  KCl  
ü Sudan solution: 0.5% sudan III and 0.5% sudan IV in a solution of 35% ethanol/50% 
acetone. The solution was filtered and protected from light. 
2.1.2.6 BUFFERS FOR DNA AND RNA-RELATED PROCEDURES  
ü 10X Tris-acetate-EDTA (TAE) buffer (DNA): 0.4 M Tris-HCl; 10 mM EDTA, pH 
8.5. Prior to use,  buffer was diluted 10 times in ddH20. 
ü 10X Formaldehyde (FA) buffer (RNA): 200 mM 3-[N-morpholino]propanesulfonic 
acid (MOPS), 50 mM sodium acetate, 10 mM EDTA, pH to 7.0. Prior to use as 
running buffer, it was diluted 10 times in 0.5 M formaldehyde RNAse free H20. 
2.1.3 PLASMIDS  
All plasmids used, including the ones modified and generated during this project, are 
described in this section:  
ü pMIG-hOCT4: retroviral transfer plasmid encoding the human OCT4 cDNA linked 
to an internal ribosome entry site (IRES) green fluorescent protein (GFP). This 
plasmid was originally produced in Dr. George Q Daley’s laboratory (Harvard Stem 
Cell Institute, USA) and it was used in Park et al., 2008 for the generation iPSCs. It 
is now available through Addgene (Cat. No. 17225). 
ü pMIG-hSOX2: retroviral transfer plasmid encoding the  human Sox2 cDNA linked to 
an IRES GFP. This plasmid was originally produced in Dr. George Q Daley’s 
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laboratory (Harvard Stem Cell Institute, USA) and it was used in Park et al., 2008 for 
the generation of iPSCs. It is now available through Addgene (Cat. No. 17226).  
ü pMIG-hKLF4: retroviral transfer plasmid encoding the  human Kfl4 cDNA linked to 
an IRES GFP. This plasmid was originally produced in Dr. George Q Daley’s 
laboratory (Harvard Stem Cell Institute, USA) and it was used in Park et al., 2008 for 
the generation of iPSCs. It is now available through Addgene (Cat. No. 17227).  
ü pMSCVhcMYCIRESGFP: retroviral transfer plasmid encoding the  human cMyc 
cDNA linked to an IRES GFP. This plasmid was originally produced in Dr. John 
Cleveland’s laboratory (St. Jude Children's Research Hospital, USA) and it was used 
in Park et al., 2008 for the generation of iPSCs. 
ü p5E18-VD2/9: rAAV9 packaging plasmid encoding the AAV2 rep gene and the 
AAV9 capsid gene. This plasmid was initially obtained from Dr. Jim Wilson 
(University of Pennsylvania, USA) and provided by Prof. George Dickson (Royal 
Holloway, University of London, UK). 
ü pAdDeltaF6: adenoviral helper plasmid for rAAV production encoding the 
adenoviral genes required for the generation of rAAV particles. This plasmid was 
initially obtained from Dr. Jim Wilson (University of Pennsylvania, USA) and 
provided by Prof. George Dickson (Royal Holloway, University of London, UK). 
ü pscAAVCageGFP: self complementary AAV (scAAV) transfer plasmid with the 
expression cassette contained between two AAV2 inverted terminal repeats. The 
original pscAAVCag backbone (Yue & Dongsheng 2002) was used to generate the 
pscAAVCageGFP encoding the green fluorescent protein (eGFP) kindly provided by 
Dr George Dickson (Royal Holloway, University of London, UK). The eGFP in this 
plasmid is driven by a short version of ubiquitous cytomegalovirus enhancer/ chicken 
beta actin promoter (CAG promoter). 
ü pscAAVCaghSMN1F: scAAV plasmid generated through the insertion of a flag-
tagged version of the human Survival Motor Neuron 1 (hSMN1) cDNA  in the  
pscAAVCageGFP backbone, replacing eGFP. 
ü pscAAVCaghSMN1NoF: scAAV plasmid generated through the insertion of the 
hSMN1 cDNA  in the  pscAAVCageGFP backbone, replacing eGFP. 
ü pCCLsc_HB9_eGFP_W: third generation recombinant lentiviral (rLV) transfer 
plasmid encoding the green fluorescent protein (eGFP) under the control of a short 
version of the motor neuron-specific HB9 promoter. This plasmid is a kind gift from 
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Fred Gage’s laboratory (Salk Institute, USA). 
ü pCCLsc_HB9_RFP_W: third generation rLV transfer plasmid encoding the red 
fluorescent protein (RFP) under the control of a short version of the motor neuron-
specific HB9 promoter. This plasmid is a kind gift from Fred Gage’s laboratory (Salk 
Institute, USA). 
ü pRRLsc_C_mSmn_eIeGFP_W: third generation rLV transfer plasmid encoding the 
mouse Smn cDNA linked to an IRES eGFP under the control of the cytomegalovirus 
promoter (CMV). The plasmid was made by Dr. Sherif Ahmed in Dr Yáñez’s 
laboratory. 
ü pMDLg/pRREintD64V: Packaging plasmid for rLV production  encoding the group 
specific antigen (GAG), polymerase (POL) and integrase (IN) genes. This plasmid 
was a kind gift from Luigi Naldini’s laboratory (San Raffaele Telethon Institute for 
Gene Therapy, Italy). 
ü pRSV-REV: Rev plasmid for rLV production  encoding the Rev protein which is 
necessary for the nucleic acid transfer from the nucleus to the cytosol. This plasmid 
was a kind gift from Luigi Naldini’s laboratory  
ü pMD2.VSV-G: Envelope plasmid for rLV production encoding the glycoprotein 
from the vesicular stomatitis virus (VSV-G). Virus pseudo-typed with this envelope 
can infect both mammalian and non-mammalian cells. This plasmid was a kind gift 
from Luigi Naldini’s laboratory. 
2.1.4 DNA/RNA/PROTEIN SIZE MARKERS AND MODIFYING AND 
RESTRICTIONS ENZYMES  
All restriction enzymes were used following manufacturer’s recommendations. The type of 
DNA molecular weight marker used depended on the percentage of the gel and the size of 
the fragments to be analysed 
ü Antarctic Phosphatase (NEB, Cat. No. M0289S) 
ü AscI (NEB, Cat. No. R0558S) 
ü ClaI (NEB, Cat. No. R0197S)  
ü DdeI (NEB, Cat No. R0175L) 
ü FastDigest® AgeI (BshTI) (Fermentas, Cat. No FD1464) 
ü FastDigest® BglII (Fermentas, Cat. No FD0083) 
ü FastDigest® SbfI (SdaI) (Fermentas, Cat. No FD1194) 
ü FastDigest® SmaI (Fermentas, Cat. No FD0663) 
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ü GeneRuler™ 100bp Plus DNA Ladder (Fermentas, Cat. No SM0321) 
ü GeneRuler™ 1kb DNA Ladder (Fermentas, Cat. No SM0311) 
ü GeneRuler™ 1kb Plus DNA Ladder (Fermentas, Cat. No SM1331) 
ü GoTaq® Flexi DNA Polymerase (Promega, Cat. No. M8305) 
ü Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV, Promega, cat 
M1701) 
ü Oligo(dT) 15 primer (Promega, Cat No. C1101) 
ü Prestained Protein Molecular Weight Marker (Fermentas, Cat. No SM0441) 
ü PvuII (NEB Cat. No. R0151T) 
ü Recombinant RNasin Ribonuclease inhibitor (Promega, Cat. No. N2611) 
ü RiboRuler™ High Range RNA Ladder (Fermentas, Cat. No #SM1823) 
ü RQ1 RNase-Free DNase (Promega, Cat No. M6101) 
ü T4 ligase (NEB, Cat. No. M0202S) 
ü XbaI (Promega, Cat. No. R6181)  
 2.1.5 BIOLOGICAL KITS AND SYSTEMS  
ü Amersham ECL Direct Nucleic Acid Labelling And Detection Systems kit (GE 
Healthcare, Cat No. RPN3000). 
ü DC protein Assay (Biorad, Cat No 500-0116) 
ü DNeasy Blood & Tissue Kit  (Qiagen, Cat. No. 69506) 
ü EndoFree Plasmid Giga Kit (Qiagen, Cat. No. 12391). 
ü EndoFree Plasmid Maxi Kit (Qiagen, Cat. No. 12362). 
ü EndoFree Plasmid Mega Kit (Qiagen, Cat. No. 12381). 
ü MycoAlert Mycoplasma Detection Kit (Lonza, Cat. No. LT07-218) 
ü Periodic Acid-Schiff (PAS) staining system (Sigma-Aldrich, Cat. No. 395B). 
ü Powerplex 1.2 system (Promega, Cat, No DC6101) 
ü QIAprep Spin Miniprep Kit  (Qiagen, Cat. No. 27104).  
ü QIAquick Gel Extraction Kit  (Qiagen, Cat. No. 28704).  
ü QIAquick Nucleotide Removal Kit instead (Qiagen Cat. No. 28304).   
ü QIAquick PCR purification Kit  (Qiagen, Cat. No. 28104) 
ü Wizard SV genomic DNA purification system (Promega, Cat No. A2361). 
2.1.6 PRIMERS  
A list of all primers used in this study is shown in Appendix 2. The list includes size of the 
amplicons, sequences of the primers (where available), specific use (cloning, sequencing, 
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viral titre determination, iPSCs’ quality control, follow up of transcripts in cells during MN 
differentiation and detection of SMN isoforms) and original reference. Appendix 3 
presents the quality control of the primers used for quantitative polymerase chain reaction 
(qPCR) and quantitative reverse transcription PCR (qRT-PCR). 
2.1.7 ANTIBODIES 
 Antibodies used for immunoblotting, flow cytometry assays/analyses and 
immunofluorescence are shown in tables 2.1, 2.2 and 2.3 respectively. 
 
Table 2. 1: Antibodies for immunoblotting assays. 
 
 
 
 
 
Table 2. 2: Antibodies for flow cytometry analysis. 
 
*Dilutions shown correspond to the labelling of 5x105 cells. All flow cytometry antibodies are already 
conjugated to a reporter fluorescent dye. 
 
 
Antibody (primaries) Company
Catalogue 
number Dilution
Mouse anti-survival motor neuron (SMN)
BD 
Biosciences 610646 1 in 5000
Mouse anti FLAG M2 Stratagene 299472 1 in 1000
Rabbit Anti-T Plastin antibody ABCAM AB128690 1 in 1000 
Rabbit anti-Alpha tubulin ABCAM AB4074 1 in 2000
Mouse anti-Actin DSHB
JLA20. 
Supernatan
t 1 in 100
Mouse anti- Glucose phosphate isomerase 
(GPI1) DSHB
CPTC-GPI-
1. 
Supernatan
t 1 in 100
Antibody (secondaries) Company
Catalogue 
number Dilution
IRDye 800CW goat anti-mouse LI-COR 92632210 1 in 2000
Goat anti-Rabbit alexa flour 680 
Molecular 
Probes A21076 1 in 5000
Antibody Company
Catalogue 
number Dilution Target Cell
Alexa Fluor® 647 anti-human SSEA-3 BioLegend 330308 0.125 µg
iPSCs and 
EP212
Alexa Fluor® 647 Rat IgM, ! Isotype Ctrl BioLegend 400813 0.125 µg
iPSCs and 
EP212
PE anti-human TRA-1-81 BioLegend 330708 0.125 µg
iPSCs and 
EP212
PE Mouse IgM, ! Isotype Ctrl BioLegend 401609 0.125 µg
iPSCs and 
EP212
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Table 2. 3: Antibodies for immunofluorescence assays  
 
 
 
Antibody (primaries) Company
Catalogue 
number Dilution Target Cell
Mouse anti-OCT4 Chemicon MAB4401 1 in 500 iPSCs
Mouse anti-TRA-1-60 Chemicon MAB4360 1 in 500 iPSCs
Rabbit anti-SOX2 Chemicon AB5603 1 in 500 iPSCs
Mouse anti NANOG Abcam AB62734 1 in 100 iPSCs
Mouse anti-Neuronal class III beta tubulin 
(TUJ1) Eurogentec mms-435p 1 in 200 EBs
Rabbit anti-PAX6 Eurogentec prb-278p 1 in 500 EBs
Mouse anti-Smooth muscle actin (SMA) DAKO M0851 1 in 100 EBs
Rabbit anti-Desmin Abcam AB15200 1 in 200 EBs
Rabbit anti-Brachyury Santa Cruz sc-20109 1 in 100 EBs
Rabbit anti-Alpha Fetoprotein
Molecular 
Probes 18-0055 1 in 100 EBs
Goat anti-SOX17 R&D systems AF1924 1 in 100 EBs
Goat  anti-SOX1
R&D  
systems AF3369 1 in 500 
Neural 
Rosettes
Mouse anti-PAX6 DSHB Supernatant 1 in 500
Neural 
Rosettes
Goat anti-OLIG2 Santa Cruz  sc-19969 1 in 50
MN 
progenitors
Goat anti- ISL1 R&D systems AF1837 1 in 50 MNs
Goat anti-Choline acetyltransferase (ChAT) Chemicon AB144P 1 in 50 MNs
Mouse anti-Nerve-growth factor receptor 
p75 (P75-NGFR)
Michael 
Sentners' lab  - 1 in 100  MNs
Rabbit  Anti-Neuronal class III beta tubulin 
(TUJ1) Sigma T 2200 1 in 3000 Neurons
!-Bungarotoxin, Alexa Fluor® 555 
Conjugate
Molecular 
Probes B35451 1 in 500 Muscle
Rabbit anti-Glial Fibrillary Acidic Protein 
(GFAP) DAKO Z0334 1 in 3000 Astrocytes
Mouse Anti-alpha 1 Fetoprotein Abcam AB3969 1 in 200 Hepatocytes
Antibody (secondaries) Company
Catalogue 
number Dilution
Alexa Fluor 568 donkey anti - mouse IgG
Molecular 
probes A10037 1 in 1000
Alexa Fluor® 488 donkey anti-mouse IgG 
(H+L)
Molecular 
probes A21202 1 in 1000
Alexa Fluor® 488 donkey anti-goat IgG 
(H+L)
Molecular 
probes A-11055 1 in 1000
Alexa Fluor® 546 donkey anti-goat IgG 
(H+L)
Molecular 
probes A11056 1 in 1000
Alexa Fluor® 555 goat anti-rabbit IgG 
(H+L)
Molecular 
probes A21428 1 in 1000
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L)
Molecular 
probes A-11034 1 in 1000
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2.1.8 CELLS  
Information about the initial provider (manufacturer’s company and catalogue number) is 
not available for all cells. Continuous cell lines have been stored and maintained in my 
laboratory for several years in a common stock in liquid nitrogen identified with their 
passage number. When more information is available, this is stated next to the particular 
cell type. 
2.1.8.1 BACTERIA 
ü TOP 10 E. coli: E. coli strain genetically modified for high-efficiency cloning and 
plasmid propagation (Invitrogen).  
Genotype: F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara 
leu) 7697 galU galK rpsL (StrR) endA1 nupG 
2.1.8.2 CELL LINES 
ü HEK293T: variant of the human embryonic kidney 293 cell line containing a 
temperature-sensitive SV40 Large T-antigen. 
ü HeLa: human cell line derived from cervical cancer.  
ü HT1080: human cell line derived from a fibrosarcoma. 
ü C2C12: mouse myoblast cell line derived from C3H mice (ATCC, CRL-1772). 
ü Platinum retroviral packaging cell line E (PlatE): human cell line based on the 
HEK293Ts which also containing GAG, POL and ENV genes for easier retroviral 
production (Cell Biolabs). 
ü BJ1: telomerase-immortalised human BJ1 cell line derived from a skin biopsy 
(Clontech, Cat. No. C4001-1) and genetically modified in the Institute for Stem cell 
Therapy and Exploration of Monogenic diseases (I-STEM. Evry, France) for stable 
production of Fibroblast growth factor (FGF) 2 (Clone HF8).  
ü EP2102: human embryonic carcinoma cell line derived from a primary testicular 
teratocarcinoma. This cell line is used as a reference standard of pluripotency 
(Andrews et al., 1982).  
2.1.8.3 PRIMARY CELLS 
ü IMR90: human fibroblasts harvested from the lung of a healthy human female at 16 
weeks of gestation  (ATCC, Cat No. CCL-186). 
ü 4603 fibroblasts: human fibroblast harvested from the skin of a healthy adult human 
 67 
male (Coriell, Cat. No. GM04603). 
ü SMA1 and SMA2 fibroblasts: human fibroblast harvested in Santa Creu i Sant Pau 
Hospital (Barcelona) from skin biopsies of patients with SMA type 1 and type 2 
respectively. Cells were obtained with informed consent by our collaborator Dr 
Eduardo Tizzano. 
ü AC, TC, CC, RC and NC fibroblasts: human fibroblasts harvested in Santa Creu i 
Sant Pau Hospital (Barcelona) from skin biopsies of members of the SMA family 
of study. Cells were obtained with informed consent by our collaborator Dr 
Eduardo Tizzano. Samples are coded as follows: 
*RC: healthy mother of the family carrying a mutation in exon 3 
(c.399_402delAGAG) of the SMN1 gene in heterozygosis.  
*AC: SMA IV/asymptomatic sibling carrying a mutation in exon 3 
(c.399_402delAGAG) of the SMN1 gene in homozygosis.  
*CC, TC and NC: siblings with SMA type III, all carrying a mutation in exon 3 
(c.399_402delAGAG) of the SMN1 gene in homozygosis.  
A more detailed description of the family members can be found in Chapter 4. 
2.1.8.4 PLURIPOTENT CELLS 
ü iPSC clones derived from the family of study: derived  by myself in I-STEM from 
fibroblasts RC, AC, TC, and NC of the family of study. Several clones were derived 
from each family member, except for RC. Please refer to Appendix 4. 
ü 4603: iPSC clone derived in I-STEM from 4603 fibroblasts in the same way as the 
clones derived in this study. 
ü SMA-19: iPSC clone SMA-19 derived in Beckman Research Institute (California, 
USA) from human primary fibroblasts from a type I SMA patient (Coriell, Cat. No. 
GM09677) and published in Chang et al., 2011. 
ü hESC H9: embryo-derived pluripotent cells generated from embryos discarded from 
an in vitro fertilization donation in the University of Wisconsin (USA) and published 
in Thomson et al., 1998. 
 2.1.9 MEDIA 
All media were prepared under sterile conditions in a class II biosafety cabinet. Solutions 
containing supplements that had to be weighted or that came in non-sterile conditions were 
filtered with a 0.22 µm pore filter prior to use. All mammalian media were pre-warmed in a 
 68 
37 °C water bath prior to use. All basal media, supplements and pre-made media are listed 
in Appendix 1 under “Special reagents and media components”. 
     2.1.9.1 BACTERIAL MEDIA 
All bacterial media were prepared in ddH20 and sterilized by autoclaving at 120 °C for 20 
min. After sterilization part of the medium was supplemented with 100 µg/ml of ampicillin 
and kept at 4°C for up to 1 month. 
ü Luria Broth (LB) liquid medium: 2% Luria broth.  
ü LB agar medium: 2% Luria broth, 1.5% bacteriological agar. To prepare LB agar 
plates, the medium was heated until it became liquid and approximately 20 ml were 
poured onto 100 mm bacterial Petri dishes in a bacterial safety cabinet. If needed, 
antibiotics were added before pouring the plates, when the medium was 
approximately at 55 °C.  
2.1.9.2 MEDIA FOR EUKARYOTIC CELL LINES 
ü Standard growth medium: Dulbecco's modiﬁed Eagle's medium (DMEM) high 
glucose (4.5 g/L) with stable glutamine supplemented with 10% Foetal bovine serum 
(FBS), 100 U/ml Penicillin and 100 µg/ml Streptomycin (Pen&Strep).  
ü Standard freezing medium: 40% DMEM high glucose (4.5 g/L) with stable 
glutamine, 50% FBS and 10% DMSO. 
ü Standard growth medium high serum: DMEM high glucose (4.5 g/L) with stable 
glutamine supplemented with 20% FBS and Pen&Strep.  
ü Plat medium: DMEM high glucose (4.5 g/L) with glutamax supplemented with 10% 
FBS, 1 mM sodium pyruvate, 50 µM β- mercaptoethanol and 1 µg/ml gentamicine.  
ü C2C12 differentiation medium: DMEM high glucose with stable glutamine 
supplemented with 2% horse serum, and 1 µg/ml gentamicine. 
2.1.9.3 MEDIA FOR PRIMARY CELLS 
ü Primary human fibroblast medium: 64.8% DMEM high glucose with stable 
glutamine, 21% M-199, 10% FBS, 10 ng/ml FGF2, 25 ng/ml Epidermal growth factor 
(EGF), 1 µg/ml gentamicine. 
2.1.9.4 MEDIA FOR iPSCS AND iPSC-DERIVED CELLS 
All iPSC-related media were aliquoted into volumes used for one day of work and only this 
aliquot was pre-warmed. 
 69 
ü Reprogramming Fibroblast medium: DMEM high glucose (4.5 g/L) with glutamax 
supplemented with 10% FBS, 1 mM sodium pyruvate, 1X Minimum Essential Media 
(MEM) non essential amino acids, 1mM L-Ascorbic acid 2-phosphate, 10 ng/ml 
Recombinant Human FGF2 and 1 µg/ml gentamicine.  
ü hESC medium: Knockout DMEM supplemented with 20% Knockout serum 
replacement, 1X MEM non essential amino acids, 2mM Glutamax, 10 ng/ml 
recombinant Human FGF2, 50 µM β- mercaptoethanol and 1 µg/ml gentamicine.   
ü Stemedia™ NutriStem™ XF/FF Culture Medium (premade), supplemented with 1 
µg/ml gentamicine. 
ü Feeder medium: MEM Alpha Modification Liquid with Ribonucleosides L-glutamine 
supplemented with 10% FBS, 1X MEM non-essential amino acids and 1 µg/ml 
gentamicine. 
ü Feeder freezing medium: 90% FBS, 10% Dimethyl sulfoxide.  
ü Vitrolife freezing medium A: Vitro PBS supplemented with 10% DMSO and 10% 
Ethylene Glycol. 
ü Vitrolife freezing medium B: Vitro PBS supplemented with 20% DMSO, 20% 
Ethylene Glycol, 0.3 M trehalosa and 10 µM of Rock inhibitor.  
ü CryoStem™ Freezing Medium (pre-made) 
ü Vitrolife thawing medium A: 0.1 M trehalosa in Vitro PBS.  
ü Vitrolife thawing medium B: 0.2 M trehalosa in Vitro PBS.  
ü Neural differentiation medium: DMEM Nutrient mix F12 supplemented with 1X N2, 
1X MEM non essential amino acids, 2 µg/ml heparin and 1 µg/ml gentamicine.  
ü MN differentiation medium 1528: DMEM Nutrient mix F12 supplemented with 1X 
N2, 1X B27, 1X MEM non essential amino acids, 2 µg/ml heparin, 0.1 µM retinoic 
acid, 1 µM pumorphamine and 1 µg/ml gentamicine. 
ü Complete MN differentiation medium: DMEM Nutrient mix F12 supplemented with 
1X N2, 1X B27, 1X MEM non essential amino acids, 2 µg/ml heparin, 50 nM 
retinoic acid, 0.5 µM pumorphamine, 0.1 µM cyclic adenosine monophosphate 
(cAMP), 200 ng/ml ascorbic acid, 10 ng/ml Brain-derived neurotrophic factor 
(BDNF), 10 ng/ml Glial cell-derived neurotrophic factor (GDNF) and 10 ng/ml 
Insulin-like growth factor 1 (IGF-1) and 1 µg/ml gentamicine. 
ü Hepatocyte differentiation medium 1-3: RPMI 1640 medium supplemented with 0.5 
mg/ml BSA, 100 ng/ml Activin A and 1 µg/ml gentamicine. 
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ü Hepatocyte differentiation medium 4-7: complete Hepatocyte Culture Medium 
(HCM) further supplemented with 30 ng/ml FGF4, 20 ng/ml Bone morphogenetic 
protein 2 (BMP2) and 1 µg/ml gentamicine. 
ü Hepatocyte differentiation medium 8-13: complete HCM further supplemented with 
20 ng/ml HGF, 20 ng/ml Keratinocyte growth factor (KGF) and 1 µg/ml gentamicine. 
ü Hepatocyte differentiation medium 14-18: complete HCM further supplemented with 
10 ng/ml oncostatin-M, 0.1 µM dexamethasone and 1 µg/ml gentamicine. 
ü Hepatocyte differentiation medium 19-21: DMEM high glucose with stable 
glutamine supplemented with 1X N2, 1X B27, 1 mM glutamax, 1X MEM non 
essential amino acids, 0.1 mM β-mercaptoethanol and 1 µg/ml gentamicine. 
2.1.10 PLASTICWARE AND CULTURE SURFACES  
All plasticware used in this work, including standard and special tissue culture tubes, 
dishes, flasks, plates, coverslips, centrifuge tubes, filter devices and other general 
plasticware, are listed in Appendix 5. 
2.1.11 INSTRUMENTS AND SOFTWARE  
All the instruments and software used for the methods employed in this work are shown in 
the list “Instruments and Software” in Appendix 6. Instruments and software used in 
methods performed by our collaborators are not included on this list. 
 2.2 MOLECULAR METHODS 
 2.2.1 CLONING 
2.2.1.1 DETERMINATION OF NUCLEIC ACID CONCENTRATION 
All quantifications were performed at 260 nm with 1 µl of undiluted nucleic acid in a 
NanoDrop™ 1000 Spectrophotometer using settings DNA-50 for DNA and settings RNA-
40 for RNA. The purity of the sample was also assessed with the ratio of the readings at 
260/280 nm. 
2.2.1.2 RESTRICTION ANALYSIS   
All enzyme digestions in this study were performed at 37 °C for 30 min (for fast Digest 
Fermentas enzymes) or 1-3 hours (for New England Biolabs enzymes) using 0.4-10 µg of 
plasmid DNA, 2.5-5 U of the restriction enzyme/s and 1X of the corresponding buffer in a 
final volume of 20 µl. All enzymes were used with their respective most efficient buffer. 
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The units of enzyme used in each reaction were adjusted according to the number of target 
sites within the plasmids. A list of the restriction enzymes used is shown in section 2.1.4 
2.2.1.3 GEL ELECTROPHORESIS 
Plasmid DNA and PCR products were visualized in 0.8-3% agarose gels using 1X TAE 
buffer and ethidium bromide at a final concentration of 0.5 µg/ul, both in the gel and in the 
running buffer. 300 ng of 100 bp and 1kb molecular weight ladders were used as reference 
and each sample was loaded in 1X loading buffer. All the runs were performed in a 
Flowgen Bioscience chamber and an Electrophoresis Power Pac Basic power source at 50 
V.  The visualization and recording of the images of the gels were done in an InGenius gel 
documentation and analysis system, using GeneFlash syngene Bio Imaging software. 
2.2.1.4 CLONING IN PLASMID VECTORS 
Cloning methods are broad, but they all include (i) generation of a fragment containing the 
desired sequence (insert), (ii) treatment of both, the plasmid containing the backbone of 
interest and the insert with suitable restriction enzymes that allow their union, (iii) ligation 
of backbone and insert, (iv) transformation (v), screening of transformants, (vi) sequencing, 
(vii) amplification and storage of the new construct. 
All inserts generated in this study were produced by PCR amplification 
2.2.1.4.1 PCR amplification 
Specific fragments of ~70-1000 bp, such as the ones of interest in the current work, can be 
amplified from a DNA source by the use of primers located at the beginning and the end of 
the target sequence. A list of the primers used in this study can be found in  Appendix 2.  
PCRs were performed in a PCR gradient Thermal cycler TC-512 under the following 
general conditions:  0.3-0.6 µM of each primer, 1-3 mM MgCl2, 200 µM deoxynucleotide 
triphosphates (dNTPs), 0.25U GoTaq® Flexi DNA Polymerase in its 1X Green GoTaq 
Flexibuffer and 1-100 ng of template in a final volume of 25-50 µl. The cycling conditions 
were variable, but they all included an initial denaturation cycle at 95 °C for 5 min, and at 
least 30 cycles of denaturation/anneling/extension with a final extension at 72 °C for 5 min. 
PCR amplification was assessed by running 5-10 µl of the product in an agarose gel. All 
PCR products were kept at -20 °C 
2.2.1.4.2 Digestion, isolation of bands and ligation 
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As summarized before, both, the insert (all the volume of the PCR product left after 
assessing the amplification) and 10 µg of the plasmid, were digested with suitable 
restriction enzymes as described previously, but scaling up the amount of enzyme (usually 
4 times) and performing the digestion in the smallest volume possible. The resulting 
products were run in agarose gels and the bands with the expected molecular weight were 
excised with a scalpel in a UV transiluminator Gel doc 2000. The bands were then purified 
with the QIAquick Gel Extraction Kit following manufacturer’s instructions. The purified 
digested plasmid vector was incubated with 5 U of Antarctic Phosphatase for 30 min at 37 
°C/5 min 65 °C to prevent re-ligation. 
Both purified fragments were then ligated in a 3:1 insert/backbone ratio using 100 ng of the 
vector, the respective amount of purified fragment and 400 U of T4 DNA ligase in its 1X 
ligase buffer in a final volume of 10 µl. The reaction was incubated overnight at 
approximately 18 °C, time after which the DNA was transformed into E. coli TOP10 cells. 
2.2.1.4.3 Transformation in E. Coli TOP 10 
In order to finalize the ligation process and to amplify the new molecules, the ligation 
product was transformed into an E. coli strain genetically modified for high-efficiency 
cloning and plasmid propagation. The transformation process includes the conditioning of 
E. Coli TOP 10 for DNA uptake (preparation of competent cells) and the DNA transfer. 
The calcium chloride method was the chosen transformation strategy. Bacteria and their 
media were always handled and kept under sterile conditions. 
2.2.1.4.4.1 Preparation of competent cells  
E. coli TOP 10 was grown in a fresh LB plate and a single colony was inoculated in 5 ml of 
LB medium and grown overnight at 37 °C, 180 revolutions per minute (RPM) in a bacterial 
incubator/shaker. This preparation is referred as mini-culture. The next day the 5 ml mini-
culture was added to 100 ml of LB medium and grown at 37 °C, 180 RPM for 1.5-2 hours 
until cells reached an OD550 of 0.5. The optical density measurements were performed in a 
Biophotometer 613101139. Cells were then chilled on ice-water for 5 min, centrifuged, re-
suspended in 40 ml of competent cells-Buffer 1, incubated on ice-water for 10 min, 
centrifuged, re-suspended in 4 ml of competent cells-Buffer 2, incubated on ice-water for 
15 min, aliquoted in 100 ul aliquots, flash-frozen in liquid nitrogen and stored at -80 °C. 
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2.2.1.4.4.2 DNA transfer 
The calcium chloride method for DNA transfer has been modified since it was first 
discovered in the 1970s. The exact protocol used in this study is briefly described as 
follows: the entire ligation product (or 100 ng of plasmid DNA) was added to a 100 µl 
aliquot of competent cells, the solution was gently mixed, kept on ice for 30 min, placed in 
a 42 °C water bath for 45 seconds (s) (heat shock step) and then placed back in ice again for 
10 more min. The transformed cells were then maintained in 1 ml of LB medium at 37 °C 
180 RPM for 1 hour, and were finally seeded in LB/ampicilin plates for an overnight 
incubation at 37 °C. A standard plasmid and pure LB medium were also transformed in 
separate aliquots of the same competent cells as positive and negative controls of the 
transformation respectively. 
2.2.1.3.4 Screening of transformants 
The day after transformation, several colonies were selected from the plates and each one 
was used to set up a 4 ml mini-culture in LB/ampicillin medium. After an overnight 
incubation of no more than 16 hours at 37 °C 180 RPM, 1 ml of the mini-culture was used 
to extract the plasmid DNA using the QIAprep Spin Miniprep kit following manufacturer’s 
instructions. Plasmids were subjected to diagnostic restriction analysis to confirm the 
correct insertion of the new sequence. Three to five clones with the right restriction pattern 
were sent for sequencing and the results were analysed using the software Vector NTI. 
2.2.1.3.5 Storage of bacteria 
Once the sequence of the plasmid in the selected clone was validated, a glycerol stock was 
made from its mini-cultures. For this, 500 µl of the miniculture was mixed with sterile 
glycerol at a final concentration of 15% in a cryovial and stored at -80 °C. The map of the 
plasmid with its key features and available sequences was constructed and analysed with 
the software Vector NTI. The files were incorporated in the Laboratory database.     
2.2.1.5 AMPLIFICATION OF ENDOTOXIN FREE PLASMID DNA  
For high, endotoxin free yields of plasmid DNA (up to 2.5 mg), a bacterial streak was 
prepared in a fresh LB/ampicilin agar plate from the glycerol stock. A mini-culture was set 
up the next day from a selected colony, and 16 hours later 1 ml of the mini-culture was 
added to 500 ml of LB/ampicilin in a 1l flask in order to set up a so called “mega-culture”. 
After an overnight incubation of no more than 16 hours at 37 °C 180 RPM, the whole 
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mega-culture was used to extract the plasmid DNA with the Qiagen EndoFree Plasmid 
Mega Kit following manufacturer’s instructions.  
2.2.2 RT-PCR  
2.2.2.1 RNA ISOLATION, QUANTIFICATION AND QUALITY CONTROL  
RNA was extracted with TRIZOL® Reagent from freshly harvested cells or from cells 
stored frozen at -80 °C immediately after the harvest, following manufacturer’s 
instructions.  RNA yield and purity were measured in a NanoDrop 1000 Spectrophotometer 
and in some cases also by running 0.5 µg in an agarose gel under denaturing conditions. For 
this, samples were run using the same procedures used for DNA, but (i) formaldehyde was 
added to the gel and the running buffer at a final concentration of 0.25 M (ii) a RNA ladder 
was used and (iii) samples were mixed with RNA loading buffer, incubated 5 min at 65 C 
and chilled on ice before loading them in the gels. (Please refer to the list of buffers and 
markers in sections 2.1.2.6 and 2.1.4 for more details). RNA samples were stored at -80 °C.  
2.2.2.2 REVERSE TRANSCRIPTION 
Before cDNA synthesis, 1 µg of RNA was subjected to DNase treatment with 1U of RQ1 
RNase-free DNase for 30 min at 37 °C. The reaction was stopped by adding 1 µl of RQ1 
DNase stop solution and incubating at 65°C for 10 min. 0.5 µg of Oligo(dT) 15 primer was 
added to the RNA and the mix was incubated at 70°C for 5 min, time after which it was 
immediately cooled on ice to prevent secondary structures. The RNA was then retro-
transcribed to cDNA using 200 U of Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV), 0.5 mM dNTPs, 20 U of recombinant RNasin ribonuclease 
inhibitor, and 1X of M-MLV Reaction buffer. The reaction was performed at 37°C for 60 
min and the enzyme was inactivated by incubation at 95°C for 5 min. cDNAs were kept at -
20 °C. 
2.2.2.3 RT-PCR 
RT-PCR was performed similarly to PCR, but using RNA as template instead of DNA. For 
transgene amplification during iPSC quality control, the following specific conditions were 
used 0.4 µM of each primer, 1.5 mM MgCl2, 200 µM dNTPs, 0.25U GoTaq Flexi DNA 
Polymerase in its 1X Green GoTaq Flexibuffer and 2 µl of a 1 in 10 dilution of the cDNA 
(200 ng) in a final volume of 25 µl. The cycling conditions were 95 °C for 5 min, 35 cycles 
of 95 °C for 60 s/ 60 °C for 30 s/ 72 °C for 30 s and a final extension at 72 °C for 5 min. 
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RT-PCR amplification was assessed by running 5 µl of the product in an agarose gel. All 
RT-PCR products were kept at -20 °C. 
2.2.2.3.1 Determination of the origin of FL-SMN 
An RT-PCR amplifying the junction between exons 6 and 8 followed by a restriction 
analysis with DdeI was performed in order to determine the allelic origin of the FL-SMN 
mRNAs. During the RT-PCR amplification, internal control primers for the beta actin gene 
were included in the cocktail as followes: 0.4 µM of each of the exons 6-8 primers, 0.08 
µM of each of the beta actin primers, 1 mM MgCl2, 200 µM dNTPs, 0.25U GoTaq Flexi 
DNA Polymerase in its 1X Green GoTaq Flexibuffer and 2 µl of a 1 in 5 dilution of the 
cDNA (200 ng) in a final volume of 25 µl. The cycling conditions were 95 °C for 10 min, 
30 cycles of 94 °C for 30 s/ 60 °C for 30 s/ 72 °C for 45 s and a final extension at 72 °C for 
5 min. RT-PCR amplification was assessed by running 5 µl of the product in an agarose 
gel. For the DdeI restriction analysis, RT-PCR products were digested for at least 4 hours 
before loading them in an agarose gel. 
2.2.3 q RT-PCR and qPCR 
2.2.3.1 VALIDATION OF PRIMERS 
All primers used for qRT-PCR and qPCR were validated (i) in silico for specificity,  (ii) in 
agarose gels by the amplification of a single band of the expected size and (iii) by a qRT-
PCR/qPCR run of serial dilutions of a control sample, for assessment of the amplification 
efficiency and the minimum linear dilution. A summary table of the quality control of the 
primers used is shown in Appendix 3.  
Two methods of qRT-PCR were used: the delta-delta cycle threshold (ddCt) method and 
the semi-quantitative method. Each of them required a specific validation procedure. 
2.2.3.1.1 ddCT method 
For the ddCT method, the target gene was validated with each of the reference genes used 
for the normalization step in order to confirm that they behaved in the same way and thus, a 
standard curve was not required. For the validation, serial dilutions of the cDNA of a 
control sample were amplified by qRT-PCR with the primers for each combination of 
target-reference genes. All individual genes had an amplification efficiency of 100% ± 
10%, their slope was 3.3 ± 10% and the slope of the difference between the CTs of the 
target and the reference gene was less than 0.1. 
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2.2.3.1.2 Semi-quantitative method  
For the semi-quantitative method, ten-fold serial dilutions of a plasmid containing the target 
sequence or a solution containing a known number of target sequences were amplified by 
qPCR with the corresponding primers. All dilutions (standards) out of the linear range of 
amplification were discarded and the ones within it were used for the construction of a 
standard curve in the corresponding reactions. The number of copies of the target sequence 
in the plasmids was determined based on their molecular weight. Table 2.4 contains an 
example of the calculations of the first standard (1010 molecules) for the target sequence of 
the Poly A primers used to assess the rAAV titre by qPCR: 
 
Table 2. 4: Calculations of the standards for the relative quantification of srAAVs through qRT-PCR. 
Calculations are based on the molecular weight of the plasmid pscAAVCaghSMN1F 
 
Parameter  pscAAVCAGhSMN1F 
Base pairs 4868 
Molecular weight in Daltons (1 bp=650 Da) 3.16 x 106 
Moles  for 1010 molecules (1 mol=6.023x 1023) 1.66 x 10-14 
Weight for 1010 molecules (g) 5.25 x 10-8 
Weight for 1010 molecules (ng) 52.54 
 
2.2.3.2 ENDOGENOUS STABILITY TEST  
In order to determine the most appropriate reference genes for each particular study, a 
stability test was performed using the freely available geNorm VBA applet for Microsoft 
Excel. For this, a sample from all cell types included in the qRT-PCR analysis was 
amplified in triplicate with the primers of all proposed reference genes. The reference genes 
with lower variability of expression between cell types were chosen and used for 
normalization during the corresponding experiments.  
2.2.3.3 mRNA LEVEL AND COPY NUMBER ESTIMATIONS 
2.2.3.3.1 mRNA levels (ddCt method)  
The ddCt method was used for the study of the down-regulation of transgenes in iPSCs and 
for the follow up of SMN and plastin 3 levels during iPSC-MN differentiation. In all cases, 
samples were run in triplicate for all target genes and the validated reference genes (as well 
as negative controls for each reaction). The geometric mean of the most stable reference 
genes chosen was used for normalization. One sample was chosen as the calibrator, setting 
its value arbitrarily to one and comparing all other samples to it. 
All mRNA levels were calculated with the following formula: 
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Gene expression= [2^-(sample x target gene CT- normalizing sample target gene CT)]/[2^-
(sample x geometric mean of reference genes CT- normalizing sample geometric mean of 
reference genes CT)] 
* CT= cycle threshold 
2.2.3.3.1.1 Transgene down-regulation in iPSCs 
qRT-PCR was performed in order to measure and compare the endogenous expression and 
total expression (which includes exogenous and endogenous expression) of OCT4, SOX2, 
KLF4 and c-MYC. RNA extraction and cDNA synthesis were performed as previously 
described on colonies carefully selected from each iPSC clone, avoiding the inclusion of 
feeder cells. mRNA was amplified with primers binding to two internal sequences of the 
cDNA (for total expression) and a 3’ UTR sequence and an internal sequence of the cDNA 
(for endogenous expression) for all transcription  factors. All reactions were run in a Rotor-
Gene ™ 6000 real-time rotary analyser using the following conditions: 0.4 µM of each 
primer, 1X SensiMixPlus SYBR and 2 µl of a ten-fold dilution of cDNA in a final volume 
of 20 µl. The cycling conditions were: 1 cycle at 95˚C for 10 min and 40 cycles of 95˚C for 
15 s/ 60˚C for 30 s. A melting curve calculation was performed at the end with a 
continuous reading between 50 and 100 ˚C.   
mRNA levels of target genes were normalized to the geometric mean of the mRNA levels 
of Ribosomal protein L13a (RPL13) and ribosomal protein S18 (18S) and calibrated to the 
value of EP2102, a carcinoma cell line with embryonic stem cell-line expression profile 
(section 2.1.8.2) . BJ1, IMR90 human fibroblasts undergoing reprogramming (harvested 4 
days post transduction) and hESC H9, were included in the analysis as references. EP2102 
carcinoma cells were used as the calibrator instead of hESCs H9 because the RNA 
extraction and cDNA synthesis of the later were performed in I-STEM by different 
methods as the ones described here (specifically, the endogenous expression might be 
underestimated compared to the other samples).   
2.2.3.3.1.2 mRNA levels during MN differentiation 
All qRT-PCR reactions for the follow up of mRNA levels of full length survival motor 
neuron (FL-SMN), SMN Delta 7 isoform (D7-SMN), total SMN (FL-SMN + D7-SMN), and 
plastin3 (PLS3), along with their respective reference genes, were performed by Dr Sara 
Bernal in Santa Creu i Sant Pau Hospital (Barcelona, Spain). RNA extraction was 
performed as previously described, but cDNA synthesis was done in Barcelona from 0.5 ug 
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of RNA per sample. All reactions were run in an ABI PRISM® 7900HT Sequence 
Detection System using the following conditions: 0.45 µM of each primer, 0.25 µM of the 
probe, 1X TaqMan® Universal PCR Master Mix and 2.5 µl of a five-fold dilution of cDNA 
in a final volume of 12.5 µl. The cycling conditions were: 1 cycle at 50˚C for 2 min, 1 cycle 
at 95˚C for 10 min and 40 cycles of 95˚C for 15 s/ 60˚C for 1 minute. mRNA levels of 
target genes were normalized to the geometric mean of the mRNA levels of beta actin, 
peptidylprolyl isomerase A (PPIA) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and calibrated to various samples depending of the analysis.  
2.2.3.3.2 Copy number (semi-quantitative method) 
The semi-quantitative method was used to determine the titre of rAAVs and rH1LVs 
produced in this project. The specific determination of the titre is described in the section 
on viral vectors (2.3.5). All reactions were performed in a Rotor-Gene ™ 6000 real-time 
rotary analyser using the Rotor Gene Software 1.7.  
 2.2.4 WESTERN BLOTTING 
For the isolation of proteins, cells were harvested (using a cell scraper if necessary) and 
washed carefully with PBS before adding 100-1500 µl of ice-cold RIPA buffer containing a 
cocktail of protein inhibitors and transferring them to a microfuge tube. The cells were 
centrifuged at 13,000 rpm 4 °C for 10 min, after which the supernatant was transferred to a 
new microfuge tube and kept at -80 °C until further use. The total protein concentration 
was measured following the instructions of the DC protein Assay. From each sample 7-25 
µg of protein was loaded onto a discontinous (4% stacking, 12% separation) gel in order to 
perform a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
samples were loaded with 1X WB loading buffer (after a 10 min incubation at 95 °C) and 
the run was perform at 150 V in cold 1X WB migration buffer in a Mini-PROTEAN Tetra 
Electrophoresis System until the bromophenol blue front came out of the gel. Proteins were 
then transferred to an Amersham Hybond™ ECL™ membrane in a Mini Trans-Blot Cell at 
150 mA for 2 hours using fresh cold 1X WB transfer buffer, a cooling unit and a magnetic 
stirrer. The efficiency of transference was assessed with a fast incubation with Ponceau red 
solution. After the transfer, the membrane was incubated for 2 hours at room temperature 
(RT) with WB blocking buffer, and then overnight at 4°C with the primary antibody diluted 
in 5 ml of WB blocking buffer. The next day, the membrane was washed with TBS-T in a 
shaker four times (incubating 5 min per wash) at RT before incubating it for 2 hours at RT 
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with the secondary antibody diluted in 5 ml of WB blocking buffer. The membrane was 
then washed again four times as described previously before performing the detection and 
quantification with an Odyssey Infrared Imaging System and the corresponding application 
software V1.  If further proteins were to be detected on the membrane, the same steps were 
repeated by adding a new primary antibody without stripping. 
2.2.5 GENOTYPE ANALYSIS 
Two of our collaborators performed the genotype analysis. The analysis for clones AC28, 
RC26, TC64 and NC21 was performed by Dr. Julien Come in I-STEM and the analysis for 
clones NC32, NC42 and TC63 was performed by Dr Sara Bernal in Santa Creu i Sant Pau 
Hospital (Barcelona, Spain). 
Cell identity was verified by comparing the short tandem repeat (STR) profile at several 
loci. The profile was compared between each iPSC clone and the original fibroblast cells 
that were used for reprogramming. In France, cell identity was verified with STRs included 
in the Powerplex 1.2 system (D16S539, D7S820, D13S317, D5S818, CSF1PO, TPOX, 
TH01, vWA and Amelogenin).  In Barcelona, cell identity was verified with STRs D1S305, 
D2S443, D2S291, D19S420, D19S112, D19S562 and  INT25-2.0. 
DNA was prepared as follows: Cells from each clone were grown in a 30 mm Petri dish for 
4 days and colonies were carefully and manually picked (avoiding the inclusion of feeders) 
for DNA extraction using the Wizard SV genomic DNA purification system.  
 2.3 CELLULAR METHODS 
2.3.1 FLOW CYTOMETRY  
All flow cytometry measurements were performed in a BD FACSCanto II and data was 
collected and analysed using the BD FACSDiva™ Software. The flow rate was set to 
“low”, and the recorded count within the gated population to 10.000 events. For all 
experiments, a plot showing forward scattered light area (FSC-A) vs side scattered light 
area (SSC-A) (setup in linear scale) was used to define the target population of single, live 
cells.  
2.3.1.1 QUANTIFICATION OF CELLS EXPRESSING eGPF 
Cells endogenously expressing GFP were gently harvested by tryptinization and their 
viability was measured by trypan blue exclusion. Cell were further re-suspended in 4% 
PFA and immediately quantified in the FITC channel. A mock sample from the same cell 
type (which did not express GFP) was used as to establish the threshold. 
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2.3.1.2 QUANTIFICACION OF CELLS EXPRESSING SPECIFIC MARKERS  
In order to quantify the number of cells expressing one or more specific surface markers, 
cells were cultured, harvested gently in a small volume and labelled with primary 
antibodies already coupled with fluorescent dyes. The flow cytometer settings, including 
the calibration and thresholds were established before quantification. The experiment was 
performed in order to assess the pluripotency of the iPSC culture during iPSC quality 
control. 
2.3.1.2.1 Assessment of pluripotency in the iPSC culture 
In order to quantitatively assess pluripotency in the iPSC cultures, the number of cells co-
expressing surface markers SSEA3 and TRA 1-81 were quantified. For this purpose, cells 
from each clone were grown in 60 mm Petri dishes for 4 days, washed with PBS and gently 
detached by a 5 min incubation with Tryple at 37 ºC. Cells were harvested in 1 ml of hESC 
medium and gently pipetted up and down before passing them through a 40 uM pore size 
nylon sieve in order to get a single cell suspension. After counting the cells and assessing 
their viability by trypan blue exclusion, cells from each clone were individually centrifuged 
at 250 x g for 5 min in order to discard the supernatant and re-suspend them in cold 0.1% 
BSA in PBS at a final concentration of 1x107 cells/ml. The number of feeders was 
subtracted from the initial count (1x106) in order to have a better estimation of the number 
of iPSCs present in each plate. 5x105 cells (50 µl) were added to each flow cytometry (fc) 
tube and primary antibodies were added for a one-hour incubation. From this step on, the 
cells were kept on ice and protected from light. All the antibodies used were directly 
coupled with a fluorochrome and the specificity was assessed with isotype controls 
conjugated with the same fluorochrome. For a detailed description of antibodies and their 
dilutions, please refer to section 2.1.7. After the incubation with the antibodies, cells were 
washed with 0.1% BSA in PBS and re-suspended in 300 µl of this same buffer before 
analysis. Flow cytometry was performed on the same day. Propidium iodide (PI, 2.5 µg) 
was added just before analysing the mock tube in order to exclude the dead cells from the 
analysis. Compensation between the Fluorescein isothiocyanate (FITC), phycoerythrin (PE) 
and allophycocyanin (APC) channels was performed using EP2102 cells, stained 
individually with the previously described antibodies. Feeders were included in the 
compensation (given their stable production of GFP) so they could be excluded from the 
analysis using a gate in the FITC channel.  Fluorescence minus one test tubes (where all 
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fluorescent markers where present except one) were used to establish the threshold for each 
fluorochrome after compensation.  
2.3.2 STAININGS  
2.3.2.1  IMMUNOFLUORESCENCE (IF) 
Two different microscopes were used for immunofluorescence imaging, an inverted and a 
confocal microscope.  Most images were taken in the former. The inverted Axio 
observer.D1 had filters for the red, green and blue channels, and pictures were taken with 
Axio Vision 4.8.1 software. The Olympus LX81, confocal Fluoview FV1000 (confocal 
microscope) had four lasers for the cyan, green, red and far-red channels. Pictures were 
taken with Olympus FV10 –ASW Vs 3 software. Adobe Photoshop CS4 and image J 1.45S  
were also used for the analysis and improvement of the pictures. More detailed information 
about the microscopes can be found on the instruments list in the appendix section.  
In all IF stainings, secondary antibody negative controls were included. A cell type known 
to constitutively express the marker recognised by the primary antibody as well as a cell 
line known not to express it, were included as positive and negative controls respectively 
when available.   
2.3.2.1.1 IF of cells in tissue culture plates  
Once cells were cultured to the desired confluence, they were washed once with PBS 
before a 15 min fixation at RT with 4% PFA. Cells were then washed three times with PBS, 
permeabilised with 0.2% triton X-100 in PBS for 10 min at RT, washed again two times 
with PBS, blocked with IF blocking buffer for 1 hour at RT and incubated with the desired 
primary antibodies in IF blocking buffer overnight at 4 °C. Next day, cells were washed 
three times with PBS, incubated with the corresponding secondary antibodies in IF 
blocking buffer for one hour at RT, washed three times with PBS for 5 min, incubated with 
100 ng/ µl DAPI in PBS for 5 min and finally washed with PBS one last time.  Plates were 
kept in PBS at 4°C protected from light for up to 2 weeks.  
2.3.2.2.2 IF of cells cultured on coverslips 
Once cells were cultured to the desired confluence, they were washed once with HBSS 
before a 15 min fixation at RT with 4% PFA and two washes with TBS-T. After fixation, 
coverslips were carefully taken out of the tissue culture plate with tweezers and placed on 
top of labelled parafilm in a sealed container. Cells were then blocked with IF blocking 
buffer for 1 hour at RT and incubated with the desired primary antibodies in IF blocking 
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buffer overnight at 4 °C. Next day, cells were washed three times with TBS-T, incubated 
with the corresponding secondary antibodies in IF blocking buffer for one hour at RT, 
washed three times with TBS-T for 5 min, incubated with 100 ng/ µl DAPI in TBS for 5 
min and finally washed with TBS-T one last time.  Coverlips were then mounted on slides 
using AquaPolymount, left at RT overnight protected from light and then kept in a dark box 
at 4 °C for long term storage.  
2.3.2.2 NON FLUORESCENT STAININGS 
For visualisation of all non-fluorescent staining, a Leica DM IRB microscope was used 
along with the Leica application suite software. 
2.3.2.2.1 Alkaline phosphatase (AP) staining 
For the AP staining, cells were fixed with 95% ethanol for 10 min at RT and incubated in 
the dark at 37 °C for 5 min with the substrate SIGMAFAST™ BCIP®/NBT (5-bromo-4-
chloro-3-indolylphosphate/nitro blue tetrazolium). After a wash with PBS, cells were left to 
dry completely and were kept at RT. 
 2.3.2.2.2 Periodic Acid-Schiff (PAS) staining 
PAS staining was performed with the PAS staining system from Sigma-Aldrich following 
manufacturer’s instruction with some modifications. Briefly, Cells were fixed with 4% PFA 
for 15 min at RT, washed two times with PBS and permeabilized with 0.5% Triton X-100 
in PBS. Control cells were incubated with 1mg/ml α-Amylase for 30s-1 min at 37°C. Cells 
were then incubated with periodic acid for 5 min, washed with water 6 times, incubated 
with Schiff’s solution for 15 min, wash with water 6-10 times, incubated with hematoxylin 
for 3 min and wash with water another 6 times. Cells were kept in ddH20 at 4°C. 
2.3.2.2.3 Sudan staining  
Cells were fixed with 4% PFA for 15 min at RT, washed two times with PBS, six times 
with water, incubated with 50% ethanol for 2 min, 70% ethanol for 1 minute and Sudan 
solution for 5 min. Cells were washed twice with 70% ethanol, once with 50% ethanol and 
six times with water. Cells were kept in ddH20 at 4 °C. 
2.3.3 KARYOTYPE ANALYSIS 
Two of our collaborators performed the karyotype analysis. Multicolor fluorescent in situ 
hybridization (mFISH) and G-Banding analysis for clones AC28, RC26, TC64 and NC21 
were performed by Christine Varela in I-STEM and G-banding for clones NC32, NC42 and 
TC63 were performed in the Karyotyping service in Santa Creu i Sant Pau Hospital 
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(Barcelona, Spain). Fixed nuclei in metaphase were prepared and shipped as follows: cells 
from each clone were grown in 60 mm petri dishes for four days and incubated for 90 min 
at 37 ºC, 5% CO2 in hESC medium containing 0.9 mg/ml colchicine. Cells were then rinsed 
with PBS, tryptinised, harvested in PBS 2% FBS and centrifuged at 250 x g for 10 min. 
After centrifugation, most of the supernatant was removed leaving 0.5 ml of liquid to re-
suspend the cells before carefully adding 5 ml of warm hypotonic solution. After 
incubating for 14 min at 37 ºC, cells were centrifuged as previously described and the 
supernatant was removed leaving 0.5 ml of liquid to re-suspend the cells for the further 
addition of 5 ml of CARNOY fixative. Cells were immediately centrifuged and the fixation 
process was repeated 2 more times. After the final removal of the liquid (leaving 0.5 ml), 
cells were stored at -20 ºC, and one aliquot was kept overnight at 4 ºC for observation 
under the microscope.  
The next day, the quality and quantity of the fixed nuclei were assessed by direct 
visualisation under the microscope after spreading them onto glass slides. For this, a 10 µl 
drop of the suspension containing the cells was spread from a distance of approximately 40 
cm on top of a glass slide held over a water bath at 80-90 ºC. The slide was held for 40 s 
more over the water bath before checking it under the microscope. The procedure for 
spreading the fixed nuclei in shown in Figure 2.1 
 
 
Figure 2. 1: Spreading of fixed nucleus for quality control. 
A drop of fixed nuclei is being spread on a glass slide held over a water bath. The impact, humidity and heat 
break the cell membrane of the cells that were on metaphase at the moment of harvest. 
 
2.3.4 TISSUE CULTURE  
All cells were handled and maintained in sterile conditions. All tissue culture-related work 
was performed in a class II biosafety cabinet, unless otherwise stated. Cells were 
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maintained in a tissue culture incubator at 37 °C, 5% CO2 or frozen in aliquots stored in 
liquid nitrogen. 
2.3.4.1 METHODS AND CONDITIONS FOR CONTINOUS MAMALIAN CELL 
LINES AND PRIMARY CELLS 
Cell lines and primary cells were cultured following similar procedures. The main 
differences between cell types are their growth rate (and senescence), their susceptibility to 
sub-confluence or over-confluence (and thus their split ratio) and the culture medium 
required. A brief description of all cells used in this project can be found in section 2.1.8 
2.3.4.1.1 Culture and maintenance  
HEK293T, HeLa, HT1080, EP2102 and C2C12 cells were cultured in standard growth 
medium and split every 2-4 days. EP2102 sub-confluence leads to lost of pluripotency and 
C2C12 over-confluence leads to myotube formation and thus under general maintenance 
conditions this was avoid.  In order to intentionally induce the latter, C2C12 differentiation 
medium was used and cells were no longer split. PlatE were cultured in Plat medium, BJ1 
in feeder medium and human fibroblasts in primary human fibroblast medium, except when 
they were cultured for iPSC reprograming, in which case they were cultured in 
reprogramming fibroblast medium. 
All cells were split using the following protocol: cells were washed with PBS, incubated 
with trypsin-EDTA or TrpLE Express at 37 °C for 3-5 min, re-suspended with mechanical 
support in the appropriate culture medium and transferred to a conical tube for a 5 min 
centrifugation at 200 x g. After centrifugation, the medium was removed, the cells were re-
suspended in the appropriate culture medium and a fraction of the total volume was 
transferred to a new tissue culture plate/flask/dish, already containing a suitable volume of 
the appropriate culture medium. For counting, 10 µl of the re-suspended cells were mixed 
with 10µl of 0.4% trypan blue, placed in a haemocytometer and counted under the 
microscope. 
2.3.4.1.2 Freezing 
For freezing, cells were harvested by tryptinisation (or TrpLE Express treatment) and re-
suspended in standard freezing medium in aliquots of 0.5-1.5 ml. BJ1 cells were re-
suspended in feeder freezing medium instead. The aliquots were immediately transferred 
into an isopropanol freezing container and stored and -80°C overnight.  The next day, the 
cryovials were transferred to a liquid nitrogen storage tank for long-term storage. 
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2.3.4.1.3 Thawing 
For thawing, the cryovial was retrieved from the liquid nitrogen storage tank and 
immediately placed into a 37° C water bath for 2-3 min. The content of the vial was 
transferred to the bottom of a 15 ml conical tube and 9 ml of pre-warmed cell culture 
medium was added to the cells, followed by centrifugation the at 200 X g for 5 min.  After 
centrifugation, the supernatant was removed, the cells were re-suspended in cell culture 
medium and transferred to a tissue culture plate/flask/dish. 
2.3.4.1.4 Transfection  
The most frequently used method for transfection of mammalian cell lines in this project 
was the calcium phosphate method. For this, cells were plated 24 h before, to reach 50-60% 
confluence on the day of transfection. The medium was changed 1-2 hours before starting 
the procedure in order to boost cell metabolism. CaCl2 was added to the plasmid DNA (2-
10 µg) at a final concentration of 0.25 M. Five min later, an equal volume of 2X HBS 
buffer was added drop-wise to the DNA/CaCl2 mixture while vortexing the mix at full 
speed. The mixture was then added to the cells and dispersed homogeneously. The cells 
were grown at 37 °C and 5% CO2 for 24 hours, when the medium was changed.  
For transfection of PlatE cells during retroviral production (which was performed in I-
STEM) Fugene HG Transfection Reagent was used according to manufacturer’s 
instructions. 
In order to estimate transfection efficiency with plasmids containing a fluorescent reporter, 
bright-field and fluorescence images of the same field were compared.  For quantitative 
measurements flow cytometry was employed (section 2.3.1.1). 
2.3.4.1.5 Transduction  
The method of transduction was dependant on the viral vector used and the cells to be 
transduced. Please refer to the viral vector section for details of the transduction strategies 
(section 2.3.5). 
2.3.4.2 METHODS AND CONDITIONS FOR iPSCs 
Almost all iPSCs culture techniques were performed with the use of a Lynx Stereo 
Dynascopic microscope (which will be further referred as to as “stereomicroscope”), which 
was located inside the safety cabinet. Images of the technical procedures for culturing iPSC 
are shown in Figure 2.2. 
2.3.4.2.1 Culture and maintenance  
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Established iPSCs were grown on mytomycin-C growth-arrested human fibroblasts (BJs) in 
Stemedia™ NutriStem™ XF/FF Culture Medium. Medium was changed daily and colonies 
were passage either mechanically or enzymatically every 5-7 days. Mechanical passage was 
performed when the morphology of the colonies was heterogeneous and there were few 
cells, while enzymatic passage was performed when the morphology of the colonies was 
homogeneous and there was a high density of cells. A 1 in 4 to 1 in 5 split was the general 
rule to passage the cells. Cleaning of the colonies (see below) was optional and could be 
performed one to three times a week.  
2.3.4.2.1.1 Growth arrest and seeding of feeder cells 
BJ1s cells were cultivated to confluence in feeder medium in T175 flasks. Once the flasks 
were 90% confluent, mytomicin C was added to the medium at a final concentration of 10 
µg/ml. Cells were incubated at 37 °C, 5% CO2 for 2.5 hours, time after which the medium 
was removed, cells were washed once with PBS and then harvested with TrpLE Express. 
After performing a viability count, cells were either frozen at a concentration of 1x106 
cells/ml in MEF freezing medium for later use or plated with feeder medium at a density of 
5x104 cell/cm2 in organ cells (OC), 30 mm petri dishes (B3) or 60 mm petri dishes (B6), 
previously coated for 20 min with 0.1% gelatine.  
The day after seeding the BJ1 cells, the feeder medium was removed and after a wash with 
PBS, Stemedia™ NutriStem™ XF/FF Culture Medium supplemented with 2 µM 
thiazovivin was added to the plates. iPSC clumps were then seeded on top of these cells. 
2.3.4.2.1.2 Monitoring and cleaning  
The morphology of iPSC colonies was monitored in an inverted microscope with a 10 X 
magnification lens every two-three days, and removal of differentiated cells (cleaning) was 
performed one to three times a week depending on the quality of the culture. For cleaning, 
the differentiated parts were carefully scratched and then aspirated with a 200 µl tip under 
the stereomicroscope inside the safety cabinet. 
2.3.4.2.1.3 Manual passage 
For manual passage, each colony was cut around the edges and divided into squares of 
approximately 200 µm with a needle mounted on a 1 ml syringe. The colony was then 
carefully scratched and aspirated with a p200 micropipette and a tip and finally transferred 
to dish with feeders in Stemedia™ NutriStem™ XF/FF Culture Medium supplemented 
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with 2 µM thiazovivin. Approximately 10, 50 and 100 clumps were seeded in OCs, B3s and 
B6s respectively.  
2.3.4.2.1.4 Enzymatic passage 
For enzymatic passage, cells were washed with PBS and incubated at 37 °C for 3-8 min 
with 1 mg/ml of dispase until the edges of the colonies began to curl. At this point, dispase 
was removed, cells were washed once with PBS and then scratched in Stemedia™ 
NutriStem™ XF/FF Culture Medium with a 5ml pipette. Clumps were collected in a 
falcon, centrifuged for 2 min at 50 x g, re-suspended in Stemedia™ NutriStem™ XF/FF 
Culture Medium supplemented with 2 µM thiazovivin and transferred to a dish with 
feeders. 
2.3.4.2.2 Freezing 
For the first freezing and thawing of all the clones, the Vitrolife system was use.  For all the 
subsequent freezing and thawing procedures the Stemgent method was used since it was 
found to be more efficient.  
2.3.4.2.2.1 Vitrolife system 
Three different drops were added on the lid of a B6: one drop of 200 µl of Vitrolife 
freezing medium A and two drops of Vitrolife freezing medium B. The lid was closed and 
the inverted dish was transferred to the incubator for 15 min. Meanwhile, iPSC colonies 
were cut as previously described for manual passage. After cutting, 15-20 clumps were 
carefully scratched and aspirated in a volume not exceeding 50 µl and transferred to the 
drop of Vitrolife freezing medium A. In less than one minute, the clumps were aspirated 
back in a volume not exceeding 50 ul and transferred into the first drop of Vitrolife freezing 
medium B. In less than 30 s the clumps were aspirated back in a volume not exceeding 50 
µl and transferred into the second drop of Vitrolife freezing medium B.  The clumps were 
then taken back, transferred to a cryovial, plunged immediately in liquid nitrogen and kept 
in a liquid nitrogen storage tank. 
 2.3.4.2.2 2 Stemgent system  
iPSCs were harvested enzymatically as described previously and after centrifugation and 
removal of the medium, cells were re-suspended in CryoStem™ Freezing Medium 
supplemented with 2 µM of thiazovivin. The content of one B6 was re-suspended in 1 ml of 
supplemented medium and dispensed into 4 cryovials which were immediately transferred 
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into an isopropanol freezing container and stored at -80°C overnight, as it was described for 
mammalian cell line and primary cells. 
2.3.4.2.3 Thawing 
2.3.4.2.3.1 Vitrolife system 
Three different B6 lids were used: one drop of 500 µl Vitrolife freezing medium D was 
added to one B6 lid, 500 µl of hESC medium was added to the second B6 lid and the third 
B6 lid remained empty. The cryovial was removed from liquid nitrogen and submerged in a 
water bath at 40°C for 30 s. In less than one minute 500 µl of Vitrolife freezing medium C 
was added into the cryovial, mixed and placed into the empty B6 lid. Under the 
stereomicroscope, clumps were aspirated back in a volume not exceeding 50 µl and 
transferred onto the lid containing Vitrolife freezing medium D. In less than 1 minute the 
clumps were aspirated and transferred into the drop of solution with hESC medium. In less 
than 5 min the clumps were further diluted by aspirating them in 50 µl, dispensing on the 
lid as a separate drop and adding 500 µl hESC medium.  The clumps were then transferred 
with a tip in a volume not exceeding 50 µl into a B3 plated with feeders in Stemedia™ 
NutriStem™ XF/FF Culture Medium supplemented with 2 µM thiazovivin.   
2.3.4.2.3.2 Stemgent system       
This method is very similar to the thawing of mammalian cell lines. Briefly, the cells were 
thawed and transferred to a conical tube where 9 ml of Stemedia™ NutriStem™ XF/FF 
Culture Medium was added, followed by centrifugation at 200 X g for 5 min. After 
centrifugation, the supernatant was removed and the cells were re-suspended in Stemedia™ 
NutriStem™ XF/FF Culture Medium supplemented with 2 µM thiazovivin and transferred 
to a B3 plated with feeders. 
 
Figure 2. 2: Technical procedure for handling, cutting and picking iPSCs. 
The operators are: identifying the colonies through a stereomicroscope located inside a class II BioSafety 
cabinet (A), cutting iPSC colonies with a needle (B) and aspirating the colony clumps with a 200 µl tip (C). 
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2.3.5 VIRAL VECTORS  
Three types of recombinant viral vectors were used in this study: two derived from 
members of the Retroviridae family: rMMLVs and rH1LVs; and one derived from a 
member of the Parvoviridae family: scAAVs. The self- complementary term is not related 
to a different species of AVV, but rather to a genetic manipulation of the rAAV genome 
(Please refer to section 1.3.1.1.3 in the introduction). The latter two vectors where 
produced in Royal Holloway-University of London (RHUL. Egham, UK), whereas the 
former was produced in I-STEM. 
2.3.5.1 rMMLVs 
2.3.5.1.1 Production 
For rMMLV production, PlatE cells were grown to confluence in Plat medium in 10 cm 
dishes coated with 0.1% gelatine. Cells were transfected separately with 26 µg of each of 
the four plasmids containing the reprograming factors (pMIG-hOCT4, pMIG-hSOX2, 
pMIG-hKLF4 and pMSCVhcMYCIRESGFP. Please refer to section 2.1.3) with Fugene HG 
Transfection Reagent following manufacturer’s instructions. The medium was changed 24 
hours later and the 8 ml supernatants were harvested the following day (48 hours after 
transfection). The four supernatants were filtered through a 0.45 µM-pore filter and 
polybrene and HEPES buffer were added at a final concentration of 4 µg/ml and 1 mM 
respectively. 
MMLVs were produced by Cécile Denis and Mathilde Girard. 
2.3.5.2 rH1LVs 
2.3.5.2.1 Production 
For rH1LV production, a 150 mm culture dish with 50-60% confluent HEK293T cells 
maintained in standard growth medium, was used for transfection using the calcium 
phosphate method previously described (section 2.3.4.1.4). For each plate, 58 µg of total 
plasmid DNA in a 1:1:1:5 molar ratio was used [packaging plasmid 
(pMDLg/pRREintD64V), rev plasmid (pRSV-REV), envelope plasmid (pMD2.VSV-G), 
and transfer plasmid]. Please refer to section 2.1.3 for more detailed information about the 
plasmids. The medium was changed the next day in order to remove the CaCl2. Forty-eight 
and seventy-two hours after the transfection, the medium was harvested and centrifuged at 
215 x g for 10 min.  The supernatant was filtered through a 0.22 µM-pore filter and further 
concentrated by ultracentrifugation on the day of harvest.  
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2.3.5.2.2 Concentration 
The filtered supernatant containing the lentiviral vector was transferred to a Thinwall, 
Polyallomer, 17 mL, 16 x 102 mm tube and spun at 50,000 x g for 2 h at 4 °C in a Beckman 
Optima L7 ultracentrifuge using a SW32.1Ti rotor. After centrifugation, the supernatant 
was discarded, the pellet was re-suspended in 50 µl of DMEM without supplements, 
transferred to a microfuge tube, centrifuged at 200 x g for 10 min and transferred again to a 
new microfuge tube. MgCl2 was added to the vector at a final concentration of 10 mM 
followed by the addition of DNase I (final concentration 5 U/ml) for a 30 min incubation at 
37 °C. The vectors were further aliquotated in 5-10 µl aliquots. 
2.3.5.2.3 qPCR titration  
To assess the titre of rH1LVs (genome copy transducing units; qPCR TU), HeLa cells were 
transduced with dilutions of the concentrated vectors and qPCR was performed on total 
DNA extracted from these cells. For this, 1x105 cells were seeded in 6 well plates with 
standard growth medium the day before transduction. Cells were transduced in parallel with 
a 1 in 4,000 and 1 in 40,000 dilution of the virus preparation (Each rLV had two 
preparations, harvest d1 and harvest d2) in 2 ml of standard growth medium containing 8 
mg/ml of polybrene. A mock sample incubated only with standard growth medium and 
polybrene was also included. 24 hours post transduction, cells were harvested by 
tryptinization and their DNA was extracted using the QIAGEN DNeasy tissue kit. DNA 
was harvested in a final volume of 400 µl through two sequential column elutions as per 
manufacturer recommendation. 
Once extracted, vector genomic DNA in transduced cells was quantified by qPCR by 
amplification of the late reverse transcript (LRT) region, common to all lentiviral vectors. 
The reaction was performed under the following conditions: 0.3 µM of each primer, 1X 
SensiMixPlus SYBR and 5 µl of the template in a final volume of 20 µl. 1x10-2-1x10-7 
copies of the DNA of pCCLsc_HB9_RFP_W were used as standards. Samples were done 
in duplicate and standards were done in triplicate (including the negative control). The 
cycling conditions were: 1 cycle at 50˚C for 2 min, 1 cycle at 95˚C for 10 min and 50 
cycles at 95˚C for 15 s/ 60˚C for 1 min. A melting curve calculation was performed at the 
end with a continuous reading between 50 and 100 ˚C. The LRT copy number titre was 
normalised to the number of cells transduced, which was determined though a parallel 
qPCR reaction. The number of cells was quantified using primers located in the beta actin 
gene following the same cycling conditions as the LRT reaction. DNA extracted from 
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1x106 HeLa cells with the QIAGEN DNeasy tissue kit was used to prepare the standard 
curve (100-105 cells) for this reaction. The final titre was expressed as qPCR transducing 
units/ml vector stock. 
2.3.5.2.4 Transduction of MNs  
 Four neurospheres were incubated in a microfuge tube for 2 hours (37°C) with 200 µl of 
MN differentiation medium 1528 containing rLVs for a qPCR MOI of 200. Neurospheres 
were then seeded on PO-laminin coated coverslips as will be described in the protocol for 
iPSC differentiation into MNs (section 2.3.7.2). 
2.3.5.3 rAAVs 
2.3.5.3.1 Production  
For rAAV production, ten 150 mm culture dishes with 50-60% confluent HEK293T cells 
maintained in standard growth medium, were transfected using the calcium phosphate 
method previously described (section 2.3.4.1.4). For each plate, 50 µg of total plasmid 
DNA in a 1:1:1 molar ratio was used [adenoviral helper plasmid (pAdDeltaF6), packaging 
plasmid (p5E18-VD2/9) and transfer plasmid]. Please refer to section 2.1.3 for more 
detailed information about the plasmids. The medium was changed the next day. Seventy-
two hours after the transfection, the cells were detached mechanically from the dishes and 
centrifuged at 215 x g for 10 min. Cell pellet and supernatant were processed separately. 
The pellet was re-suspended in 15 ml of AAV cell lysis buffer and stored at -80°C. 50 ml of 
AAV precipitation buffer was added to the collected supernatant (200 ml), the solution was 
mixed by inversion and incubated overnight at 4°C. The next day the mix was centrifuged 
at 2500 x g for 30 min at 4 °C, the supernatant was discarded and the pellet was mixed with 
the 15 ml lysis buffer containing the cell pellet from the day before. 
2.3.5.3.2 Purification 
The lysate of the vector producing cells was subjected to three freeze/thaw cycles, by 
repeatedly placing it in a water bath for 10 min at 37 °C and then in the freezer for 30 min 
at -80 °C. After the third cycle, benzonase was added at a final concentration of 50 U/ml, 
incubating for 30 min at 37 °C.  The lysate was clarified by a 25 min centrifugation at 3360 
x g at RT and further filtration through a 0.45 µm porous size filter. 
A discontinuous iodixanol gradient was prepared by layering the iodixanol solutions very 
carefully into a QuickSeal®, Polyallomer, 39 mL, 25 x 89 mm tube. The layers were added 
as follows (a representative image of the gradient is shown in Figure 2.3):  
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ü 9 ml of Iodixanol gradient 15% (transparent appearance) 
ü 6 ml of Iodixanol gradient 25% (reddish appearance) 
ü 5 ml of Iodixanol gradient 40% (transparent appearance) 
ü 5 ml of Iodixanol gradient 60% (yellowish appearance) 
 The clarified and filtered lysate was then layered over the top of the gradient and the tube 
was filled to the rum with AAV cell lysis buffer and heat-sealed with with a Beckman 
centrifuge sealer, Tube Topper, 60 Hz. The gradient with the lysate was subjected to 
ultracentrifugation at 255,000 x g (av.) (60 000 RPM) for 85 min at 18 °C in a Beckman 
Optima L-100XP ultracentrifuge using a Type 70Ti rotor. After centrifugation, the 40% 
layer was recovered by perforation of the side of the tube with a needle attached to a 
syringe and dispensed into a new tube. The vectors were stored at -80 °C in 50-100 µl 
aliquots. 
 
Figure 2. 3: Ioxidianol gradient ready for rAAV purification.  
The lower layer at the bottom of the tube is the 60% fraction, which is characterized by a yellowish colour. 
The following layer is the 40% fraction, which will contain the virus after the ultracentrifugation, and it is 
characterized by a transparent colour. Above the latter layer is the reddish 25% fraction followed by the 
transparent 15% fraction. The top of the tube contains the filtered lysate immediately before centrifugation. 
Phenol red was used for visualization purposes. 
 
For desalting and concentration of the collected iodixanol fraction, Amicon Ultra -15 
PL100 devices were used. The 40% iodixanol fraction was added to the device and washed 
3 times with PBS-MK buffer centrifuging at 3360 x g for 17 min at RT. On the final spin, 
the volume was reduced to 500-1000 µl and dispensed in 50-100 µl aliquots for long-term 
storage at -80 °C. 
2.3.5.3.3 Titration   
Two methods were used to assess rAAV titre, both of which estimate genome copy number 
of viral particles (infectious and not infectious particles). The first step for both methods 
was the extraction of the vector DNA with phenol/chloroform. For this, 5 µl of the purified 
vector stock were incubated for 1 hour at 37 °C with 5 U of Dnase I in a final volume of 
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200 µl pure DMEM. 100 µg of proteinase K in 200 µl 1X proteinase K buffer was mixed 
with the DNase-treated vectors for a 1 hour incubation at 37 °C. An equal volume of 
25:24:1 phenol/chloroform/isoamyl alcohol was then added, the solution was mixed 
thoroughly and centrifuged at 14,000 rpm for 10 min at 4 °C. The supernatant was 
transferred to a new microfuge tube and the DNA was precipitated with 1/10 volume of 3M 
sodium acetate, 40 µg of glycogen and 2.5 volumes of 100% ethanol. The solution was 
incubated at -80°C for 30 min, centrifuged at 13,000 rpm for 20 min at 4°C and the 
supernatant was discarded. The pellet was washed with 1 ml of 70% ethanol, spun again 
and after the centrifugation it was re-suspended either in 400 µl of TE (for qPCR titration) 
or 400 µl of dot blot re-suspension buffer (for dot blot titration). 
2.3.5.3.3.1 Titration by qPCR 
The DNA in TE from the previous section was used for qPCR with primers located in the 
poly A region (present in all rAAV). The reaction was performed under the following 
conditions: 0.3 µM of each primer, 1X SensiMixPlus SYBR and 5 µl of undiluted, 1x10-2 
and 1x10-4 dilutions of the template in a final volume of 20 µl. 1x10-1-1x10-8 copies of the 
DNA of pscAAVhSMN1F were used as standards. Samples were done in duplicate and 
standards were done in triplicate (including the negative control). The cycling conditions 
were: 1 cycle at 95˚C for 10 min and 45 cycles at 95˚C for 15 s/ 60˚C for 1 min. A melting 
curve calculation was performed at the end with a continuous reading between 50 and 100 
˚C. The titre was expressed as genome copies per ml of vector stock. 
2.3.5.3.3.2 Titration by dot-blot 
The dot-blot titration method relied on the hybridization of a PCR amplification product 
corresponding to the CMV promoter of the pscAAVCAG backbone with the viral DNA. 
The probe was amplified using the following conditions: 0.6 µM of each primer, 1.5 mM 
MgCl2, 200 µM dNTPs, 0.25 U GoTaq® Flexi DNA Polymerase in its 1X Green GoTaq 
Flexibuffer and 5 ng of template  (pscAAVhSMN1F) in a final volume of 25 µl. The 
cycling conditions were: 1 cycle at 95 °C for 5 min, 35 cycles at 95 °C for 1 min /56 °C for 
1 min/ 72 °C for 45 s and with a final extension at 72 °C for 5 min. 100 ng of the CMV 
amplification product was labelled on the first day of the dot blot procedure following the 
instructions of the Amersham ECL Direct Nucleic Acid Labelling And Detection Systems 
kit. 
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As standards, a 2-fold serial dilution of pscAAVCAGhSMN1F was prepared in a volume of 
20 µl (containing 80 ng-0.3125 ng; 9 different standards). All standards were further diluted 
in 400 µl of dot blot re-suspension buffer. Vector samples and standards were heated at 
100°C for 5 min and immediately cooled on ice for 2 min. To blot, denatured viral vector 
samples and standards were added onto the Hybond N+ hybridization membrane using a 
minifold (96 well dot blotter) SRC-96/1 with a capex L2C vacuum source. The blotter was 
dismounted and the membrane was then exposed to UV light for 30 s in a UV trans-
illuminator and rinsed with 2x SSC before placing it in a hybridization tube with 15 ml of 
hybridization buffer. The tube was placed in a hybridization oven for a one-hour incubation 
at RT with rotation. The labelled probe was then added to the hybridization buffer in the 
tube and the membrane was incubated overnight at 42°C. The next day the membrane was 
washed twice with 100 ml of dot blot primary wash buffer for 20 min at 42°C and then 
twice with 100 ml of 2X SSC. The development of the blot was performed with the 
Amersham ECL Direct Nucleic Acid Labelling And Detection Systems kit, following 
manufacturer’s instructions. In order to estimate the concentration of the viral samples, 
their intensity was visually compared to the intensities of the standards. Figure 2.4 shows 
the results of the dot blot measurement of several rAAV preparations, where the DNA 
contained in 2 and 5µl of purified viral stock were probed.   
 
Figure 2. 4: Titration of rAAV vectors by dot blot.  
2 and 5µl of the purified viral stock were hybridized with a probe against the CMV enhancer. The 
estimation of the titre was done by visually comparing the intensity of each pair of samples with the 
ones in the standards.  
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2.3.5.3.4 Transduction  
2.3.5.3.4.1 Mammalian cell lines 
Transduction of rAAV in mammalian cell lines was performed to assess transduction 
efficiency in vitro. For this, 1x105 HEK293T or HeLa cells were seeded in wells of a six- 
well plate with standard growth medium. 24 hours later, the medium was removed and 1 ml 
of fresh standard growth medium containing 109 copies of scAAV9CageGFP (genomes 
copies as measured by qPCR) was added per well, for a MOI of 10,000. 1 ml of standard 
growth medium without vector was used as negative control. Cells were incubate at 37°C, 
5% CO2 for 2 hours, shaking the plates at 30-minute intervals during the incubation. After 2 
hours, 1 ml of standard growth medium high serum (20% FBS) was added to each well. 
After 72 hours the cells were harvested by tryptinization and analysed by flow cytometry. 
2.3.5.3.4.2 MNs 
The transduction of MNs was done in two different ways. For MOI purposes, it was 
assumed that one neurosphere had approximately 1x104 cells. In the first method, four 
neurospheres were incubated in a microfuge tube for 2 hours (37°C) with 200 µl of MN 
differentiation medium 1528 containing rAAVs for a qPCR MOI of 50,000. Neurospheres 
were then seeded on PO-laminin coated coverslips, as will be described in section 2.3.7.2. 
The second method differs in that the neurospheres were transduced and seeded at the same 
time. This last method was employed for the transduction of cells later harvested for 
western blot and qRT-PCR (40 neurospheres and 20 neurospheres respectively).  
2.3.6 iPSC GENERATION 
All iPSC generation-related procedures, as well as some quality control tests were 
performed in the Centre for the Study of Stem Cells (CECS, Centre d’Étude des Cellules 
Souches), a laboratory funded by the French Muscular Disease Association (AFM, 
Association Française contre les Myopathies), which is integrated in I-STEM at Genopole 
campus (Evry), France. Most of the protocols presented here are used or modified from 
those used in I-STEM, where I took part in a three-months workshop (April-July, 2010) 
and a two-months laboratory visit (February-March, 2011) under the supervision of Cécile 
Denis and Mathilde Girard.  
iPSCs were generated from skin fibroblasts of three siblings of a consanguineous family 
harbouring the same homozygous deletion (c.399_402delAGAG in exon 3) of the SMN1 
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gene. iPSCs were also obtained from the carrier mother. The coding of the family members, 
and their pedigree can be found in Chapter 4 (Figure 4.1).   
2.3.6.1 SKIN BIOPSY AND FIBROBLAST CULTURE 
The skin biopsy was performed in Santa Creu i Sant Pau Hospital (Barcelona).  A 5 mm 
punch biopsy was extracted from the forearm after informed consent. The biopsy was 
placed under sterile conditions on a dish containing HBSS supplemented with 1% 
Penicillin-Streptomycin-Fungizone (PSF) in order to separate the adipose tissue, connective 
tissue and blood vessels. The biopsy was then cut with a scalpel into fragments of 
approximately 4x4 mm, moved to a new 60 mm dish and incubated overnight at 37 °C, 5% 
C02 in conditioning media (M-199, 15% FBS, 1% PSF). The next day the fragments were 
cut in half and seeded over plasma-gelatine coated dishes in biopsy culture medium (65% 
D-MEM, 22% M-199, 10% FBS, 2 mM glutamine, 10 ng/ml FGF2, 25 ng/ml EGF and 1% 
PSF). The medium was changed every three days and a second explant was performed once 
the cells growing from the fragments got confluent. The fibroblasts that grew out from the 
first explant were trypsinised as previously described (Section 2.3.4.1.1) and expanded 
twice (to passage 3) before shipping them to I-STEM in 25 cm2 tissue culture flasks 
completely filled with biopsy culture medium. The biopsy and culture from CC was 
performed using a similar procedure, but a 5-years old biopsy (with two previous explants) 
was used instead of a fresh one given that the patient died before the new biopsies were 
taken. 
2.3.6.2 CELL TRANSDUCTION AND iPSC EMERGENCE 
A diagram of the entire procedure for iPSC reprogramming is depicted in Figure 2.5. The 
protocol used for fibroblast transduction and iPSC generation has been recently published 
(Mangeot et al., 2011).  It involves the use of the so-called “gesicles”, which carry the 
receptor for the MMLV envelope protein [murine cationic amino acid transporter-1 
(mCAT-1)] and allow the infection of ecotropic vectors in human cells. For this study, 
mCAT-1 gesicles were supplied by I-STEM and details of their production were not 
provided. 
The first step for the reprogramming process was the generation of four rMMLVs, each 
carrying one of the four transcriptions factors of Yamanaka’s cocktail:  OCT4, SOX2, KFL4 
and c-MYC (Takahashi et al., 2007). The transfer plasmids used were the same as the ones 
published by Park et al., 2008. Refer to section 2.1.3 for more information.   
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For transduction, 100,000 fibroblasts from each patient were seeded in a well of a 6-well 
plate in reprogramming fibroblast medium. The next day, most of the medium was 
removed from, leaving only 0.5 ml per well, and 15 µl of mCAT-1 gesicles were added. 
Cells were returned to the incubator for one hour, after which 1 ml of a premix containing 
equal proportions of all four vector supernatants was added to each well. The next day, the 
medium was changed. Four days port-transduction, cells were harvested by triptinisation 
and 43,000-100,000 cells from each patient were seeded per well in 6-well plates coated 
with 0.1% gelatin (a whole plate for each patient) in reprogramming fibroblast medium. 
Given the different growth rates of cells from different subjects, 0.1% gelatine-coated 100 
mm dishes were also seeded with approximately 300,000 cells in some cases. 24 hours after 
re-plating, the reprogramming fibroblast medium was changed to hESC medium 
supplemented with 10 ng/ml FGF2 and 0.5 mM VPA. Cells were incubated without 
splitting until iPSC colonies emerged.  The hESC medium was changed daily for ten days 
maintaining the FGF2 and VPA supplementation, time after which VPA supplementation 
was discontinued.  
 
Figure 2. 5: Diagram of the procedure followed for the generation of iPSCs from human fibroblasts.  
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2.3.6.3 SELECTION AND ESTABLISHMENT OF CLONES 
iPSC colonies emerged between 2 to 5 weeks post-transduction. The identification of iPSC 
colonies was first done under an inverted microscope with 4X magnification lens. The 
selection was performed based on morphology: round-shaped colonies of tightly packaged 
cells with scant cytoplasm and bright-defined borders around them, although the 
morphologies were very heterogeneous at this point. Once the emerging iPSC colonies 
were identified they were manually passage to an OC with feeder cells in hESC medium 
supplemented with 2µM thiazovivin as previously described. hESC medium  was switched 
after several passages to Stemedia™ NutriStem™ XF/FF Culture Medium as described in 
the section for culture of iPSCs. 
2.3.7 iPSC DIFFERENTIATION  
iPSCs were differentiated into several immature cell types through the platting of embryoid 
bodies and into more mature cell types such as MNs and hepatocytes through the use of 
selective cultures. In all cases the differentiation yield very heterogeneous populations, and 
cell identity was performed by immunofluorescence. 
2.3.7.1 IN VITRO DIFFERENTIATION ASSESSMENT     
When iPSCs are grown in suspension without FGF2, they form floating, spherical 
aggregates called EBs. These structures contain cells going though differentiation, and if no 
coaxing is performed, they give rise to cell types representative of the three germ layers, a 
major characteristic of bona fide iPSCs.  
In order to form EBs, iPSCs were grown for 5 days and disaggregated in clumps as 
described previously for the enzymatic passaging (section  2.3.4.2.1.4); the optimal size of 
the clumps in this procedure was between 50-200 µM.  After centrifugation and removal of 
the medium, clumps were re-suspended in hESC medium and transferred to low-binding 6-
well plates. The next day, the remaining feeders in the incipient EBs were removed by 
filtration through a 20 µm pore cell strainer and transferred to new low-binding 6-well 
plates. EBs were cultured in suspension in hESC medium for 7 days and then equally 
distributed in 0.1% gelatine-coated wells of 24 well plates using the same medium. 
Attached EBs were cultured further for 7 days, fixed and stained with antibodies 
recognizing epitopes characteristic of the three germ layers: Neuronal Class III β-Tubulin 
(TUJ1) for the ectoderm; Actin Smooth Muscle Actin (SMA) and desmin for mesoderm; 
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alpha fetoprotein (AFP) for endoderm. For a detailed description of the antibodies and their 
dilutions, please refer to the section 2.1.7.2. 
2.3.7.2  DIFFERENTIATION TO MNS  
MN differentiation was performed following Hu and Zhang’s protocol, originally designed 
for hESCs (Hu and Zhang, 2009).  Briefly, for the first two weeks iPSCs were induced to 
neuroepithelial (NE) cells that formed neural tube-like rosettes in the absence of 
morphogens, by generating EBs in the first week and plating them out with neural 
differentiation medium in laminin-coated 6-well plates during the second week. Between 
days 10-17 neural tube like-rosettes became apparent within the plated clusters, and the 
percentage of the area covered by the rosettes within the cluster was used as an indicator of 
neural induction efficiency, together with the co-expression of the NE markers PAX6 and 
SOX1. NE cells were then lifted by manual selection under the stereomicroscope and 
grown in suspension as neurospheres in MN differentiation medium 1528 (containing 0.1 
µM retinoic acid [RA], a caudalising agent and 1 µM purmorphamine, a ventralising agent) 
for two weeks. The aggregates were split by a 5 min incubation at 37 °C with 1ml of 
accutase when they became too big (more than 300 µm). Neurospheres were then plated on 
Poly-L-Ornithine-Laminin  (PO-laminin)-coated 10 mm coverslips, dishes or plates at day 
28 and cultured in a medium supplemented with 10 ng/ml FGF2, BDNF, GDNF and IGF, 
200 ng/ml ascorbic acid, 1 µM cAMP, b27 and N2 as well as 50 nM RA and 0.5 µM 
purmorphamine (complete MN differentiation medium) to generate post-mitotic MNs. The 
medium was changed every other day (Hu and Zhang, 2009). 
All procedures were performed as described in Hu and Zhang (2009), except the coating 
and seeding of neurospheres, which was done as follows: PO (100 µg/ml) was added to the 
culture surface and incubated at RT for two hours, washed three times with HBSS without 
drying and incubated overnight at 4°C with 20 µg/ml of murine laminin diluted in neural 
differentiation medium. The next day, laminin was removed and a minimum amount of 
complete MN differentiation medium was added just before seeding the selected 
neurospheres (3-5 neurospheres per coverlip for staining, 10 neurospheres per 30-mm dish 
for axon growth, 20 neurospheres per well of 12-well plates for qRT-PCR and 40 
neurospheres per well of 6-well plate for WB). Two hours later, when the cells were 
attached, the rest of the MN differentiation medium was added. 
2.3.7.2.1 Co-culture of iPSC-derived MNs and mouse myotubes 
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iPSC-derived MNs were grown on mouse myotubes in order to observe the formation of 
NMJs. For this, permanox TC chamber slides were coated with 20 µg/ml of murine laminin 
and incubated at 37 °C for one hour. Laminin was removed and C2C12 cells were then 
seeded in standard growth medium at two different confluences: 2.3 x 105 cells/cm2 (for 
70% confluence at 24 h) and 1.7 x 105 cells/cm2 (for 50% confluence at 24 h). The next day 
the medium was switched to C2C12 differentiation medium and cells were grown for four 
more days, at which time 4-6 D39 Neurospheres were seeded on these cells with in 1:1 mix 
of C2C12 differentiation medium and complete MN differentiation medium. Cells were 
then cultured for 3 days and fixed at D42 of MN differentiation for staining. In order to 
accomplish the timings, C2C12 cells were initially seeded at D34 of MN differentiation. 
2.3.7.2.2 Axon length measurement 
In order to measure axon length growth, ten neurospheres were seeded on PO-laminin 
coated 30-mm petri dishes on D26. Images of 5 neurospheres were taken on D27, D29, D32 
and D34 with an inverted microscope and a 2X lens.  For each day, the length of the five 
longest neurites was measured using Image J and the values were averaged.   
2.3.7.3 DIFFERENTIATION TO HEPATOCYTES 
Hepatocyte differentiation was performed following Song’s protocol (Song et al. 2009). A 
diagram summarizing the complete protocol is shown in Figure 2.6.  The protocol did not 
include lifting or manual selection of the cells, but only the addition of coaxing molecules 
in a stepwise manner. Briefly, iPSCs growing on feeders were maintained in hepatocyte 
differentiation medium 1-3 (containing 100 ng/ml Activin A) for three days, further 
supplementing the medium with 0.1 and 1% insulin-transferrin-selenium on days 2 and 3 
respectively. After ectodermal induction, cells were cultured for four days in hepatocyte 
differentiation medium 4-7 (containing 30 ng/ml FGF4 and 20 ng/ml BMP2) in order to 
induce hepatic differentiation. Cells were then maintained for six days in hepatic 
differentiation medium 8-13 (containing 20 ng/ml HGF and 20 ng/ml KGF), five days in 
hepatic differentiation medium 14-18 (containing 10 ng/ml oncostatin-M, 0.1 µM 
dexamethasone) and three days in hepatic differentiation medium 19-21 (containing N2, 
B27).  The protocol was followed exactly as described by the author. For a detail 
description of the component of the media please refer to section 2.1.9.4. 
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Figure 2. 6: Stepwise differentiation protocol from iPSC to hepatocytes.  
Taken from (Song et al. 2009). 
 2.4 STATISTICAL ANALYSES  
Statistical Package for the Social Sciences (SPSS) and GraphPad Prism software were used 
for all statistical analyses. All data are presented as mean ± standard error of the mean 
(SEM) and groups are compared either by one-way or two-way ANOVA. For the neurite 
growth analysis one-way ANOVA with repeated measures was used. For the molecular 
analyses (qPCR and western blot) between patients and unaffected individuals and between 
cellular types, two-way ANOVA with the Bonferoni post hoc was employed to compare 
control and SMA individuals across each cellular type, and the Scheffe post hoc to compare 
all individuals across each cellular type. One-way ANOVA and the post hoc for linear trend 
were used to assess the decay in the molecular analyses (qPCR and western blot) of all 
individuals. Differences were considered statistically significant if P<0.05 (*), P<0.01 (**) 
and P<0.001 (***). 
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CHAPTER 3: RESULTS- VIRAL VECTOR GENERATION AND 
CHARACTERISATION 
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This chapter describes all the work related with the production of viral vectors and their 
characterisation in vitro, including the plasmids used to generate the vectors, the cloning of 
new transfer plasmids and the transduction efficiency, when feasible and available. For 
rH1LVs, and rMMLVs no new transfer plasmids were created and particularly for the 
latter, no accessory plasmids were necessary for production, since they were transfected in 
the PlatE cells which already contained the necessary genes for rMMLV production. For 
rH1LVs, only the identity of the transfer plasmid was assessed, given that members of my 
laboratory have extensively characterised all other plasmids for LV production and they 
were all produced in large quantities by Plasmid Factory. LV transduction efficiency could 
not be assessed in continuous mammalian cell lines because a MN specific promoter (HB9) 
was driving the expression of the reporter gene. LV and AAV transduction efficiency in 
iPSC-derived MNs is presented in chapter 5. rMMLV transduction efficiency was not 
assessed in RHUL and final results were not provided by I-STEM. 
 3.1 rAAVs  
3.1.1 CHARACTERISATION OF PLASMIDS FOR rAAV9 PRODUCTION 
Restriction analysis was performed on each of the three plasmids used in rAAV production 
in order to characterise them. The original rAAV transfer plasmid obtained was provided 
with an enhanced version of the reporter eGFP. For the transfer plasmid, 
pscAAVCageGFP, the enzymatic digestion with AgeI + SbfI produced a 761 bp and a 3945 
bp fragment from the original 4706 bp plasmid (Figure 3.1A). For the packaging plasmid 
p5E18-VD2/9, the digestion with PvuII yielded a 2513 bp and a 4816 bp fragment from the 
original 7329 bp plasmid (Figure 3.1B). Finally the helper plasmid pAdDeltaF6 was 
digested with BglII yielding several fragments of different sizes from the original 15414 bp 
plasmid: 1625 bp, 1698 bp, 2151 bp, 4647 bp and 5031 bp (Figure 3.1C). The band with 
the smallest size from pAdDeltaF6 was not visualised in the gel (272 bp).  
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Figure 3. 1: Characterisation of the three basic plasmids for the production of rAAV9 through their 
restriction pattern.  
All plasmids are presented along with their map and the relevant restriction sites. Lane 1 in all images shows 
the corresponding undigested plasmid and lane 2 the digestion products.  (A):  pscAAVCageGFP was 
digested with SbfI and AgeI yielding 761 bp and 3945 bp fragments. (B): p5E18-VD2/9 was digested with 
PvuII generating 2513 bp and 4816 bp fragments. (C): pAdDelta6 was digested with BglII yielding the 
fragments: 1625 bp, 1698 bp, 2151 bp, 4647 bp and 5031 bp. M1Kb: 1 Kb molecular size marker. 200 ng of 
DNA were loaded in all lanes except for the marker that contained 500 ng. The main identified elements of 
the plasmids are as follows: ITR: inverted terminal repeat; CMV: cytomegalovirus promoter; CAG: short 
version of ubiquitous cytomegalovirus enhancer/ chicken beta actin promoter; eGFP: enhanced green 
fluorescent protein; Poly(A): poly(A) tail; trs: terminal resolution site; AmpR: ampicillin resistance gene; 
AAV2 REP: AAV2 replication proteins AAV9 CAP: AAV9 capsid proteins. Depicted sequences in 
pAdDeltaF6 correspond to adenoviral genes, but details were not made available. 
            AmpR 
            
AAV2  REP 
AAV9 CAP 
pscAAVCageGFP
4 706  bp
AmpR
eGFP
CMV
5' ITR
3' ITR   trs
Poly (A)
CAG
AgeI (9 9 3)
Sbf I (1754 )
??
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3.1.2 CLONING OF hSMN1 INTO THE rAAV TRANSFER PLASMID  
The eGFP cDNA in pscAAVCageGFP was replaced by the hSMN1 cDNA in two versions: 
a flag-tagged version at the N terminus and a simple version without flag tag, generating 
pscAAVCaghSMN1F and pscAAVCaghSMN1NoF respectively. The hSMN1 cDNA was 
amplified by PCR from a Genecopoeia clone (product ID: K2843, Cat. No. FL15214), 
using primers that added the AgeI restriction site at the 5´end and the SbfI restriction site at 
the 3´end. In the case of the pscAAV9CaghSMN1F, the 5´ primer also included the 
sequence of the flag tag (24 nucleotides). In order to incorporate the new restriction sites 
and the flag tag in the amplification product, the melting temperature of the first seven 
cycles of the PCR reaction was lowered beyond the theoretical one, increasing then 2 °C 
per cycle  (from 59°C to 70 °C). 
The 937 bp flag-tagged hSMN1amplification product and the 910 bp hSMN1 amplification 
products were digested with AgeI and SbfI and gel-purified. Smaller non-specific bands 
were distant enough to avoid their presence in the excised fragments when the cutting was 
performed (Lanes 1, 2, 4 and 5, Figure 3.2). pscAAVCageGFP was also digested and gel-
purified in the same way, releasing a 761 bp fragment containing the eGFP cDNA, leaving 
a 3945 bp backbone fragment to be excised and purified (Lanes 6 and 7, Figure 3.2). 
 
Figure 3. 2: Purification of fragments for the production of the new rAAV transfer plasmids.  
A flag-tagged hSMN1 cDNA (lanes 1 and 2) and a hSMN1 cDNA without any tag (lanes 4 and 5) were 
amplified by PCR generating fragments of 937 bp and 910 bp respectively. The specific products are shown 
inside red boxes. The pscAAV9CageGFP was digested with AgeI and SbfI to release the eGFP fragment of 
761 bp that was further replaced by the new amplified products. The fragment corresponding to the backbone 
of the rAAV transfer plasmid is also shown inside a red box (lanes 6 and 7). 
 
After ligation and bacterial transformation, 5 clones of each construct were screened, 
performing a double restriction with AgeI and SbfI. All clones showed the correct 
restriction pattern: 923 bp and 3945 bp fragments for pscAAVCaghSMN1F clones and 896 
bp 3945 bp fragments for pscAAV9CaghSMN1NoF clones. The map of the starting plasmid 
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pscAAVCageGFP, the new constructs pscAAVCaghSMN1F and pscAAV9CaghSMN1NoF 
along with their respective restriction digestion with AgeI and SbfI are illustrated in Figure 3.3.  
 
 
 
 
Figure 3. 3: Cloning of hSMN1 and flag-tagged hSMN1 in the pscAAV9 backbone.  
A, B, and C: Maps of the starting plasmid pscAAV9CageGFP and the resulting plasmids 
pscAAV9CaghSMN1F and pscAAV9CaghSMN1NoF, respectively, describing their common elements and the 
two restriction sites used for cloning the new genes, AgeI and SbfI. (D) Restriction pattern of each of the 
plasmids with the cloning enzymes AgeI and SbfI. Undigested (1) and digested pscAAVCageGFP (2), with 
the expected 761 pb band; undigested (3) and digested pscAAVCaghSMN1NoF (4), with the expected 896 pb 
band; undigested (5) and digested pscAAVCaghSMN1F (6), with the expected 923 pb band. M1Kb, M100 bp: 
1 Kb and 100 bp molecular size markers. 200 ng of DNA were loaded in all lanes except for the marker that 
contained 500 ng. The main elements of the plasmids are as follows: ITR: inverted terminal repeat; CMV: 
cytomegalovirus promoter; CAG: short version of ubiquitous cytomegalovirus enhancer/ chicken beta actin 
promoter; eGFP: enhanced green fluorescent protein; Poly(A): poly(A) tail;  trs: terminal resolution site; 
AmpR: ampicillin resistance gene 
 
Clone 2 of the pscAAVCaghSMN1NoF and clone 3 of the pscAAV9CaghSMN1F (the same 
clones whose restriction analyses are shown in Figure 3.3) were sequenced from the 5’ end and 
the 3’ end with primers annealing at least 70 bp from the junction sites used for ligation. Both 
plasmid clones were found to contain the corresponding inserts correctly cloned into the rAAV 
transfer plasmid backbone, confirming the results from the restriction analysis (Figure 3.4). It 
was also confirmed that the whole inserts, including the hSMN1 open reading frame, had the 
expected sequence. 
3945 bp 
923 bp 
896 bp 
3945 bp 
761 bp 
3945 bp 
A B 
eGFP 
Flag- tagged 
hSMN1 
C eG
FP
 
  h
S
M
N
1 
D 
pscAAVCaghSMN1F
4 86 8 bp
hSMN1
AmpR
CMV
5' ITR
3' ITR    trs
FLAG TAG
Poly (A)
CAG
AgeI (9 9 3)
Sbf I (19 16 )
pscAAVCageGFP
47 06 bp
AmpR
eGFP
CMV
5' ITR
3' ITR   trs
Poly (A)
CAG
AgeI (993)
SbfI (1 7 54)
pscAAVCaghSMN1NoF
4 84 1 bp
hSMN1
AmpR
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5' ITR
3' ITR     trs
Poly (A)
CAG
AgeI (9 9 3)
Sbf I (1889 )
??
??
??
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Figure 3. 4: Sequencing and alignment of the new SMN1 clones. 
(A) pscAAVCaghSMN1NoF clone 2 and (B) pscAAVCaghSMN1F clone 3 were sequenced from the 
5’ end, shown in the upper section of each panel, with a primer localized at the Cag promoter, and 
from the 3’ end, showed in the lower section of each panel, with a primer localized around the poly 
A sequence.  Each sequencing product was aligned with the expected PCR product after digestion 
with AgeI and SbfI and the complete sequence of the expected plasmid.  
 
3.1.3 ASSESSMENT OF  hSMN1 EXPRESSION FROM THE NEW CONSTRUCTS 
In order to assess the correct expression of the hSMN1 genes inserted into the rAAV 
transfer plasmid backbone, hSMN protein production was assessed by western blot in 
HEK293T cells transfected with pscAAVCaghSMN1F or pscAAVCaghSMN1NoF. Figure 
3.5 shows a qualitative control of the transfection efficiency with the original rAAV 
transfer plasmid pscAAVCageGFP. The transfection efficiency of the plasmid used as a 
positive control of flag expression (a lentiviral backbone with a flag-tagged mSmn, 
pRRLsc_C_mSmn_eIeGFP_W) is also shown. eGFP protein production from both 
plasmids seems to be high and similar. 
AgeI 
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Figure 3. 5: Transfection efficiency in 
HEK293T cells before harvesting for 
protein extraction 72h later.  
(A) pscAAVCageGFP transfected into cells as 
a control for the efficiency of the transfection 
method using an rAAV transfer plasmid. (B) 
LV plasmid encoding the flag-tagged mSmn 
with an IRES eGFP transfected into the cells 
as a positive control of flag expression. 
Images are shown as bright field and the 
corresponding fluorescence field for eGFP. 
Scale bar= 100 µm. 
 
 
A 40 KDa protein corresponding to the expected size of the flag-tagged hSMN1 was 
detected in cells transfected with pscAAVCaghSMN1F as well as in cells transfected with a 
similar plasmid containing the flag tag in the C terminus of hSMN1 (a plasmid produced by 
Pavlina Petrova, an undergraduate student under my supervision), but not in the cells 
transfected with pscAAVCaghSMN1NoF or in the mock, as expected (Figure 3.6).  The 
level of flag-tagged protein was apparently higher from the LV plasmid encoding flag 
tagged mSmn, although similar amount of proteins were loaded onto all the wells. 
 
Figure 3. 6: Assessment of the expression of flag-tagged hSMN1 from the rAAV transfer plasmid.  
10 µg of pscAAVCaghSMN1NoF (2), pscAAVCaghSMN1F (4), a similar plasmid to pscAAVCaghSMN1F, but 
with a flag tag in the C terminus (3) and a positive control LV plasmid expressing flag-tagged mSmn 
downstream of the CMV promoter, pRRLsc_C_mSmn_eIeGFP_W (5) were transfected into HEK293T cells. 
Cells were harvested 72 h later. Non-transfected cells were also harvested (1). 25 µg of total protein extract 
were loaded onto a 12% SDS-PAGE gel for western blot analysis with an antibody against the flag tag (for 
detection of the flag-tagged hSMN/mSmn). An anti-α tubulin antibody was used as a loading control. L: 
protein Ladder 
 
3.1.4. IMPROVEMENTS IN THE PRODUCTION OF rAAVs  
For the production of rAAVs, two main parameters have been changed over the time in 
order to improve the titre. The first parameter considered was the confluence of the 
HEK293T cells at the time of transfection. For quantification purposes, the reporter plasmid 
pscAAV9CageGFP was used.  As shown in Figure 3.7, the transfection efficiency, as 
assessed by the number of eGFP+ cells by flow cytometry, was higher when the confluence 
??????????
???????????????????????
???????
???????
???????
???????
????????
?? ?? ?? ?? ?? ??
m
S
m
nI
R
E
S
eG
FP
 
ps
cA
AV
C
ag
eG
FP
 
A 
B 
Brightfield GFP 
 109 
of the cells was lower, producing 84% eGFP+ cells at 48 h post-transfection when the 
transfection was performed at confluence of approximately 50%.  
 
Figure 3. 7: Optimization of HEK293T transfection.  
(A) Bright field image of the confluence of the cells on the day of transfection. (B) Fluorescence (green 
channel) image of the cells 48 hours after transfection with 3 µg of pscAAV9CageGFP. (C) Flow cytometry 
analysis for the quantification of the percentage of eGPF+ cells. Scale bar= 100 µm. 
 
The second parameter, which was shown to improve the viral titre, was the precipitation of 
the viral particles in the supernatant of the producer cells with Polyethylene glycol (PEG). 
Initially, only the viral particles contained within the cells were harvested and purified. 
Figure 3.8 shows the titres for several batches of rAAVs. The last two batches presented 
(19mar2010) correspond to productions where the transfection of the plasmids was 
performed with less confluent cells (~50% as opposed to 85%) and where viral particles in 
the supernatant were precipitated with PEG (as described in Materials and Methods, 
Chapter 2). These last two rAAV batches show a higher titre than the previous batches  
(approximately a total of 7x1010 qPCR genome copies or 1.7x1012 dot blot genome copies). 
It is important to mention that as it can be appreciated from the figure, the titres measured 
by dot blot were always higher than the ones measured by qPCR, even though both 
methods assessed genome copy number. The difference between both methods nonetheless 
is consistent: dot blot titre is always one log unit higher that the qPCR titre.  
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Figure 3. 8: qPCR and dot blot titres of four rAAV batches.  
The last two batches, as opposed to the first three, were produced performing the plasmid transfection when 
cells were 50% confluent and included the harvest of viral particles in the supernatant besides the ones 
contained within the producer cells. All batches were prepared by the transfection of cells in ten 150 mm 
plates. Data are presented as total yields instead of concentration, given the fact that batches were not re-
suspended in the same volume during the desalting procedure. eGFP: scAAV9CageGFP, hSMNNoF: 
scAAVCaghSMN 1NoF,  hSMNF: scAAVCaghSMN1F,  DB: dot blot. 
 
3.2.5 TRANSDUCTION EFFICIENCY IN MAMMALIAN CELL LINES 
AAV9 is well known to have very low transduction efficiency in vitro, so high multiplicity 
of infections (MOIs) were used in order to confirm the ability of the rAAV9s produced to 
transduce cells and to express the target gene. scAAV9CageGFP was used for this purpose 
given that upon effective transduction it drives the exogenous expression of the eGFP 
reporter protein, which can be easily quantified by flow cytometry.   
As shown in Figure 3.9 HeLas and HEK293T cells transduced with a qPCR MOI of 
10,000 show very low transduction efficiency at 72h, as expected. The higher transduction 
efficiency obtained was in HEK293T (7.5%).  
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Figure 3. 9: Transduction efficiency of scAAV9CageGFP in mammalian cell lines. 
HeLa and HEK293T cells were transduced at qPCR MOI 10,000 and harvested 72 hours later. All 
transduction experiments are shown with a bright field image of the cells prior to transduction at D0 (A). For 
the flow cytometry analysis, the respective mock cells were used to identify the negative population (B) for 
the quantification of eGFP+ cells harvested at D3 (C). Scale bar= 100 µm. 
 
 3.2 rH1LVs 
3.2.1 CHARACTERISATION OF THE TRANSFER PLASMID IDENTITY 
The rH1LV transfer plasmid pCCLsc_HB9_RFP_W was kindly provided by Dr. Fred Gage 
(Salk Institute, USA). However, no plasmid map was made available with the construct and 
only some of features were known. Figure 3.10 shows the map constructed for the plasmid 
from the GenBank sequences of the various elements. The identity of the short version of 
the HB9 promoter was confirmed by DNA sequencing. The identity of the plasmid was 
also checked through restriction analysis with the two enzymes originally used by the 
provider lab to clone the HB9:RFP insert into the LV backbone. The enzymatic digestion 
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with ClaI + XbaI produced a 7867 bp and a 4488 bp fragment from the original 12355 bp 
plasmid (Figure 3.10). Other restriction analyses were also performed. The characterisation 
of this plasmid was part of the 3rd year project of Lauren Hutchinson, an undergraduate 
under my supervision. 
 
 
 
Figure 3. 10: Representative characterisation of the rH1LV transfer plasmid pCCLsc_HB9_RFP_W 
through its restriction pattern.  
pCCLsc_HB9_RFP_W was digested with ClaI and XbaI yielding 7867 bp  and 4488 bp fragments (1). 
Undigested plasmid (2). M: 1 Kb molecular size marker. 200 ng of DNA were loaded in all lanes 
except for the marker that contained 500 ng. The map of the plasmid is presented along with the 
restriction analysis. The main elements of the plasmid are as follows: CMV: cytomegalovirus promoter; RU5 
and dLTR: recombinant sequences of the long terminal repeats; pbs: primer binding site; RRE: rev response 
element; PPT: polypurine track; HB9: short version of MN- specific HB9 promoter; RFP: red fluorescent 
protein; WPRE: Woodchuck hepatitis virus post transcriptional regulatory element; AmpR: ampicillin 
resistance. Relevant restriction sites are also indicated. 
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CHAPTER 4: RESULTS- iPSC GENERATION AND 
CHARACTERISATION 
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This chapter describes the generation and quality control of iPSCs from fibroblasts obtained 
from skin biopsies of the members of the discordant consanguineous family of study. In this 
family, both parents are carriers of a 4-bp deletion in exon 3 (c.399_402delAGAG) of the 
SMN1 gene, which produces a frame-shift that predicts a stop codon 40 bp downstream 
(Bussaglia et al. 1995). Four of the offspring received the mutated allele in homozygosis, 
nevertheless the clinical manifestations are discrepant, ranging early-onset SMA type III 
(age of onset ≥18 months, bound to wheelchair since infancy) to SMA type 
IV/Asymptomatic (walker presenting cramps and minor electromyographic abnormalities). 
The pedigree of the family is shown in Figure 4.1, and a more detailed description 
summarizing the results of previous studies involving the family can be found in Table 4.1. 
For abbreviation purposes, cells from the unaffected carrier mother are coded as “RC”, the 
SMA type IV/asymptomatic sibling as “AC”, and the SMA type III siblings as “TC”, “NC” 
and “CC” (section 2.1.8.3). 
 
Figure 4. 1: Pedigree chart of the family under study.  
The diagram shows the carrier parents and siblings (grey/black circle and squares) and the SMA type 
IV/unaffected and SMA type III siblings (grey circles) harbouring the SMN1 mutation (c.399_402delAGAG, 
exon 3). The code for each individual within this study is shown along with the respective symbol of 
representation within the diagram. 
 
 
 
 
 
 
 
RC  
Carrier 
AC CC TC NC 
SMA type IV/
Asymptomatic 
SMA type III SMA type III SMA type III 
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Table 4. 1: Clinical and molecular data of the individuals included in this study. 
 
 
*Values were calibrated to the one of a control individual without SMA, which expression was set to 1. The 
data in this table are described in (Also-Rallo et al. 2011; Bernal et al. 2011). NAIP: neuronal apoptosis 
inhibitory protein; NA: not applicable/not determined. 
 
Further chapters will describe the differentiation of the clones obtained here as well as the 
molecular analyses of these cells and their differentiated progeny regarding key proteins 
known to be involved in SMA pathogenesis. 
 4.1 iPSC PRODUCTION  
This section provides a description of the characteristics of the fibroblasts before and after 
retroviral transduction and the emergence of iPSC clones. A diagram of the reprogramming 
procedure can be found in section 2.3.6.1 
4.1.1 FIBROBLAST REPROGRAMMING.  
The morphology and doubling time (DT) of the fibroblasts were assessed before and during 
reprogramming in order to determine the health and mitotic potential of the primary cells 
(Figure 4.2). All fibroblasts showed a healthy morphology. They had an average 50 h DT 
after thawing from liquid nitrogen (passage 3-4), but they started to divide faster in 
subsequent passages and just before transduction (passage 5-6 for AC, RC and CC and p6-
p7 for TC and NC), their average DT was 26.5 hours. NC had a comparatively longer DT 
Patient RC AC TC NC CC
Ethnicity Spanish Spanish Spanish Spanish Spanish
Sex Female Female Female Female Female
SMN2 copy 
number 3 4 4 4 4
Presence of variant 
c.859 G>C in 
SMN2 NA No No No No
Presence of NAIP NA Yes Yes Yes Yes
SMA locus NA
*mRNA PLS3 
levels  in 
lymphoblasts NA 1.92
0.008. Similar to 
control sample
0.59. Similar to control 
sample 8.76
*mRNA  PLS3  
levels in fibroblasts NA 1.25
0.73. Similar to control 
sample
0.89. Similar to control 
sample
0.73. Similar to 
control sample
Age of onset of 
weakness NA NA 18 months 18 months 24 months
Wheelchar bound 
(age they stopped 
being able to walk) NA NA 14 years 8 years 8 years
Electromyography 
results NA Minimal changes Denervation Denervation Denervation
Phenotype Healthy carrier of mutation
Asymptomatic or SMA type 
IV SMA type III SMA type III SMA type III
Age of indivual 
when biopsy  for 
iPSC generation 
was taken >60 45 38 36 30
All sibling are haploidentical for the SMA locus (Also-Rallo et al, unpublished
data)
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just before transduction. After transduction, all the cells except NC showed an increase in 
their DT, in particular TC. The decrease in the DT of NC was persistent even after further 
seeding on gelatin-coated plates. 
Given the different growth rates of the cells, transduced fibroblast were seeded in 6-well 
plates (TC and CC) or in 6-well plates and 10 cm dishes (AC, RC and NC) at an average 
density of 7 x 104 cells/cm2. The morphology of the transduced fibroblasts after seeding on 
gelatin-coated surfaces in shown in Figure 4.3. 
 
  
 
Figure 4. 2: Morphology and growth of fibroblasts before and after RV transduction.  
The doubling time of the fibroblasts from the five family members from passage 3 to passage 8 is shown on 
the histogram. Passage 3-4 corresponds to the first passage after thawing the cells and the last passage shown 
(p6-p7 for AC, RC and CC and p7-p8 for TC and NC) corresponds to the count made before seeding the cells 
in gelatin-coated plates after retroviral transduction. Pictures of the cells from each family member a few 
hours before viral transduction are shown with their corresponding passage number. Scale bar= 200 µm. p: 
passage number.  
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Figure 4. 3: Fibroblast morphology after rMMLV transduction.  
Images shown correspond to transduced cells 24 hours after seeding them with supplemented hESC medium 
on gelatin-coated surfaces for maintenance in culture until the emergence of iPSC clones. Scale bar= 200 µm. 
B10: cells seeded in 10 cm dish, 6W: cells seeded in wells of a 6-well plate. 
 
4.1.2 iPSC EMERGENCE 
12-15 days post-transduction iPSC-like colonies began emerging from the cells of all 
patients except for CC (the deceased SMA type III patient). Transduced cells grew very 
fast, quickly forming a layer over the whole plate; nevertheless, close monitoring could still 
identify potential iPSC colonies. As it can be seen in Figure 4.4 different morphologies 
were observed in emerging iPSC-like colonies: round brown clusters of cells, brown/bright 
oval-like clusters and bright round clusters. All cell clusters presenting these morphologies 
were selected for a first expansion over feeder cells. 
Hfibroblast after transduction 1 day after seeding in gelatin plates 
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Figure 4. 4: Representative iPSC-like clones emerging from reprogrammed cells.  
Different morphologies and appearances are shown in order to represent the heterogeneity of the emerging 
iPSC-like clones 2-3 weeks after retroviral transduction. Scale bar= 200 µm. 
 
The behaviour of the iPSC-like clones during the first passages was also very 
heterogeneous. Some clones that made it to passage 2 presenting a good morphology on 
passage 1, spontaneously developed a differentiated morphology a few days after being 
passaged (Figure 4.5, p1 and p2 respectively).  In this case, a new passage 2 was done 
from the cells left behind in the plate corresponding to passage 1, where after the first 
picking and passage some clumps detached and formed new colonies (Figure 4.5, p1’).  
This emphasized the importance of keeping the plates until the attachment and expansion of 
the colonies in the new passages was confirmed.  
 
 
Figure 4. 5: Emergency and first 
passages of clone AC28.  
Morphology on p0, p1 and p2 just 
before cutting and passaging. Cells at 
p2 differentiated, as judged by their 
morphology. In order to recover the 
clone, a new colony was picked and 
passaged from the same p1 plate some 
days after  (p1´) and further expanded 
into a new plate. Scale bar= 200 µm. 
p: passage number. 
 
 
 
p1 p0 
p2 p1’   
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Approximately 70 iPSC-like clones from all patients altogether were picked and cultured 
individually over feeders in organ cells. Most of them did not grow and after 10 days those 
plates were discarded. The fibroblasts that produced more iPSC-like colonies were AC 
(type IV/asymptomatic sister), followed by NC (SMA type III patient). iPSC-like colonies 
from RC (healthy mother) and TC (SMA type III patient) cells were very rare and none 
were observed in the case of CC cells.  A table with the clones finally selected from each 
family member is included in Appendix 4. For AC and NC 5 clones were selected, but 
several more were generated in the original plates.  
 4.2 iPSC QUALITY CONTROL  
This section presents the results for the quality control of selected iPSC clones. Several 
parameters were measured in order to assess pluripotency, differentiation potential, stability 
and identity of the clones. After the initial expansion of several clones from each family 
member, one single clone from each of them (except from CC, from whom no clone was 
obtained) was selected for further expansion and characterisation: clone 28 from AC, clone 
21 from NC, clone 64 from TC and clone 26 from RC. Unfortunately, after the assessment 
of these first 4 clones, two of them (TC64 and NC21) did not pass all the requirements of 
the quality control and three new clones were expanded and characterised: clone 63 from 
TC and clones 42 and 32 from NC. The results from all seven clones are presented together.  
4.2.1 PLURIPOTENCY ASSESMENT 
The first parameters to assess pluripotency were the morphology and the expression of the 
proper surface and nuclear markers. As it is shown in Figures 4.6 and 4.7, all seven clones 
have a typical hESC morphology (round shape, large nucleoli and scant cytoplasm) and 
they all express AP, OCT4, NANOG, SOX2 and TRA-1-60. NANOG and OCT4 staining in 
clone RC26 is dimmer than in the rest of the clones.  
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Figure 4. 6: Morphology of a representative colony in selected iPSC clones.  
iPSCs were grown on of human feeders as described in M&M. Scale bar= 100 µm. 
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Figure 4. 7: Expression of pluripotency markers in selected iPSC clones.  
AP, OCT4, NANOG, SOX2, and TRA-1-60 are all produced in representative iPSC colonies from the 
selected clones. Scale bar= 200 µm. 
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In order to assess quantitatively the proportion of cells expressing pluripotency markers, 
a multi-parameter flow cytometry-based analysis was performed. SSEA3 and TRA 1-81 
were chosen for the analysis, and the percentage of double-positive cells was the criteria 
chosen for assessing the level of pluripotency of the culture. Conversely, the difference 
between 100 and the percentage of double-positive cells represents the proportion of 
cells undergoing spontaneous differentiation. As can be seen in Figure 4.8, most clones 
are ≥85% SSEA3+/TRA 1-81+, with the exception of clones AC28 and TC64, which are 
66% and 71% SSEA3+/TRA 1-81+, respectively. These results are consistent with the 
morphologies found in culture, were these two clones have a higher propensity for 
spontaneous differentiation and require a more aggressive cleaning procedure. 
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Figure 4. 8: Quantitative assessment of pluripotency markers in iPSCs through flow cytometry.  
Multi-parameter flow cytometry was performed on the selected iPCS clones for the determination of the 
proportion of cells co-expressing the surface markers SSEA3 and TRA 1-81. (A) The top three plots 
correspond to the control samples (unstained and FMOs) after calibration and setting of appropriate 
thresholds. (B) The percentage of double-positive SSEA3/TRA1-81 cells is shown on the plot 
corresponding to each clone. Feeder cells were excluded from the analysis using the FITC channel, given 
their stable expression of GFP. FMO: fluorescence minus one. 
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One key event during the establishment of true iPSC is the down-regulation of the 
exogenous expression of the RTFs and the up-regulation of their endogenous expression. 
Figure 4.9 shows the qRT-PCR quantification of the endogenous and total expression of 
the four RTFs used during reprogramming (OCT4, SOX2, KFL4 and c-MYC) in mRNA 
samples from iPSCs harvested at p37 (AC28), p40 (RC26), p40 (TC64), p12 (TC63), 
p15 (NC32) p16 (NC42) and p27 (NC21). Two cell lines were used as standards of 
pluripotency: hESC H9 and EP2102. hESC H9 is common human embryo-derived 
pluripotent cell line used as standard reference for pluripotency (Thomson et al. 1998) 
and EP2102 is a human embryonic carcinoma cell line with simple culture conditions 
that expresses most of the pluripotent markers found in hESCs (Andrews et al. 1982; 
Josephson et al. 2007). Given the fact that the RNA extraction and cDNA synthesis from 
the hESC H9 sample were not performed in the same way as it was done for the rest of 
the samples, EP2102 was chosen as the calibrator instead. Total expression should be 
comparable across all samples, because the amplification primers are located within the 
genes. However, endogenous expression may not be comparable with hESC H9 (where 
a mix of poly dT and random primers was used for cDNA synthesis, unlike the poly dT 
primers used on the other samples). The expression of all four transgenes was down-
regulated in the seven clones, as judged by the similar values of their endogenous and 
total expression and by comparison with the expression profile in IMR90 fibroblast 
undergoing reprogramming and harvested 4 days post transduction (IMR90 D4). There 
was however, a high persistent SOX2 transgene expression in all iPSC clones. OCT4 and 
SOX2 were expressed at very low levels in BJ1 cells and their expression was induced 
after reprograming (IMR90 D4), whereas KFL4 and c-MYC were already expressed in 
fibroblasts at comparable levels to those in iPSCs. Total expression of OCT4 and SOX2 
in all clones seems to be similar to those in hESC H9 (despite variation among the 
clones), but for c-MYC and KFL4 total expression in the iPSC clones is at least one log 
lower than in hESC H9 (Figure 4.9).  RT-PCR analyses with primers amplifying 
transgene-specific sequences (Figure 4.10) showed that there was residual transgene 
expression of one or more RTFs in some clones, particularly in clones AC28 and TC64. 
Transgenic expression in clone TC63 seemed to be completely silenced.   
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Figure 4. 9: Down-regulation of transgenes in selected iPSCs.  
qRT-PCR was performed to measure the endogenous and total expression of the transgenes (A) OCT4, (B) 
SOX2, (C) cMYC and (D) KFL4. Gene expression was normalized to RPL13 and 18S and plotted (log10 
scale) relative to the expression in EP2102, which was arbitrarily set to 1. BJ1, IMR90 D4 and hESC H9 
were included in the analysis as references. Data is presented as mean ± standard deviation. 
 
 
Figure 4. 10:  Transgenic expression in selected iPSC clones.  
The expression of each transgene was measured by RT-PCR with a primer from retroviral vector sequence 
and another internal to the corresponding gene. 18S is shown as a loading control. BJ1, IMR90 D4 and 
hESC H9 were included in the analysis as references. 
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4.2.2 DIFFERENTIATION POTENTIAL 
True iPSCs should, as it is the case in hESCs, be able to differentiate into cells of the 
three germ layers. An in vitro assessment of differentiation potential was undertaken by 
producing EBs. iPSC-derived EBs are a mix of cell populations in differentiation, and 
when plated, multiple cell lineages start growing out the cluster, so representatives of all 
germ layers can be found in the same well. Figure 4.11 shows that indeed, markers from 
all three layers can be found in cells from iPSC-derived EBs of the selected clones: 
TUJ1 as representative of the ectoderm, SMA and Desmin for mesoderm and AFP for 
endoderm. NC21, unlike the other clones, underwent low differentiation levels, 
producing iPSC colonies even after EB formation. Very few cells representative of each 
layer could be found for this clone, particularly for mesoderm.  
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Figure 4. 11: In vitro differentiation potential of selected clones of iPSCs. 
EBs produced from the representative clones generated cell derivatives of the three primary germ cell 
layers. Immunofluorescence analysis shows the expression of markers from (A) ectoderm (TUJ1, red), (B) 
mesoderm (SMA red/ or Desmin, green) and (C) endoderm (AFP, green). Cell nuclei were counterstained 
with DAPI (blue). Scale bar= 200 µm. 
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4.2.3 STABILITY AND IDENTITY ASSESMENT  
Karyotype and genotype analyses of selected clones were performed in order to assess 
their chromosomal stability and genetic identity respectively.  Two types of karyotype 
analyses were performed by two different laboratories: the first four clones expanded 
after iPSC generation (AC28, RC26, TC64 and NC21) were analyzed by mFISH in 
iSTEM (Evry, France), while the three clones expanded later (NC32, NC42 and TC63) 
were analyzed by G-banding in Santa Creu i Sant Pau Hospital (Barcelona, Spain). 
Figure 4.12 shows a representative karyotype analysis for each clone, along with the 
passage number at the time of cell preparation. All clones show a normal karyotype, 
except for TC64, which presents a partial gain of chromosome X on chromosome 1 
(1qter). This abnormality seems to have arisen early in the reprogramming process or 
have been present in the reprogrammed fibroblast, given the fact that it is present in all 
the metaphases analysed for this particular clone. 
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Figure 4. 12: Karyotype analysis of selected clones.  
mFISH or G-banding analyses were performed in metaphase preparations from clones AC28, RC26, TC64, NC21 and clones NC32, NC42, TC63, respectively. The 
passage number at the time of metaphase preparation is shown along the clone name and karyotype.  
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The genetic identity of the clones was assessed by comparing the profile of several STRs 
between the selected clones and the parental fibroblasts from which they were generated 
as well as peripheral blood taken from the corresponding patient. Table 4.2 shows the 
correspondence between the STR profiles confirming the identity of all seven clones. 
The STR analysis shown here was performed by Dr Sara Bernal in Santa Creu i Sant 
Pau Hospital (Barcelona, Spain). 
 
Table 4. 2: STR profile of selected clones and their parental fibroblasts and peripheral blood. 
Numbers correspond to the length of the amplification products, which is directly related to the number of 
repeats 
 
 
 
Based on all the quality control assessments, two clones were excluded from further 
experiments: clone TC64 was excluded because of its karyotype abnormality and clone 
NC21 was excluded because of its low in vitro differentiation potential. The four 
selected clones were AC28, RC26, TC63 and NC32. Clone NC42 passed all quality 
control assessments, but was not used for further experiments. Table 4.3 summarizes the 
results from the quality control assessment.  
 
 
 
 Chrom 1 
D1S305 
Chrom 2 
D2S443 
Chrom 2 
D2S291 
Chrom 19 
D19S420 
Chrom 19 
D19S112 
Chrom 19 
D19S562 
Chrom X 
INT25-2.0 
RC26 iPSCs 215 / 219 223 / 231 183 / 183 109 / 109 116 /118 340 / 381 341 / 345 
RC Fibroblasts 215 / 219 223 / 231 183 / 183 109 / 109 116 /118 340 / 381 341 / 345 
RC 
Peripheral blood 
215 / 219 223 / 231 183 /183 109 / 109 116 /118 340 / 381 341 / 345 
AC28 iPSCs 219 / 219 231 / 231  183 / 198 109 / 109 116 /118 340 / 381 341 / 343 
AC Fibroblasts 219 / 219 231 / 231 183 / 198 109 / 109 116 /118 340 / 381 341 / 343 
AC 
Peripheral blood 
219 / 219 231 / 231 183 / 198 109 / 109 116 /118 340 / 381 341 / 343 
TC63 iPSCs 219 / 227 231 / 231 183 / 198 107 / 109 116 / 126 340 / 369 343 / 345 
TC64 iPSCs 219 / 227 231 / 231 183 / 198 107 / 109 116 / 126 - 343 / 345 
TC Fibroblasts 219 / 227 231 / 231 183 / 198 107 / 109 116 / 126 340 / 369 343 / 345 
TC 
Peripheral blood  219 / 227 231 / 231 183 / 198 107 / 109 116 / 126 340 / 369 343 / 345 
NC32 iPSCs 215 / 227 223 / 227 183 / 183 - 118 / 118 381 / 381 341 / 343 
NC42 iPSCs 215 / 227 223 / 227 183 / 183 109 / 109 118 / 118 381 / 381 341 / 343 
NC21 iPSCs 215 / 227 223 / 227 183 / 183 109 / 109 118 / 118 - 341 / 343 
NC Fibroblasts 215 / 227 223 / 227 183 / 183 109 / 109 118 / 118 381 / 381 341 / 343 
NC 
Peripheral blood 
215 / 227 223 / 227 183 / 183 109 / 109 118 / 118 381 / 381 341 / 343 
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Table 4. 3: Summary of the results from the quality control assessments of selected clones 
 
 
 
QC: quality control; IF: immunofluorescence; FC: flow cytometry.  
QC test RC26 AC28 TC64 TC63 NC21 NC32 NC42
Alkaline Phosphatase
Pluripotency markers 
expressed as assesed 
by IF
Proportion of 
SSEA3+/TRA 1-81+ 
cells by FC 87% 66% 71% 88% 87% 85% 89%
Transgene 
downregulation
in vitro differentiation Excellent Excellent Excellent Excellent Poor Excellent Excellent
Karyotype 46, XX 46, XX
46, XX, 
der(1)t(x;1) 46, XX 46, XX 46, XX 46, XX
STR profile
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
iPSC clone 
corresponds 
to parental 
primary 
cells
Final QC criteria Passed Passed Did not pass Passed Did not pass Passed Passed
Clones selected x x x x
Positive
OCT4, NANOG, SOX2, SSEA4, TRA 1-60
All downregulated
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CHAPTER 5: RESULTS- iPSC DIFFERENTIATION 
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This chapter describes the phenotypic characterisation of the cells derived through directed 
differentiation of iPSCs to MNs and hepatocytes. Six clones were differentiated into MNs: 
the four selected clones (AC28, RC26, TC63 and NC32) from the members of the Spanish 
family, whose characterisation was presented in the previous chapter (Chapter 4), and two 
additional clones (SMA1 and 4603) generated and characterised by our collaborators. 
Clone SMA1 was derived in the Beckman Research Institute (California, USA) from 
fibroblasts of a patient with Spinal Muscular Atrophy type 1 (SMA1) and clone 4603 was 
derived in I-STEM from fibroblasts of a healthy adult (Please refer to section 2.1.8 for 
more details). Only clone RC26 was differentiated into hepatocytes, as an alternative 
mature lineage for comparison purposes in the next chapter (Chapter 6). 
 5.1 iPSC-DERIVED MNS 
This section describes the cellular work related to the differentiation of iPSCs into MNs, 
including the assessment of the identity of the intermediate progenitors and the fully 
differentiated cells, the description of the behaviour of the cells during the period of culture, 
the neurite growth test and the co-culture of iPSC-derived MNs with mouse myotubes. MN 
transduction with rH1LVs and rAAV9s carrying reporter and/or therapeutic genes is also 
presented here. 
5.1.1 TRACKING THE DIFFERENTIATION OF iPSCs INTO MNs 
iPSC clones AC28 and RC26 were differentiated to MNs three times, iPSC clones TC63 
and NC32 two times and the reference iPSC clones SMA1 and 4603 one time. The 
difference in the number of iPSC-MN differentiations is related to the time frame when the 
clones were fully characterised or available from our collaborators. The results presented 
here correspond to the last iPSC-MN differentiation performed, where all mentioned clones 
were included. 
As described in detail in Materials and Methods (2.3.7.2), iPSC differentiation into MNs is 
a stepwise process that involves the generation and selection of intermediate progenitors 
whose fate is directed by the culture conditions, particularly by the presence of RA and 
purmorphamine. A diagram summarizing the complete iPSC-MN protocol is shown in 
Figure 5.1, along with representative images of the markers expressed at different stages of 
the procedure, which will be described in detail in the this section 
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Figure 5. 1: MN differentiation from iPSCs 
MN differentiation was performed following Hu and Zhang’s protocol. Details of the procedure are provided in the text. PAX6 and SOX1 are neuroepithelial markers, 
OLIG2 and p75 are MN progenitor makers, TUJ1 is a neural marker and ISL-1, HB9 and ChAT are MN markers. All images depicted were taken from the 
differentiation of iPSC clone AC28. Diagram taken and modified from (Hu & Zhang 2009).  
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The fist steps of the differentiation were the formation of EBs (D0-D7) and their plating in 
laminin-coated 6-well plates (D7). Fourteen days after the start of the differentiation 
protocol several neural tube-like rosettes appeared within the clusters of plated EBs, which 
were distinguished by their columnar disposition (Figure 5.2A).  Clones AC28, TC63 and 
NC32 showed a similar yield of rosettes (covering ~50-60% of the cluster area in ~80% of 
the plated clusters), whereas clones RC26 and 4603 presented a higher neural induction 
with almost 100% coverage of rosettes in all clusters, which also started to appear earlier 
than in the rest of the clones. Clone SMA1 had the lowest neural induction, with only a few 
clusters (~10-20%) containing rosettes and with many cells detaching from the plate. The 
same behaviour described for clones AC28, RC26, NC32 and TC63 was also observed in 
previous MN differentiations from these clones. Neuroepithelial cell identity was 
confirmed in the cells forming rosettes by the co-expression of Paired box gene 6 (PAX6) 
and Sex determining region Y-box1 (SOX1) (Figure 5.2B).  
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Figure 5. 2: Rosette 
formation and 
neuroepithelial identity. 
 (A) Several neural–tube like 
rosettes are found within each 
cluster of the plated embryoid 
bodies 14-15 days after the 
start of the differentiation 
protocol. (B) Co-expression of 
PAX6 (red) and SOX1 (green) 
confirms neuroepithelial 
identity. Images A and B for 
each clone are taken from 
different fields/wells. Scale 
bar= 100µm. 
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Subsequently, the rosettes were manually separated from the EBs and grown in suspension 
as neurospheres, which were then plated on polyornithine-laminin (PO-Laminin) surfaces. 
Figure 5.3 shows the presence of two MN progenitor markers (p75-NGFR and OLIG2) in 
a high percentage of the population. Almost all cells within the cultures of each of the 
clones were positive for OLIG2, even though the exact proportion could not be quantified 
due to the three dimensional disposition of the cells within the clusters (this will be 
discussed in the following sections). P75-NGFR expression was also found to be very high 
(~80-85% of the population) when dissociated cells were subjected to immunopanning with 
this antibody, as judged by the proportion of cells that effectively remained attached to the 
antibody-treated plate after the washing steps  (data not shown). The results from the 
immunopanning experiments are not presented here, since single cells did not survive in 
culture. 
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Figure 5. 3: iPSC differentiation into MN progenitors.  
Neurospheres from all clones were plated on PO-laminin coated-coverslips and stained on D28 for the MN 
progenitor markers (A) p75-NGFR (red) and (B) OLIG2 (green). Cell nuclei were counterstained with DAPI 
(blue). Images for each clone were taken from different fields/wells. Images for OLIG2 staining of clone 4603 
could not be obtained due to technical issues with cell attachment. Scale bar= 50µm 
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Several hours after the neurospheres were plated on PO-laminin surfaces, they started 
extending projections (putative neurites), which progressively grew reaching lengths of 
more than 3 mm after one week in some cases. Figure 5.4 shows the typical morphology 
and organization of the cells in culture. In all clones, the clusters contained most of the cell 
bodies within a 3D structure from which long projections extended. In general, plating 
more neurospheres into the same well produced healthier cultures and longer neurites. On 
the other hand, plating big neurospheres (>300 µm in diameter) usually had a negative 
effect on their ability to attach, a situation that made the long-term culture and staining 
cumbersome. Since the outgrowth behaviour of different neurospheres of the same clone 
varied considerably, no conclusions can be made about possible differences in the 
phenotype of the cultures between the different clones. Only the cells of clone SMA1 
repeatedly presented an idiosyncratic migration behaviour with many cell bodies migrating 
out of the clusters. As can be seen in Figure 5.5, most of the projections in the MN cultures 
extended from neuronal cells as shown by the positive staining for TUJ1, thus confirming 
them as neurites. Neurite growth estimates are presented in the next section of this chapter. 
There was also a small proportion of glial cells present in the cultures as judged by positive 
Glial fibrillary acidic protein (GFAP) staining (data not shown). 
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Figure 5. 4: Cytoplasmatic projections after plating of neurospheres. 
A few hours after plating neurospheres on PO-laminin surfaces, long projections began to grow the clusters. 
The images shown here were taken from clusters seeded at high confluence on D28 and photographed twelve 
days later. Scale bar= 500 µm. 
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Figure 5. 5: Neuronal identity of cytoplasmatic projections.  
TUJ1 expression on D35 shows that a high proportion of projections in the cultures are of neuronal origin, 
confirming them as neurites. Cell nuclei were counterstained with DAPI (blue). Scale bar= 100 µm.  
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From D28 onwards, definitive MN markers started to be expressed, with the postmitotic 
immature MN marker ISL-1 showing earlier that the mature MN marker Choline 
Acetyletransferase (ChAT). Figure 5.6 shows positive signals for both markers, confirming 
the presence of MNs in the cultures derived from iPSCs of all clones. Nuclear markers such 
as ISL-1 and HB9 could not be quantified within the three-dimensional clusters, since the 
density of cells was too high and even confocal microscopy could not resolve the layers 
properly.  Given that most of the cells bodies of the MNs were immersed within these 
clusters, it was not possible to determine the yield of MNs in the culture. An estimation 
from the pictures seems to suggest that the average MN yield was ~10-15%, again, with a 
high degree of variability between the clusters of the same clone.  MN cultures were only 
maintained until the presence of ChAT was assessed (around D47). 
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Figure 5. 6: Definitive MN identity.  
Between days 28-47 of MN differentiation, the cells in the neurospheres start expressing definitive MN 
markers. Neurospheres from all clones were plated on D28 on PO-laminin coated coverslips and stained (A) 
on D35 for ISL-1 (red) and (B) on D46 for ChAT (green). Cell nuclei were counterstained with DAPI (blue).  
Images of panels A and B were taken from different fields/wells of the respective clone. Scale bar= 50µm. 
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5.1.2 NEURITE GROWTH IN iPSC-DERIVED MNS 
Neurite growth was monitored during the first 8 days after the plating of neurospheres. In 
order to avoid the overlapping of neurites during their outgrowth, 10 neurospheres of 
similar size were homogeneously seeded in 30 mm dishes. At least 5 neurospheres per 
clone remained attached and were used for analysis and the measurements were performed 
on the 5 longest neurites on the day of observation (out of a total of 5-50 distinguishable 
neurites). All clones presented a similar neurite growth profile during the period of 
measurement, even though their mean absolute neurite length values were significantly 
different between each other (One-way ANOVA, repeated measures P<0.001). The 
absolute length of all selected neurites increased from 228-428 µm on day 1 to 1050-1744 
µm on day 8 (Figure 5.7A). In order to avoid the influence of the innate neural 
differentiation propensity (Hu et al. 2010; Boulting et al. 2011) and the efficiency of 
attachment of neurospheres from different clones, growth rates were compared in addition 
to the absolute length (Figure 5.7B). The comparison between the growth rates across the 
seven-day observation period shows no significant difference between the clones (One-way 
ANOVA, repeated measures P>0.05). 
 
Figure 5. 7: Neurite outgrowth from neurospheres. 
D26 neurospheres were plated on PO-laminin coated dishes and the lengths of the five longest neurites from 
each five neurospheres per clone were measured at different points for 8 days. (A) Absolute neurite length 
between day 1 and 8. (B) Average neurite growth rate during three consecutive time intervals (d3-d1, d6-d3, 
d8-d6).  Data are presented as mean ± SEM.  
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5.1.3 iPSC-DERIVED MNS IN CO-CULTURE WITH MOUSE MYOTUBES 
While most reports about SMA focus on MNs, there is evidence that actually their 
connection point with muscles, the NMJ, may be critically involved in disease 
development.  The NMJ is the synapse between lower alpha MNs and muscle fibres, and 
the functional interaction between these two entities is primarily mediated by the 
transmitter ACh (Sanes & Lichtman 2001). In order to simulate this system in vitro, D39 
neurospheres were co-cultured on differentiated mouse C2C12 myotubes for three days in 
1:1 mix of C2C12 differentiation medium and complete MN differentiation medium as 
described in Materials and Methods (2.3.7.2.1). Several hours after plating, neurites started 
to extend out of the neurospheres, exhibiting a stable attachment in this configuration as 
compared to their attachment in the absence of muscle cells. Neurite growth accelerated the 
differentiation and further fusion of C2C12 myoblasts and promoted the clustering of ACh 
receptors (AChRs).  Figure 5.8 illustrates how AChRs were clustered in fibres surrounding 
the neurospheres. Indeed, in the co-cultures of all clones it is possible to observe the 
specific co-localization of TUJ1+ neurites with compact clusters of AChRs stained with α-
bungarotoxin. It is not possible to confirm if functional NMJs are formed, but certainly, 
there is co-localization of the structures involved. Aneural cultures also showed expression 
of AChRs (Figure 5.9), but they were mostly dispersed along the fibres. A few diffused 
clusters were present in the aneural cultures as well. No difference in the clustering of 
AChRs was observed between the co-cultures of the different clones. Further 
electrophysiological analysis would be needed in order to assess a potential SMA disease 
phenotype with the use of this co-culture system. Pictures of the co-cultures were taken by 
Dr Tizzano’s group in in Santa Creu i Sant Pau Hospital (Barcelona, Spain). 
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Figure 5. 8: Co-culture of iPSC-derived MNs and mouse myotubes. 
D39 neurospheres were seeded on differentiated C2C12 mouse myoblasts and cultured for 3 days in a mixed 
MN/muscle medium.  AChRs, identified by α-bungarotoxing staining (red), clustered in myofibres 
neighbouring the cells of the neuropheres. TUJ1+ (green) neurites emerging from the neurospheres were 
observed in close proximity to the AChR clusters (as indicated by arrows). The same behaviour was observed 
in the co-cultures of all iPSC clones.  Cell nuclei were counterstained with DAPI (blue). Scale bar: 20 µm. 
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Figure 5. 9: AChR expression in C2C12 mouse myoblasts cultured aneurally or with iPSC-derived MNs 
The diffused pattern of AChR expression in C2C12 mouse myoblasts cultured aneurally was reorganized 
upon co-culture with neurospheres into localized expression within defined clusters. Aneural and neural 
cultures were maintain in a mixed MN/muscle medium.  AChRs are identified by α-bungarotoxing staining 
(red). Scale bar: 20 µm. 
 
5.1.4 MN TRANSDUCTION 
The results shown in this section are primarily a qualitative assessment of transduction 
efficiency from rH1LVs and rAAV9s in iPSC-derived MNs, and the data presented 
correspond specifically to experiments performed with iPSC clone TC63. 
As described in Materials and Methods (2.3.5.2.4 and 2.3.5.3.4.2), the transduction of 
iPSC-derived MNs was performed by incubating the viral vectors with the neurospheres 
prior to plating. This method was used to minimize the volume of medium during 
transduction in order to increase transduction efficiency. Nevertheless, the results seem to 
suggest that the vectors were not able to penetrate far into the neurospheres and thus, only 
images from cells on the edges of the neurospheres or cells which migrated out of the 
clusters are shown. The representative images of transduced cells presented here are taken 
to provide a qualitative estimation of transduction efficiencies of accessible cells. 
 5.1.4.1 rAAV TRANSDUCTION WITH A REPORTER GENE 
Cells from D22 neurospheres transduced at MOI 50,000 with scAAV9CageGFP, which 
carries a ubiquitous promoter driving the expression of the eGFP reporter, started to show a 
high level of eGFP approximately 72 hours after transduction (Figure 5.10A). For all 
neurospheres, preferential expression was observed on one side on the clusters, suggesting 
that not all cells were equally exposed or accessible to the viral vector during transduction. 
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An estimation from the pictures seems to suggest that approximately 25% of the cells 
within the whole cluster were eGFP+ five days post transduction (Figure 5.10B).  
 
 
Figure 5. 10: rAAV9 transduction in iPSC-derived MNs.   
D22 neurospheres obtained from the differentiation of clone TC63 were transduced with scAAV9CageGFP at 
an MOI of 50,000 (qPCR titre). (A) Three days after transduction GFP+ (green) cells were preferentially 
observed at one edge of the cluster as seen when superimposing bright field and fluorescent images. (B) Five 
days after transduction cells were fixed and stained with DAPI (blue) for a better estimation of the 
transduction efficiency. Scale bar = 100µm.   
 
 5.1.4.2 rH1LV TRANSDUCTION WITH A REPORTER GENE UNDER A MN 
ENHANCER/PROMOTER 
Cells from D22 neurospheres were transduced with HB9:RFP rH1LVs at a MOI of 100. 
The HB9 enhancer/promoter driving the expression of the RFP in this vector is a MN 
specific promoter, and particularly, the short version used in these recombinant vectors has 
been shown to be highly cell-type specific in vitro (Lee et al. 2004; Marchetto et al. 2008; 
Hester et al. 2011). In this particular experiment many of the cells from clone TC63 
migrated out of the clusters and grew in less confluent layers as compared with the 
previously described experiments. It was still not possible at this stage to estimate 
transduction efficiency prior to DAPI staining, but the proportion of RFP+ cells increased 
over time, particularly from D34 (Figure 5.11). These results are in agreement with what 
was previously described in section 5.1.1, which states that definitive MNs markers start to 
be expressed between days 28-47 of MN differentiation, with HB9 particularly peaking 
towards days 35-47 (Hu & Zhang 2009), suggesting active MN production during this 
period. In order to estimate the proportion of cells expressing the reporter after rH1LV 
transduction in cells that migrated out of the neurospheres, cultures were fixed and stained 
with DAPI. Quantifications made in three different fields where individual cells could be 
??
??
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counted using the Image J software (Figure 5.12). Between 12-17% of the migrated cells 
were RFP+ at D43, indicating active MN-specific promoter expression and providing an 
estimate of the efficiency of MN production at this time-point (which is in agreement with 
the rough estimations made by ISL-1 staining on D35). In this regard, it is important to 
mention again, that the proportion of positive cells varied between clusters and that the 
transduction efficiency percentages are not representative for the whole structure of the 
neurosphere.  
 
Figure 5. 11: Temporal pattern of RFP expression under a MN specific enhancer/promoter in iPSC-
derived MNs transduced with rH1LVs.   
D22 neurospheres obtained from the differentiation of clone TC63 were transduced with HB9:RFP rH1LVs at 
a MOI of 100 (qPCR titre). Bright field and RFP (red) fluorescence are shown individually and merged in 
images taken (A) 2, (B) 5, (C) 12 and (D) 21 days post-transduction (corresponding to days 24, 27, 34 and 43 
of MN differentiation, respectively). Lower images in panel D show the typical aspect of RFP expression seen 
inside the clusters. Scale bar = 100µm.   
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Figure 5. 12: RFP expression as an indicator of MN yield.  
Cells described in Figure 5.10D (21 days post-transduction, corresponding to day 43 of MN differentiation). 
were fixed and stained with DAPI (blue) for a better approximation of the proportion of cells expressing RFP 
(red) under the MN-specific enhancer/promoter HB9. Four different fields are presented. Scale bar = 100µm.   
 
 
 
 
 
 
 
 
 
 
 
 
 
DAPI RFP Merged 
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 5.2 iPSC-DERIVED HEPATOCYTES  
iPSC clone RC26 was differentiated into hepatocytes in order to provide an alternative 
mature cell type differentiated from an iPSC clone for the molecular experiments described 
in the next chapter regarding SMN regulation during iPSC differentiation. In this section, 
the characterisation of the differentiated hepatic cells is shown. 
As described in Materials and Methods (2.3.7.3), hepatocyte differentiation was done 
according to the method outlined by (Song et al. 2009). Unlike in the case of MN 
differentiation, hepatic differentiating cells were not manually selected or passaged during 
the 21 days of the protocol. Linage coaxing was accomplished by the sequential addition of 
signalling molecules such as Activin A (for endoderm induction, D1-D3), FGF4 and BMP2 
(for hepatic specification, D4-D7), HGF and KGF (for hepatoblast expansion, D8-D13), 
oncostatin M, dexamethasone, N2 and B27 (for hepatic maturation, D14-21). Figure 5.13 
shows a characterization of markers in the derived cells to assess hepatocyte identity. D21 
cells showed high and broad expression of the hepatic marker α-fetoprotein (Figure 5.13B) 
as well as storage of lipids (Figure 5.13C) and glycogen (Figure 5.13D). The specificity of 
the glycogen storage during the Periodic Acid-Schiff (PAS) test was confirmed by treating 
the cells with α-amylase before the staining procedure, a treatment that abolished the 
positive signal of the test. 
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Figure 5. 13:  Phenotypic and functional characterisation of D21 RC26 iPSC-derived hepatocytes. 
(A) Morphology of cells in bright field. (B) Expression of the hepatic cell marker AFP, (red). Cell nuclei were 
counterstained with DAPI (blue). (C) Sudan staining exposing the storage of lipid vesicles. A higher 
magnification field of the first picture is shown on the right hand side. (D) PAS staining showing the storage 
of glycogen (“-“). Treatment with alpha amylase (“+”) eliminated the positive signal in the PAS staining, 
confirming the intracellular accumulation of glycogen.  Scale bar= 50µm. 
??
??
??
??
?? ??
 153 
 
 
 
CHAPTER 6: RESULTS- SMN AND PLS3 LEVELS DURING iPSC 
DIFFERENTIATION 
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This chapter presents all the molecular analyses performed with the populations described 
in the previous chapter including fibroblasts, iPSCs, EBs, rosettes, neurospheres, MNs, 
immature hepatocytes and mature hepatocytes. The results from all terminally 
differentiated clones are presented here. Within all cell populations the expression of SMN 
splicing isoforms and PLS3 were assessed at the transcriptional (mRNA) and translational 
(protein) level, with the aim of comparing these critical SMA-related products between 
individuals and between cells types. mRNA-related experiments were performed by Dr. 
Tizzano’s group in Santa Creu i Sant Pau Hospital (Barcelona). Clones SMA1 and 4603 
were only included in this study during the last iPSC-MN differentiation, in order to 
provide a reference for the most severe disease state (SMA1) and an unaffected control 
reference with no SMN1 mutations (4603). No differentiation replicates were performed for 
the last two clones. Results from three and two iPSC-MN differentiations are presented for 
clones AC28 and RC26 and clones NC32 and TC63, respectively. 
 6.1 SMN-RELATED ISOFORM LEVELS  
The transcription and further processing of the SMN1 and SMN2 genes produces two main 
mRNAs: FL-SMN and Δ7-SMN (please refer to introduction for more details). FL-SMN 
produces a stable functional protein, whereas it is thought that the putative translation of 
Δ7-SMN produces a less functional protein that is rapidly degraded (Lorson et al. 1998; 
Lorson & Androphy 2000). As of today, no antibody has been produced against the Δ7-
SMN isoform. Therefore, only the quantification of the FL-SMN protein is shown in this 
section. Regarding transcript quantification, three different sets of primers were used. The 
first set amplified a sequence at the junction between exons 1 and 2 of the SMN mRNA and 
thus measured all spliced isoforms, denominated here as total SMN (tSMN).  The second set 
amplified a sequence at the junction between exons 6 and 7 that is only present in FL-SMN 
and the third set amplified a sequence in the junction between exons 6 and 8 that is unique 
to Δ7-SMN.  Please refer to Appendix 2 for details of the primers.  
6.1.1 ORIGIN OF FL-SMN TRANSCRIPTS  
As it has been stated before, FL-SMN can be transcribed from both SMN1 and SMN2 genes. 
Nonetheless, given that the members in the family of study possess a mutation in the SMN1 
gene that predicts an early stop codon (but does not block SMN1 transcription), I aimed to 
investigate if this mutation also prevented the generation of stable FL-SMN mRNA. For 
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this, a fragment containing exons 6-8 of the SMN transcripts (SMN1 and SMN2) were 
amplified by RT-PCR and further digested with DdeI. Given that only the SMN2 gene 
possess a recognition site for this enzyme, their transcripts can be distinguish from the ones 
originating from the SMN1 gene by their molecular size (Figure 6.1A).  Figure 6.1B shows 
that all 4603 unaffected control cells (iPSCs [D0], EBs [D7], rosettes [D15], neurospheres 
[D28] and MNs [D42]) produced FL-SMN from both SMN1 and SMN2 genes, same as cells 
from the carrier mother (RC). In contrast, essentially all FL-SMN transcripts in cells from 
the siblings of study (AC, TC and NC) originated from their SMN2 genes; this was also the 
case in SMA1 cells. However, we did observe very faint FL-SMN1 bands in some samples 
from siblings of the family of study (see for instance the neurospheres in Figure 6.1B). 
This indicates that this transcript is produced at high enough levels to allow detection in 
some cases. 
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Figure 6. 1: Origin of FL-SMN transcripts.  
(A) Diagram showing the amplification and restriction pattern analysis performed for the determination of the 
locus from which FL-SMN transcripts originated. (A1, A2) Exons 6-8 from the SMN1 and SMN2 genes were 
amplified by RT-PCR producing 504 bp and 450 bp fragments, corresponding to FL-SMN and Δ7-SMN 
transcripts respectively. (A3) The following DdeI digestion of the PCR products produced the specific 
cleavage of the SMN2 transcripts generating 382 bp and 328 bp fragments, corresponding to FL-SMN2 and 
Δ7-SMN2 respectively. (B) Restriction analysis of iPSCs (D0), EBs (D7), rosettes (D15), neurospheres (D28) 
and MNs (D42) from the six clones of study. Δ7-SMN1 transcripts are produced at very low levels. 
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6.1.2 GENERAL VARIATION OF SMN RNA AND PROTEIN LEVELS DURING iPSC-
MN DIFFERENTIATION 
In order to follow the pattern of SMN RNA and protein levels during iPSC-MN 
differentiation, clonal values were pooled together by cell type into two groups: unaffected 
individuals (RC26 and 4603) and SMA patients (SMA1, AC28, TC63, NC32) (Figure 6.2). 
AC was included in the SMA group given the patient’s lack of functional SMA1 genes (as 
her SMA type III symptomatic siblings) and the presence of minimal electromyography 
alterations.  The fibroblasts used for iPSC reprogramming are included in the graphics as a 
reference, but they are not part of the cell types harvested during the iPSC-MN 
differentiation and thus are not included in the statistical analyses to avoid bias. Unaffected 
and SMA groups showed similar variation across cell types along the MN differentiation 
process for all the parameters measured (P> 0.05), but FL-SMN mRNA, SMN protein and 
the FL/Δ7-SMN mRNA ratio were all in general significantly higher in unaffected 
individuals (P<0.001, P<0.05, P<0.001 respectively). Statistically significant changes were 
however found between both groups during post hoc analyses in the EB FL-SMN mRNA 
(P<0.05) and the rosette and MN of the FL/Δ7-SMN mRNA ratio (P<0.001). Moreover, 
further cell type analyses combining unaffected and SMA patients show that, although 
mRNA levels of FL-SMN and tSMN did not significantly vary between cell types (Figure 
6.2A and E), SMN protein levels did  (P<0.01) (Figure 6.2B).  Furthermore, SMN protein 
levels showed a gradual decay during the iPSC-MN differentiation process (linear trend 
P<0.05), with the lowest value observed specifically in MNs.  
In order to see if the decay in SMN protein was specific to iPSC-MN differentiation or a 
general pattern of iPSC differentiation, RC26 iPSCs were differentiated into hepatocytes.  
As it can be seen in Figure 6.3 during iPSC-hepatocyte differentiation the mRNA levels of 
tSMN, FL-SMN and Δ7-SMN did not change greatly, whereas SMN protein levels 
fluctuated considerably. SMN protein increased 4-fold between iPSCs and the D7 
hepatocyte differentiation culture (corresponding to immature hepatocytes), and then 
decreased by D21 (corresponding to mature hepatocytes) but to a level 2-fold higher than in 
iPSCs. Notably, SMN protein levels in the mature D21 hepatocyte cultures were also at 
least 2-fold higher than in mature MN cultures (all values shown in this chapter were 
calibrated against the same sample [SMA type II fibroblasts] unless otherwise stated).  
Therefore, it seems that the progressive reduction in SMN protein levels during 
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differentiation was peculiar to the MN cultures. It is important to emphasize again that 
hepatocyte values correspond to only one iPSC differentiation round, from a single clone 
and that RC26 iPSCs had the lowest SMN protein levels among all clones.  
 
 
Figure 6. 2: Variation of SMN RNA and protein levels during IPSC-MN differentiation.   
The expression of FL-SMN mRNA (A), SMN protein (B), Δ7-SMN mRNA (D), tSMN mRNA (E) and the 
FL/Δ7-SMN mRNA ratio (F) is shown for each cell type. Unaffected individuals (RC+4603) and SMA 
patients (SMA1, AC28, TC63 and NC32) are shown separately. Data are presented as mean ± SEM. Samples 
were calibrated to a common stock derived from SMA type II fibroblasts. For qRT-PCR, samples were 
normalized with the geometric mean of the values from beta actin (ACTB), glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) and peptidylprolyl isomerase A (PPIA). For western blot, samples were normalized 
with the geometric mean of the values from alpha tubulin (TUBA), glucose phosphate isomerase (GPI1) and 
actin. Brown, black and gray asterisks/lines in each panel compare unaffected group vs SMA group in 
general, cell types in general and unaffected group vs SMA group by cell type, respectively. *, P<0.05; **, 
P<0.01; ***, P<0.001. (C) Representative western blot showing decay in SMN protein during the iPSC-MN 
differentiation of clone TC63. 
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Figure 6. 3: Variation of SMN RNA and protein levels during iPSC-hepatocyte differentiation.  
(A) Expression of FL-SMN mRNA, Δ7-SMN, tSMN mRNA, FL/Δ7-SMN mRNA ratio and SMN protein in 
iPSCs, intermediate hepatocyte progenitors harvested at day 7 of RC26 iPSC differentiation (Hep D7) and 
mature hepatocytes harvested at day 21 (Hep D21). Samples were calibrated to a common stock derived from 
SMA type II fibroblasts. For qRT-PCR, samples were normalized with the geometric mean of the values from 
ACTB, GADPH and PPIA. For western blot, samples were normalized with the geometric mean of the values 
from TUBA, GPI1 and actin. (B) Western blot showing the fluctuation in SMN protein during iPSC-
hepatocyte diferentiation. 
 
6.1.3 PATIENT SPECIFIC VARIATION OF SMN RNA AND PROTEIN LEVELS 
DURING IPCS-MN DIFFERENTIATION 
Variation in SMN RNA and protein levels during iPSC-MN differentiation for each 
individual clone was also assessed. Individual clones showed heterogeneous mRNA 
expression levels of FL-SMN and Δ7-SMN, but fairly constant tSMN and FL/Δ7-SMN 
mRNA ratios between differentiation stages, with the exception of the increasing FL/Δ7-
SMN ratio in wt clone 4603 (Figure 6.4A, C D and E respectively). Most importantly, 
consistent with the observation made when clones were grouped by developmental stage 
(Figure 6.2B), all individual clones exhibited a gradual decrease in SMN protein during the 
MN differentiation process (Figure 6.4B). When all the cell types from each clone were 
pooled together, unaffected clones (particularly clone 4603) could be distinguished from the 
other clones by their higher FL/Δ7-SMN ratios. The distinction was shown to be statistically 
significant, but only for 4603 (P<0.001) (Figure 6.5A). These results reflect the high FL-
SMN and low Δ7-SMN mRNA levels observed for the unaffected group in the previous 
graphics, particularly towards the most differentiated stages (Fig 6.2A and D). 
Furthermore, the pooled tSMN mRNA values of SMA1 cells were found to be significantly 
lower than those observed in the clone from the carrier mother RC26 and the siblings 
(AC28, NC32 and TC63) (p<0.001) (Figure 6.5B), perhaps reflecting the reduced number 
of SMN gene copies present in SMA1.  
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Figure 6. 4: Patient specific variation of SMN RNA and protein levels during IPSC-MN differentiation.   
The expression of FL-SMN mRNA (A), SMN protein (B), Δ7-SMN mRNA (C) tSMN mRNA (D) and FL/Δ7-
SMN mRNA ratio (E) is shown for each clone/patient along all its cell types. Samples were calibrated to a 
common stock derived from SMA type II fibroblasts. For qRT-PCR, samples were normalized with the 
geometric mean of the values from ACTB, GADPH and PPIA. For western blot, samples were normalized 
with the geometric mean of the values from TUBA, GPI1 and actin. 
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Figure 6. 5: Patient specific variation of pooled values during IPSC-MN differentiation.  
FL/Δ7-SMN mRNA ratio (A) and tSMN mRNA (B) values from all tissues (iPSCs, EBs, Rosettes, 
neurospheres and MNs) were pooled together for comparison. Data are presented as mean ± SEM. Samples 
were calibrated to a common stock derived from SMA type II fibroblasts. For qRT-PCR, samples were 
normalized with the geometric mean of the values from ACTB, GADPH and PPIA. For western blot, samples 
were normalized with the geometric mean of the values from TUBA, GPI1 and actin. **P<0.01, ***P<0.001.  
 
6.1.4 PATIENT SPECIFIC SMN RNA AND PROTEIN LEVELS IN MOTOR 
NEURONS 
Given that MNs are the main affected cell type in SMA, a separate analysis was performed 
to evaluate specifically the differences in SMN RNA and protein levels between individuals 
in this particular cell type.  As can be seen in Figure 6.6, both FL-SMN mRNA and protein 
levels are particularly high for 4603 MNs, whereas the levels in SMA1 MNs are similar to 
the one seen in the siblings. The FL/Δ7-SMN ratio is also very high for 4603 cells.  
The mRNA analysis also includes levels in SMA1 MNs transduced with scAAV9s carrying 
the hSMN1 gene (scAAVCaghSMN1F), which could not be assessed at the protein level 
!"!#
$"!#
%"!#
&"!#
'"!#
(!"!#
%&
!)
#
*+
,(
#
-.
$&
#
,.
$'
#
/.
&)
#
0
.)
$#
-,/12#34567#*+0#
!"
#"
!"!#
$"!#
%"!#
&"!#
%&
!'
#
()
*+
#
,-
$&
#
*-
$.
#
/-
&'
#
0
-'
$#
()01#2,0*#
$$$"
$$$"
$$$"
$$$"
$$"
!"
#
$%
%
&'
!"
%&
'(
)*
+"
#
$%
%
&'
!"
()
*+
"
$$$"
$$$"$$"
$$$"
 162 
given the low protein yield. The results suggest an up-regulation in FL-SMN mRNA levels 
and a down-regulation in Δ7-SMN mRNA, congruent with the behaviour of unaffected 
4603 MNs.  No statistical significance can be given since these data correspond only to 2 
iPSC-MN differentiation experiments. 
 
 
Figure 6. 6: Patient specific SMN RNA and protein levels in MNs. 
(A) Expression of FL-SMN mRNA, Δ7-SMN mRNA, tSMN mRNA, FL/Δ7-SMN mRNA ratio and SMN 
protein for the iPSC-derived MNs of all individuals. Samples were calibrated to RC26 MNs. For qRT-PCR, 
samples were normalized with the geometric mean of the values from ACTB, GADPH and PPIA. For western 
blot, samples were normalized with the geometric mean of the values from TUBA, GPI1 and actin. (B) 
Representative western blot of  SMN proteins in MNs. 
  
 
 
 
 
 
!"!#
!"$#
%"!#
%"$#
&"!#
&"$#
'"!#
'"$#
()!'# *+&)# ,+&-# .+)'# /+'&# 01,%# 01,#%#,,2##
345#01/#6*/,# 78501/#6*/,# 01/9#6*/,# *,.:;#34<78#01/#6*/,# 01/#=>?9@AB#
!"
#"
!"#$%&'()*$%&!"'()*"$%&'()*$%&!"
!"
#$
%
&"
#'
%
("
')
%
*
")
#%
+'
,)
%
-.
!/
%
(01!%
234/%
!567%
-.*%
+'()*$%&!"!"&'()*$%&!" +,&"-'*./01"
 163 
 6.2 PLS3 LEVELS 
PLS3 levels were followed and analysed in a similar way as in the case of SMN. 
 
6.2.1 GENERAL VARIATION OF PLS3 RNA AND PROTEIN LEVELS DURING 
iPCS-MN DIFFERENTIATION   
 
In order to follow the pattern of PLS3 levels during iPSC-MN differentiation, the values of 
all six clones were grouped by cell type (Figure 6.7). Individuals were not separated in 
unaffected individuals and SMA patients as in the previous analysis given that the level of 
PLS3 has only been reported as a modifier factor of the severity of SMA and not as the 
cause. The fibroblasts used for iPSC reprogramming are included in the graphics as a 
reference, but they are not part of the cell types harvested during the iPSC-MN 
differentiation and thus are not included in the statistical analyses to avoid bias. Both, PLS3 
mRNA and protein levels were found to vary between cell types (P<0.001) and in both 
cases there is a gradual decay during iPSC-MN differentiation (linear trend P<0.0001). As 
in the case of SMN, cells harvested from RC26 iPSC differentiation into hepatocytes were 
used to assess the specificity of the decay. As shown in Figure 6.8, PLS3 mRNA and 
protein levels, as FL-SMN protein levels (Figure 6.3) increase from iPSCs to immature 
hepatocytes (D7), and then decreased by D21 in mature hepatocytes. PLS3 protein levels in 
mature hepatocytes are considerably higher (4 to 5-fold) than those found in neural cells. 
Hepatocyte values correspond to only one round of RC26 iPSC differentiation. 
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Figure 6. 7: Variation of PLS3 RNA and protein levels during iPSC-MN differentiation. 
 The Expression of PLS3 mRNA (A) and PLS3 protein (B) is shown for each cell type. Data are presented as 
mean ± SEM. Samples were calibrated to a common stock derived from SMA type II fibroblasts. For qRT-
PCR, samples were normalized with the geometric mean of the values from ACTB, GADPH and PPIA. For 
western blot, samples were normalized with the geometric mean of the values from TUBA, GPI1 and actin. 
*P<0.05, **P<0.01, ***P<0.001. (C) Representative western blot showing the decay in the PLS3 protein 
along the iPSC-MN differentiation of clone TC63. 
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Figure 6. 8: Variation of PLS3 RNA and protein levels during iPSC-hepatocyte differentiation.  
 (A) The expression of PLS3 mRNA and PLS3 protein is shown for intermediate hepatocyte progenitors 
harvested at day 7 of RC26 iPSC differentiation (Hep D7) and mature hepatocytes harvested at day 21 (Hep 
D21). Samples were calibrated to a common stock derived from SMA type II fibroblasts. For qRT-PCR, 
samples were normalized with the geometric mean of the values from ACTB, GADPH and PPIA. For western 
blot, samples were normalized with the geometric mean of the values from TUBA, GPI1 and actin. (B) 
Western blot showing the levels of PLS3 protein during iPSC-hepatocyte differentiation. 
 
6.2.2 PATIENT SPECIFIC VARIATION OF PLS3 RNA AND PROTEIN LEVELS 
DURING iPCS-MN DIFFERENTIATION 
The clone specific variation of PLS3 levels during iPSC-MN differentiation was also 
evaluated.  In general terms, all individuals showed the previously described gradual decay 
in PLS3 mRNA and protein (Figure 6.9). Control 4603 cells present lower PLS3 mRNA 
and protein levels compared to the rest of the clones. 
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Figure 6. 9: Patient specific variation of PLS3 RNA and protein levels during iPSC-MN differentiation. 
The expression of PLS3 mRNA (A) and PLS3 protein (B) is shown for each clone/patient during the 
differentiation process. Samples were calibrated to a common stock derived from SMA type II fibroblasts. For 
qRT-PCR, samples were normalized with the geometric mean of the values from ACTB, GADPH and PPIA. 
For western blot, samples were normalized with the geometric mean of the values from TUBA, GPI1 and 
actin.  
 
 
6.1.4 PATIENT SPECIFIC PLS3 RNA AND PROTEIN LEVELS IN MNs 
MN-specific PLS3 level in iPSC-derived cells from members of the family of study are 
compared in this section.  As can be seen in Figure 6.10 the PLS3 protein level in the MNs 
of AC28 is 150% higher than the one observed in the carrier unaffected mother (RC26) and 
it is also 65% higher than the affected siblings (TC63 and NC32). The highest mRNA 
levels were nonetheless observed in cells from NC32. No statistical significance can be 
given since the data correspond to only 2 iPSC-MN differentiation experiments. It is worth 
mentioning that apparently different forms of PLS3 were found on the western blots of 
fibroblasts and MNs which differ in ~2 kDa (Figure 6.11). 
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Figure 6. 10: Patient specific PLS3 RNA and protein levels in MNs.  
(A) Expression of PLS3 mRNA and PLS3 protein in iPSC-derived MNs of the individuals of the family of 
study. Samples were calibrated to RC26 MNs. For qRT-PCR, samples were normalized with the geometric 
mean of the values from ACTB, GADPH and PPIA. For western blot, samples were normalized with the 
geometric mean of the values from TUBA, GPI1 and actin. (B) Representative western blot of PLS3 protein. 
 
 
 
Figure 6. 11: PLS3 expression in different cell types. 
Detection of PLS3 by western blot shows proteins of apparently different sizes in MNs and fibroblasts. 
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CHAPTER 7. DISCUSSION 
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Since the SMN1 gene responsible for the SMA pathology was first identified in 1995 
(Lefebvre et al. 1995), there have been many efforts to determine the specific function that 
this gene and its highly homologous SMN2 gene accomplish in the cells. Moreover, since 
SMN is expressed in all cell types, the particular susceptibility of MNs continues to be a 
matter of controversy, which is hindered by the inaccessibility of this cell type in humans. 
iPSC technology has made possible the generation of MNs from  accessible somatic cells 
which allows the study of the disease in the human relevant cell types. I have 
reprogrammed cells from a consanguineous discordant SMA family and further 
differentiated these cells into MNs. I had three main aims with the reprogramming of the 
cells: (1) to study potential disease phenotypes in iPSC-derived MNs, (2) to follow the 
expression of SMN isoforms at the transcriptional and translational level during the iPSC-
MN differentiation process and (3) to determine whether PLS3 could be the modifier factor 
in the discordant SMA family. To accomplish these main objectives, viral vectors were 
produced for diverse purposes, iPSC clones were generated and characterised, iPSC to MN 
differentiation protocols were adapted and applied, iPSCs were differentiated to 
hepatocytes, and several molecular analyses were performed in various cell types harvested 
during the differentiation process. Given the diversity of results described, this discussion 
will be split in sections in order to provide a comprehensible structure.  
 7.1 VIRAL VECTORS 
Viral vectors were used in this project for several purposes: rMMLVs were used for the 
generation of iPSCs and their selection and transduction efficiency will be discussed in that 
section. rH1LVs on the other hand were used as vehicles for the transfer of a reporter gene 
expressed under the control of a MN specific promoter and will discussed in the iPSC-MN 
differentiation section. Lastly, rAAV9s were used primarily to restore the expression of 
SMN in cells from a patient with SMA1 for molecular studies and they will be discussed 
here and in the last section.  
rAAVs, were the viral vectors I used the most during my project, given that I cloned two 
versions of the hSMN1 therapeutic gene in the rAAV backbone (Figures 3.3, 3.4 and 3.6), 
produced the viral vectors (Figure 3.8) and I tested their transduction efficiency in vitro in 
continuous cells line prior to iPSC-MN transduction (Figure 3.9). The methods for rAAV9 
production and quantification as well as the vector transduction efficiency are discussed 
here.   
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I have modified the protocol for the production of rAAV9s over time in order to increase 
the yield and I found that one of the key aspects was the confluence of the HEK293T cells 
at the time of calcium phosphate transfection (Figure 3.7). It seems that the less confluent 
the cells are, the higher is their metabolism and hence their ability to produce viruses.  This 
parameter also influences rH1LV production, since rLV plasmids were transfected 
following the same calcium phosphate protocol. Alternative methods have been developed 
in order to standardise the efficiency of cell transfection. A polyethylenimine (PEI)-based 
transfection method recently showed to have similar transfection efficiency than the 
calcium phosphate method in mammalian cells.  Protocols based on PEI transfection have 
now been optimized for rAAV production with the main advantage of being technically 
less cumbersome and more robust than the calcium phosphate method. (Lock et al. 2010). 
A second parameter affecting viral vector yield was the recovery of the particles in the 
supernatant by PEG precipitation, which was found to contain >50% of the viral particles 
produced, as shown by the one log unit increase in the viral titre (Figure 3.8). Indeed it has 
been shown that rAAV9s unlike rAAV2s are efficiently released from the cells and thus 
can be harvested from the culture medium (Vandenberghe et al. 2010). Moreover, if 
particles are harvested 5 days post transfection instead of 3, most of the particles are 
contained in the supernatant alone (Lock et al. 2010). 
The most suitable method to determine the titre of rAAVs is a matter of discussion. In 
general there are 3 possible ways: (i) detection of fully assembled and empty particles with 
an enzyme-linked immunosorbent assay (ELISA) using the A20 antibody (this is usually 
used only for rAAV2) (Grimm et al. 1999), (ii) detection of the genome copy number of 
viral particles, through DNA extraction followed by qPCR or dot blotting (Veldwijk et al. 
2002) and (iii) detection of infectious particles by functional assays with an rAAV 
encoding a reporter gene (Zolotukhin et al. 1999). 
The three approaches measure different parameters: the ELISA measures how many 
assembled capsids are present but not how many of them contain an rAAV genome, and it 
has been reported that ~80% of rAAV particles can be empty (Grimm et al. 1999); the 
qPCR and the dot blotting measure how many genome copies contained within the capsids 
(resistant to DNAse treatment) are present, but not how many of them are in truly infectious 
particles; and the functional assay (usually performed by transduction of cells with a 
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reporter vector encoding eGFP and assessed by epifluorescent microscopy/flow cytometry) 
measures specifically the number of infectious particles. 
In the titrations for the rAAVs produced here, I used qPCR and dot blot in order to 
determine the genome copy number. It was intriguing that even though both techniques 
measure the same parameter (genome copy number), the dot blot titre was always higher. I 
anticipated that given that the dot blot titre consistently gave one log unit more than the 
qPCR titre, there might be additional difficulties associated with genomic complexities in 
the determination of the genome copy number in self complementary (sc) vectors. Indeed, 
it has been recently published that the qPCR titre in scAAVs is systematically 
underestimated (by 10 fold, as compared to the dot blot titre) because of the presence of a 
hairpin at one end on the genome (Please refer to Figure 1.13 in the introduction) (Fagone 
et al. 2012). It seems that the hairpin enhances the re-annealing of the strands at the 
expense of primer binding. Given that the primers used for qPCR titration recognized the 
same segment in all my rAAV9s (in the Poly [A] tail next to the to the hairpin), the hairpin 
inhibition should have been consistent in all amplifications, a hypothesis that is supported 
by the constant difference with the dot blot titre.  
The functional titration assay for rAAV on the other hand is more cumbersome, particularly 
for AAV9, which is a serotype with very low transduction efficiency in vitro, as compared 
with AAV2 (Gao et al. 2004).  Given this handicap, the usual functional assay involves the 
co-transduction of rAAVs with adenoviruses serotype 5 (Zolotukhin et al. 1999; 
Warrington et al. 2004). The use of these wild-type viruses requires containment level 2 
and is not standard in our laboratory hence it was not employed. It is important to mention 
that even when the co-transduction with adenoviruses is used, the quantification of 
functional transducing rAAV particles is influenced by the cell type used, the promoter 
driving the transgene or the transgene itself and the helper virus used (Grimm et al. 1999). 
Assessing the viral titre is extremely important in preclinical and clinical studies and for 
standardising results among laboratories (Grimm et al. 1999). Nevertheless, titres are only 
approximate due to semi-quantitative titration methods, and in some cases (like in the case 
of iPSCs generation) no accurate MOIs are used. The determination of the titre of RVs is 
performed in a similar way, but genome copy numbers are determined after viral 
transduction and retro-transcription in suitable cells (Sastry et al. 2002). 
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In order to test the in vitro transduction efficiency of the rAAV9s (without the use of 
adenovirus type 5) two cell lines were used: HeLas and HEK293Ts (Figure 3.9). As 
expected, the transduction efficiency (assessed by the number of eGFP positive cells by 
flow cytometry) was very low, even with a MOI of 10,000 (qPCR titre). HEK293T cells 
showed a better transduction efficiency than HeLas (7.5% vs 1.9%). It is possible that the 
endogenous expression of some adenoviral genes in HEK293Ts could enhance AAV 
transduction given that this cell line was originally derived by transformation of human 
embryonic kidney cells with sheared adenovirus 5 DNA(Graham et al. 1977).  
Each viral vector has its own advantages and disadvantages, whereas rAAV9 shows a low 
transduction in vitro, it presents a high one in vivo. For RVs such as rMMLVs, the 
transduction efficiency in vitro is high, but it is restricted to particular proliferating cell 
types. Moreover, in recombinant technologies the RV tropism is given by a process of 
pseudotyping, which can confer ecotropic (narrow host range, mouse and rats), 
amphotropic (wide host range of mammalian cell types), or pantropic (no host range 
restriction) properties. Fibroblasts, such as the ones harvested from the family of study for 
further iPSC reprogramming are one of the cell types efficiently transduced by rMMLVs 
and these were indeed selected for this purpose.  
 7.2 iPSC REPROGRAMMING  
iPSCs have been generated from several types of cells, using different combinations of 
RTFs and different methods for nucleic acid/protein delivery. Each protocol has been 
adjusted in order to reprogram cells with the highest efficiency (increasing the percentage 
of reprogrammed cells), easily distinguishing true reprogrammed clones from intermediate 
states, using the least number of RTFs and avoiding the use of integrative vectors such as 
classical rRVs and integration proficient rLVs.  For the reprogramming of fibroblasts in 
this study, the complete Yamanaka’s RTF cocktail was used (Takahashi et al. 2007), with 
transgene delivery by four independent ecotropic rMMLVs (Park et al. 2008), through a 
“gesicle” mediated transduction strategy (Mangeot et al. 2011) and transduced cells were 
cultured following Meltons’ VPA protocol (Huangfu et al. 2008b). The advantages and 
disadvantages of the elements involved in reprogramming method will be discussed in this 
section. 
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The reprogramming efficiency of the cells from the five family members was very 
heterogeneous even though all fibroblasts propagated very well before transduction and 
they all had healthy morphology and good viability as judged by trypan blue exclusion and 
general observations under microscope (Figure 4.2). No correlation was found between the 
doubling time and the reprogramming efficiency, even though this is known to be an 
important parameter for effective retroviral transduction (Miller et al. 1990). Because the 
transduced fibroblasts in this study showed very rapid growth, a layer of detached floating 
cells formed on the surface making the identification of iPSC colonies particularly difficult. 
Other fibroblasts that were reprogrammed at the same time with the same protocol (from 
patients with other diseases) did not show this behaviour and it is probable that other 
factors intrinsic to the cells (maybe even the SMA pathology) could have played a role in 
this regard. Indeed, it has been shown that the disease mechanism of some pathologies can 
significantly hinder iPSC reprogramming (Raya et al. 2009; Muller et al. 2012), and 
previous studies involving reprogramming of SMA cells have shown very low efficiency 
(Ebert et al. 2009). Even though the parameters for measuring reprogramming efficiency 
are not well defined (Gonzalez et al. 2011), the general idea is to assess the percentage of 
plated somatic cells that were transfected/transduced/treated with RTFs and actually 
became iPSCs or iPSC-like colonies (i.e. 100,000 cells plated and 100 iPSC colonies 
obtained= 0.1%). Given the fact that most of the iPSC-like colonies picked did not actually 
survive and propagate, the estimations given are very likely to be inaccurate as a measure 
for true iPSC reprogramming. The cells that produced more iPSC-like colonies (~80) were 
from AC, followed by NC, and five clones were propagated from each of them (the term 
“clone” is applied here to iPSC colonies that managed to propagate for at least 5 passages). 
Their reprogramming efficiency as measured by their ESC-like morphology was ~ 0.1%. 
Sixteen iPSC-like clones were picked from TC cells, but only two of them propagated. For 
RC, seven clones were picked and only one propagated. The reprogramming efficiency of 
the two latter clones was less that 0.01% (Please refer to Appendix 4 for a final list of the 
clones). Although heterogeneous, the range of reprogramming efficiency corresponds to 
those reported by other groups using rRV-base delivery for iPSC reprogramming, with 
clones TC and RC located in the lower limit of that range (Gonzalez et al. 2011). CC on the 
other hand did not produce any iPSC colonies.  
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Several factors can influence the reprogramming efficiency independently of the intrinsic 
characteristics of the donor’s cells, including: (i) RTFs used for reprogramming (ii) method 
and stoichiometry of RTF delivery, (iii) use of small molecules and (iv) type of somatic cell 
to be reprogrammed.  
Some of the first questions to be addressed prior to reprogramming are: what RTFs to use, 
Yamanaka’s cocktail or Thomson’s cocktail? the standard sets of four RTFs, more factors 
or fewer factors? (Takahashi et al. 2007; Yu et al. 2007). Most iPSCs-related publications 
have used (at least for the positive control derivation) Yamanaka’s cocktail instead of 
Thomson cocktail. Indeed, in I-STEM (the institute where I reprogrammed the fibroblasts), 
Yamanaka’s cocktail was chosen particularly because at that time in their hands, 
Thomson’s cocktail (delivered through rLVs) was not producing iPSCs.   
Within the last four years, several factors have been excluded from the reprogramming 
cocktail and OCT4 has been found to be the only indispensable RTF required for 
reprogramming (Kim et al. 2009b; Kim et al. 2009c), excluding the iPSC derivation 
through microRNAs (Miyoshi et al. 2011). Indeed, using a similar protocol to the one 
followed for the generation of the iPSCs in my study, it was shown that the reprogramming 
of human fibroblasts was also achieved using only SOX2, OCT4 and VPA, but the 
reprogramming efficiency dropped by 1000 fold (Huangfu et al. 2008b). Since retroviral c-
MYC reactivation has been associated with tumour formation in iPSC-derived chimeric 
mice (Okita et al. 2007), there has been an increasing pressure to dismiss this RTF from the 
reprogramming cocktail in cell therapy studies. Given that my project was designed as a 
disease modelling study and not for a therapeutic approach, we agreed to use all the factors 
in Yamanaka’s cocktail, including the oncogenes c-MYC and KFL4 in order to increase the 
probability of getting clones from the cells of all family members. 
As it is described in the introduction, several integrating, non-integrating and excisable 
methods have been developed for the delivery of RTFs, nonetheless the classical methods, 
which provide the highest reprogramming efficiencies, rely in the use of MMLV-based 
rRVs and rLVs (Takahashi & Yamanaka 2006; Blelloch et al. 2007; Wernig et al. 2007; Yu 
et al. 2007; Aasen et al. 2008; Park et al. 2008; Kim et al. 2009b). rMMLVs, unlike rLVs 
are known to be down-regulated during reprogramming (a hallmark of complete 
reprogramming), while rLVs are poorly attenuated in the pluripotent state (Okita et al. 
2007; Yu et al. 2007; Hotta et al. 2009). On the other hand, LVs transduce dividing and 
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non-dividing cells while MMLVs can only infect dividing cells, limiting the types of cells 
that can be reprogrammed (Naldini et al. 1996; Kafri et al. 1997; Miyoshi et al. 1997; 
Wanisch & Yanez-Munoz 2009). In the protocol followed in this study I used four of the 
six MMLV-based plasmids that were produced by Daley’s group (Park et al. 2008), but 
viral vectors were generated in Plat-E, in order to produce ecotropic viruses that could be 
used in a French level II containment laboratory. In order to allow the entry of the ecotropic 
viral vectors into the human cells, the latter were incubated with “gesicles” carrying the 
mCAT-1 receptor prior to transduction. Even though this protocol differs from the 
archetypical amphotropic rMMLV reprogramming, the transduction efficiencies of both 
methods have been shown to be similar (~85%) (Mangeot et al. 2011).  The batch of 
gesicles used for the reprogramming of my cells was also tested in I-STEM by the 
transduction of wild type fibroblasts with an ecotropic rMMLV carrying a reporter protein, 
and it was found to have similar efficiency.  
Apart from the delivery method of the RTFs, their relative levels also seem to have an 
impact of the reprogramming efficiency, and it has been suggested that the optimal 
stoichiometry consists of equal amounts (protein levels) of all the factors except for a 3-fold 
excess of OCT4 (Papapetrou et al. 2009). Retroviral titres were not determined prior to the 
reprogramming transduction of fibroblasts in this project, and instead a pragmatic approach 
was employed. Based on a previous titration of ecotropic rRV production in Plat-E 
(performed by I-STEM’s group), the MOI was expected to be ~250. Additionally, since the 
rMMLVs used were not naturally able to infect human cells, any MOI estimates should be 
taken with caution. In our favour, since RVs integrate efficiently in the genome, only one 
round of transduction was necessary. 
The culture of the transduced cells until iPSC emergence was performed following and I-
STEM-adapted version of the protocol published by Melton’s group (Harvard University, 
USA) (Huangfu et al. 2008b). The two main features shared by Melton’s and I-STEM 
protocols are: (i) seeding of the transduced fibroblasts on gelatine-coated plates until iPSC 
colony formation, instead of seeding immediately on feeder cells, and (ii) use of 0.5 mM 
VPA during the first two weeks post-transduction. On the one hand, seeding the infected 
cells on gelatine coated plates provided a source for the attachment of the cells that allowed 
at the same time an easier identification of the iPSC colonies in formation. This procedure 
circumvented the common difficulty associated with the distinction under the 
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microscope/stereoscope of the feeder cells from the infected cells growing on top of them. 
On the other hand, it has been shown that VPA increases the efficiency of reprogramming 
in human fibroblasts (up to 1%), up-regulating pluripotency genes and down-regulating 
linage specific genes, although the exact mechanism is not known. It seems however, that 
VPA enables an easier epigenetic remodelling through its histone desacetylase inhibitor 
function (Huangfu et al. 2008a; Huangfu et al. 2008b). This high reprogramming efficiency 
was unfortunately not observed in any of my cells, suggesting that either VPA did not 
enhance their reprogramming efficiencies or that they would have been lower in the 
absence of VPA.  
In this respect, some cell populations are more likely to be reprogrammed than others. The 
experiments from Scholer’s group (Max Planck Institute, Germany) show that the 
epigenetic pattern of the donor cells has a big influence in the efficiency and kinetics of the 
reprogramming process due to the pluripotency-associated genes already expressed in 
them. Indeed, neural stem cells endogenously express SOX2, KFL4 and c-MYC, as well as 
AP and SSEA-1, and their reprogramming can be achieved by ectopic OCT4 expression 
alone in both mice and humans (Kim et al. 2009b; Kim et al. 2009c). On the other hand, 
Hochedlinger’s group (Harvard University, USA) has shown that using the whole set of 
Yamanaka’s cocktail in mouse cells, hematopoietic stem and progenitor cells give rise to 
iPSCs up to 300 times more efficiently than terminally differentiated B and T cells do 
(Eminli et al. 2009). Another theory about cells that are more easily reprogrammed, comes 
from the observation that keratinocytes undergo faster reprogramming than fibroblasts, and 
this suggests that the culture of some cell types might contain more progenitors than others 
(Aasen et al. 2008). In this study, we chose to reprogram fibroblasts mainly because they 
can be easily obtained from the patients, cultured and transported, and because they are a 
well-established system for reprogramming. It is important to mention that the techniques 
used to obtain the tissue biopsy and to culture the cells until the time of reprogramming 
could have an important influence on reprogramming efficiency.  In this regard, 
comparisons cannot be made between the cells of the individuals of my study and the cells 
from other patients also reprogrammed in I-STEM, since they were harvested and 
maintained in different conditions. The fibroblasts from the Spanish family were harvested 
in Spain from punch biopsies from the forearm, which were cultured over plasma-gelatine 
coated dishes in medium containing FBS, glutamine, insulin, FGF2 and EGF. The medium 
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was changed every three days and cells were tryptinised twice before shipping them to 
France (Please refer to Section 2.3.6.1). One potential important difference between 
fibroblasts from CC and those from AC, TC, RC and NC is that the former were from an 
old frozen biopsy (the patient died before this study commenced), whereas the latters were 
from fresh biopsies, purpose-obtained for reprogramming. It is possible that no clones were 
obtained from CC because the cells had a metabolic disadvantage (consequence of their 
prolonged or inadequate storage), even though they were at the same passage as the others 
The exact mechanism of reprogramming is unknown and the field of iPSCs although very 
promising is also very young. As a result it is not yet understood why reprogramming 
protocols work for some cells and do not work for others. Moreover, in cells from patients 
with diseases, as in my case with SMA cells, there might be different intracellular pathways 
altering the reprogramming process. The quality control of the reprogrammed cells is 
therefore critical, because the chances of an incomplete reprogramming could potentially be 
increased.    
 7.3 iPSCs QUALITY CONTROL 
There is no strict or precise consensus on the specific characteristics that an iPSC clone has 
to show in order to be considered truly and stably pluripotent (especially in the case of 
human cells), and most criteria are based on the presence of certain ESC markers, as 
described in the Introduction.  In general terms, true human iPSCs are characterized by 
silencing/down-regulation of viral transgenes (in the cases where integrating strategies are 
used), activation of pluripotency genes, activation of telomerase, reactivation of the inactive 
X chromosome in female cells, a normal, stable karyotype, and capacity for in vitro/in vivo 
differentiation into cells/tissues of the three embryonic layers (Hochedlinger & Plath 2009). 
Nonetheless, some of these features have not been assessed in clones that have been used in 
many publications during the last six years. Some other characteristics such as 
chromosomal, epigenetic and genomic stability are starting to become fundamental in the 
assessment process (Laurent et al. 2010; Mayshar et al. 2010; Gore et al. 2011; Hussein et 
al. 2011; Lister et al. 2011; Pasi et al. 2011), but again, not many studies address these 
issues. Furthermore, even though germline transmission followed by chimaeric mice 
generation is the gold standard for pluripotency demonstrating the ability to make all cell 
types (including germ cells), these assays cannot be performed in humans. The most 
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stringent assay in human cells is generation of teratomas after injection in immunodeficient 
mice (Cox & Rizzino 2010; Muller et al. 2010).  
The markers selected to assess whether the reprogramming process has been completed are 
crucial to iPSC clone selection. In this protocol, iPSCs were obtained 4-5 weeks after 
transduction and morphological criteria (clusters of round shape, large nucleoli and scant 
cytoplasm cells) were initially used to pick the clones most likely to be fully reprogrammed 
(Figure 4.6). Given that the expansion and characterization of multiple clones is very 
demanding, we were aiming to pick five clones from each of the five patients, for a total of 
25 clones; unfortunately, this was only achievable for NC and AC cells. After expansion 
until passage 5 (with exception of the unique clone from RC, which was particularly 
difficult to expand), all clones were frozen and quality control was performed initially in 
one selected clone from each family member. Again, the selection of the four clones was 
made based on the morphology of the colonies and their ability to expand within the first 
passages, which in general correlates very well with the expression of pluripotency 
markers. After the initial quality control however, (which included assessment of 
pluripotent markers, down-regulation of transgenes, in vitro differentiation potential, 
karyotype and STR analyses), two clones (TC64 and NC21) failed to fulfil the full criteria 
and new clones (TC63, NC42 and NC32) were expanded and characterized. 
For the assessment of the expression of pluripotent markers, we used qualitative and a 
quantitative methods.  The seven selected clones expressed AP, OCT4, NANOG, SOX2, and 
TRA-1-60 as well as SSEA3 and TRA1-81 (Figure 4.7 and 4.8). Quantitative assessment of 
the co-expression of the two later markers suggests that there is only a small proportion of 
cells going through spontaneous differentiation in the cultures (<15%) (Figure 4.8). Clones 
AC28 and TC64 nonetheless, showed a higher tendency to differentiation, which correlated 
with their behaviour in culture. I tested two different culture media in order to reduce the 
proportion of differentiation, as it is known that this has a direct effect in the maintenance 
of pluripotency (Akopian et al. 2010; Roobrouck et al. 2011).  The second medium (a 
defined xeno-free medium from Stemgent, Stemedia™ NutrI-STEM™ XF/FF Culture 
Medium) dramatically reduced the differentiation of the cells in culture as compared to the 
first medium from Gibco, and the addition of a Rho-associated kinase inhibitor further 
increased the survival of cells (Xu et al. 2010). The use of natural or synthetic matrixes 
could potentially improve even more the pluripotency state of the cells (Miyazaki et al. 
2012), although this was not tested in this project. Passaging methods also vary and could 
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influence the level of pluripotency (Stover & Schwartz 2011) (complete or partial 
enzymatic dissociation, manual cutting, cutting with special devices), but in my hands they 
did not show any particular difference. 
Transgene down-regulation was also assessed in our selected clones. Exogenous RTF 
expression is spontaneously down-regulated (in integrating reprogramming strategies) at 
the time when genuine iPSCs become apparent (Okita et al. 2007; Maherali & 
Hochedlinger 2008; Chan et al. 2009; Papapetrou et al. 2009; Lister et al. 2011; Pasi et al. 
2011). There seems to be again a lack consensus in this regard, since some studies state that 
transgenes should be silenced while others state that it is enough to prove that they are 
down-regulated. The methods to detect this phenomenon are also different, some studies 
perform RT-PCR on sequences specific to the transgene and base their results in the 
presence or absence of a band (Okita et al. 2007; Park et al. 2008) and some studies 
perform a quantitative approach by qRT-PCR.  Within the qRT-PCR studies, some 
compare endogenous and total (endogenous + exogenous) expression (Yu et al. 2007; Chan 
et al. 2009), while others directly quantify transgenic expression (Takahashi et al. 2007). 
Finally the scale bars used to compare the expression values are also variable (linear or 
logarithmic), creating further differences for global comparison across laboratories. 
To test the expression profile in my clones I used a comprehensive variety of methods. First 
I compared by qRT-PCR the endogenous and total expression of each gene against the 
expression pattern in IMR90 fibroblast undergoing reprogramming and harvested 4 days 
post-transduction (IMR90 D4) (Figure 4.9). Down-regulation is effectively seen in all 
clones and for all transgenes, even though there seems to be some residual transgene 
expression of one or more RTFs in some clones. The RT-PCR amplification approach 
confirmed these residual expressions (Figure 4.10). Some studies suggest that the absence 
of proviral silencing makes iPSCs more prone to genomic instability, especially in the case 
of c-MYC (Ramos-Mejia et al. 2010; Pasi et al. 2011). This hypothesis is based on 
anticipated oncogene-induced DNA replication stress, but formal proof has not been 
provided; however, retroviral c-MYC reactivation can occur and it can induce tumours in 
vivo (Okita et al. 2007). Even though the cells reprogrammed in this study are not meant to 
be used for a therapeutically approach, genomic integrity is also deemed important in order 
to study the disease mechanism. While c-MYC is not silenced in four of the seven clones, it 
is certainly down-regulated and its total levels in all clones are even lower than in hESCs.  
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It has also been suggested that removal of the reprogramming vector significantly increase 
iPSCs capacity to undergo directed differentiation in vitro (Sommer et al. 2010), but other 
studies systematically show that there is no difference in the differentiation capacity of 
iPSCs generated with integrating or non-integrating vectors (Hu et al. 2010; Boulting et al. 
2011). The total expression levels of some RTFs have also been shown to be important in 
this regard, since increments in the expression of some pluripotency RTFs such as SOX2 
and OCT4 promote the spontaneous differentiation of hESCs in culture (Niwa et al. 2000; 
Kopp et al. 2008). Even though the range of RTF expression in pluripotent cells is not 
known, the total levels of SOX2 and OCT4 in all my clones seemed to be fairly similar to 
those found in hESCs. 
Even in the presence of some degree of transgenic RTF expression, all clones were able to 
differentiate in vitro into representative cells of the three embryonic layers, as shown by the 
embryoid body assay (Figure 4.11). It is important to emphasize in this regard that clone 
NC21 was particularly resistant to differentiation; a behaviour that was further confirmed 
when the cells were subjected specifically to MN differentiation. It is possible that this 
particular clone has genetic/epigenetic anomalies that prevent it to differentiate. For this 
reason it was considered that clone NC21 failed the quality control criteria. In vivo 
differentiation potential through teratoma formation is currently being carried out by 
Applied Stem Cell, and was not performed within the time frame of the current thesis for 
financial limitations. In the teratoma assay, iPSCs/ESCs (approximately 1 million) are 
injected into immunocompromised mice, in our case under kidney capsule and testis, until a 
tumour is formed. The tumour is then harvested, fixed, sectioned and stained with 
haematoxylin and eosin in order to identify tissues representative of the three embryonic 
layers (Tran et al. 2012). The teratoma assay is currently considered the gold standard of 
pluripotency for human pluripotent cells since it demonstrates that mature histologically 
distinct tissue types from all embryonic layers can be differentiated in vivo from these cells. 
Nonetheless the teratoma assay does not show if germline transmission is possible (Muller 
et al. 2010). Moreover, it has been shown that even though many clones fulfil most of the 
criteria regarding pluripotency phenotype, an important proportion of them are not able to 
form all the embryonic layers during the teratoma assay, and that similarly, clones that do 
form tissues from all embryonic layers in vivo, do not display a complete pluripotent 
phenotype (Boulting et al. 2011; Vitale et al. 2012). A lack of standardization in the 
methodology used to generate and analyse teratomas has been previously highlighted, 
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questioning the real value of this assay as a standard of pluripotency (Muller et al. 2010). It 
is worth to mention as well that less than half of the novel hESC and hiPSCs reported in the 
scientific literature do not shown proof of teratoma formation (Muller et al. 2010). An 
alternative to the teratomas assay based on the comparison of global gene expression data 
(determined by microarray analysis) against a data-base of validated pluripotent lines has 
been recently proposed (Goldmann et al. 2012). 
Genomic, epigenetic and karyotype stability are characteristics whose importance has been 
progressively acknowledged in the quality control of iPSCs. It is known that the 
reprogramming process places a heavy burden on cellular integrity, and there seem to be 
major genomic and epigenetic abnormalities during the reprogramming process (Mayshar 
et al. 2010; Gore et al. 2011; Hussein et al. 2011; Lister et al. 2011). All my clones showed 
a normal karyotype except for TC64, which presented a partial gain of chromosome X on 
chromosome 1 (1qter), probably present in the reprogrammed fibroblast or acquired early 
during the reprogramming process (Figure 4.12). As the consequences of this 
chromosomal abnormality are not known, I cannot foresee their potential effect on my 
study, which could very well be of relevance to pathways involved in SMA pathology. 
Therefore, I decided to discontinue the propagation of this clone and seek an alternative 
clone from this patient. It should be noted that this was a conservative approach, because 
iPSCs have been reported to contain hundreds and maybe thousands of genomic and 
epigenetic abnormalities such as protein-coding point mutations (Gore et al. 2011), copy 
number variations (Hussein et al. 2011) and somatic memory and aberrant reprogramming 
of DNA methylation (Lister et al. 2011).  
Lastly, the identity of all selected clones was confirmed by comparing STR profiles with 
parental fibroblasts and individual lymphocytes, with positive identification in all cases 
(Table 4.2). 
All in all, five clones passed the full set of quality control criteria (excluding the results 
from the on-going teratoma assay): AC28, RC36, TC63, NC32 and NC42 and the first four 
were used for further study, mainly through their differentiation into MNs (Table 4.3). 
Both clone NC32 and NC42, showed similar pluripotency properties and the selection of 
the former for further experiments was arbitrary.  
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 7.4 iPSC DIFFERENTIATION INTO MNs 
The first reported comprehensive protocol to differentiate MN from stem cells (in this case 
mouse ESC) was published by Jesell’s group (Columbia University, USA) (Wichterle et al. 
2002). This group implemented steps that are known to promote MN differentiation (as 
observed in vivo) into in vitro conditions, obtaining functional MNs that could repopulate 
the spinal cord in vivo, extend axons into the periphery and form synapses with muscles.  
After this pioneering study, several protocols for the generation of MNs from human stem 
cells have been reported. The first protocol employing human iPSCs (hiPSCs) was reported 
in 2008 (Dimos et al. 2008). Even though only very few publications have so far used 
hiPSCs for differentiation into MN (as compared to hESCs), it has been shown that these 
cells are also able to generate electrically active MNs (Karumbayaram et al. 2009). 
Differentiation protocols mostly vary in (i) the density and culture type of the stem cells at 
the starting point (feeder dependant or feeder free, media containing serum or defined 
media), (ii) the use of exogenous signalling molecules such as FGF2 and/or BMP 
antagonists, (iii) the way to achieve neuroephitelial identity (with or without EB formation), 
(iv) the concentration of RA and SHH or purmorphamine (used for caudalization and 
ventralization respectively) and (v) the specific components of the neural media (Nizzardo 
et al. 2010). The protocol used in my study was designed by Zhang’s group (University of 
Wisconsin, USA) for the differentiation of hESC to MNs and it was selected for the 
differentiation of the iPSCs in this study because it offered several advantages over other 
protocols (Hu & Zhang 2009). First, the seeding of EBs prior to rosette formation 
facilitated the identification of neuroephitelial cells and enhanced purity of the manually 
selected rosettes (Figure 5.2). In this configuration, cells were also more homogeneously 
exposed to the key signalling molecules. The second important aspect in this protocol was 
the timing of RA exposure, which has been found to dramatically affect the caudal 
patterning of cells, and which was done here at an earlier time point compared to other 
protocols.  Indeed, it has been shown that primitive neuroephitelial cells are more 
responsive than definitive neuroepithelial cells to RA (Pankratz et al. 2007). This protocol 
also replaces SHH with purmorphamine, a small molecule that activates the SHH signalling 
(Wu et al. 2004; Sinha & Chen 2006), shows the same efficiency for MN differentiation 
and is also less expensive and more chemically stable in culture (Li et al. 2008). The most 
important advantage of this protocol is the high yield of MNs obtained (50% MN for 
hESC). However, the same protocol has been reported to yield much lower numbers (which 
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vary between 7% and 30%) with iPSCs (Karumbayaram et al. 2009; Hu et al. 2010; Chang 
et al. 2011). Although the proportion of MNs could not be quantified in my study, given the 
three dimensional disposition of the cells (which will be discussed in the next section), an 
estimation of the number of ISL-1+ cells suggests that the MN yield in my cultures was 
also within the latter range (10-15%) (Figure 5.6). It is important to highlight that almost 
all the cells in our culture were positive for the MN precursor markers OLIG2 and p75-
NGFR (Figure 5.3). The latter is in agreement with the results from Zhang’s group and it 
suggests that most of our cells were committed to a spinal ventral fate (Du et al. 2006; Hu 
& Zhang 2009). High OLIG2 expression has already been reported to be a recurrent 
characteristic in iPSC-derived MNs, along with low expression of HB9, which is a marker 
for post-mitotic MNs (Hu et al. 2010). This behaviour is in contrast to the one found in 
MNs derived from hESCs. Sustained OLIG2 expression, which is dependant on SHH 
signalling, prevents the exit from the cell cycle (Du et al. 2009). Reducing the levels of 
SHH nonetheless does not accelerate the cell cycle exit in iPSC-derived MN cultures (Hu et 
al. 2010).  
Yields of MNs not only vary when comparing the differentiation from hESC and hiPSCs, 
but also between laboratories. This might at least partly be explained by differences in the 
markers used to determine the identity of MNs, as well as variations in the timing of the 
expression assessment. HB9 is considered to be the most specific post mitotic MN marker, 
but it is not expressed at the same levels all the time (Arber et al. 1999; Hester et al. 2011). 
ISL-1 is an earlier MN marker, but it is also expressed in some interneurons and in some 
cells from the dorsal root ganglia (Ericson et al. 1992; Arber et al. 1999; Wichterle et al. 
2002). In spite of these considerations, both markers are indistinguishably used for 
assessing MN yield. Some studies relevant to my project (Ebert et al. 2009; Sareen et al. 
2012) also use SMI-32 immunoreactivity for MN identification. SMI-32 antibodies 
recognise a non-phosphorylated epitope of neurofilaments, which is expressed in mature 
MNs (Carriedo et al. 1996), but also in several other neurons in the CNS (Ouda et al. 
2012). The timing is also a critical factor for assessing MN yield, since some MN 
progenitors continue to proliferate in the culture at the same time as others commit to the 
MN fate. Indeed, previous studies from Zhang’s group, whose protocol was followed in 
this study, have shown that OLIG2 expression peaks at the 4th week of differentiation and 
then goes down, whereas HB9 expression starts appearing at the 4th week, peaks at the 5th 
week and then decreases (Li et al. 2008). In order to follow the generation of post-mitotic 
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MNs over time, cells were transduced with an LV construct (HB9:RFP H1LVs) expressing 
RFP under the control of an HB9 enhancer/promoter (Figure 5.11). This particular 
construct, along with its GFP version, has previously been shown to be highly specific for 
MN identification in iPSC-derived MN cultures and also in spinal cord MNs in vivo (Lee et 
al. 2004; Marchetto et al. 2008; Hester et al. 2011). The enhancer/promoter used in this 
construct is in fact a shorter version of the 9 kb regulatory sequence located in the 5’ 
upstream region of the HB9 gene, which has been found to be sufficient to promote the 
expression of target reporters in MNs (Arber et al. 1999; Lee et al. 2004). The observations 
made from the temporal transduction pattern of TC63 iPSC-derived MNs with HB9:RFP 
H1LVs, agrees with Zhang’s group observations regarding the variation in the proportion 
of cells expressing HB9, since the proportion of RFP+ cells dramatically increased in the 
cultures during and after the 5th week (days 35-41 of the MN differentiation protocol) in 
comparison with the 4th week (days 28-34 of the MN differentiation protocol).   
Even though much effort has been put into the generation of functional MNs from human 
stem cells over the years, two main outstanding issues remain: overall low efficiency of 
MN differentiation and presence of mixed populations. Regarding the first issue, a recent 
study has shown that forced expression of three key MN transcription factors (NGN2, ISL-
1, and LIM/homeobox protein 3 [LHX3]) into NE cells significantly increased the rate of 
MN differentiation and the overall yield of these cells (Hester et al. 2011). Indeed, 
electrophysiologically mature MNs were observed 27 days earlier than with conventional 
protocols and MN yield accounted for 50-70% of the cultured cells. The main disadvantage 
of this approach, however, is that cells are subjected to additional genetic manipulations, 
which could possibly interfere with the expression of the disease phenotypes or affect drug 
targets. Furthermore, these cells would not be applicable to any cell therapeutic approaches 
for which efforts currently on-going to develop methods for iPSCs production without 
genome integration or genetic manipulation would be more relevant (Kim et al. 2009a; 
Warren et al. 2010; Okita et al. 2011). Regarding the second issue (mixed populations), 
there are several approaches that have been reported specifically for the purification of 
hESC-derived MNs: immunopanning for the transiently expressed p75-NGFR (Silani et al. 
1998; Silani et al. 2001), fluorescence-activated cell sorting (FACS) after the introduction 
of an HB9-driven GFP cassette in the NE cells prior to MN differentiation (Singh Roy et 
al. 2005), and discontinuous Biocoll gradient centrifugation (Wada et al. 2009). There are, 
however, some disadvantages associated with any of these methods. First, p75-NGFR 
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immunopanning is not based on a surface marker which is specific for human MNs. 
Although p75-NGFR has proven to be useful for isolating MNs ex vivo from spinal cord of 
various organisms such as rat, mouse and human (Silani et al. 1998), (Camu & Henderson 
1992; Wiese et al. 2010), this maker is also expressed in a wide range of cells within the 
CNS during development, all of which are likely to be present in the rather heterogeneous 
cultures derived from differentiating stem cells (Nizzardo et al. 2010; Ibanez & Simi 2012). 
Indeed, I attempted p75-NGFR immunopanning in my cultures by adapting the protocols 
used for mice (Wiese et al. 2010) and for differentiating MNs from mESCs (Bibel et al. 
2007), which I learnt during a visit to Prof Michael Sendtner’s group at the University of 
Wuerzburg, Germany. Unfortunately, the cells from my iPSC-derived neurospheres did not 
survive after complete dissociation. A positive outcome of this attempt was that the 
proportion of cells attached to the immunopanning plate could be estimated, suggesting that 
almost all cells in my iPSC-derived MN cultures produced p75-NGFR (data not shown), 
which was confirmed by the results obtained through immunofluorescent staining (Figure 
5.3A). The broad expression of p75-NGFR in the cultures makes this purification technique 
redundant in the iPSC differentiation context.    
On the other hand, the purification method involving the FACS of HB9-driven GFP-
expressing cells has been shown to yield significantly fewer MNs (~1% of the cells in 
culture) and the survival of the cells was severely affected (reduced to only a few days or 2 
weeks if co-cultured on skeletal muscle cells). Furthermore, this method also introduced an 
additional genetic manipulation with the previously mentioned disadvantages (Singh Roy et 
al. 2005). The most cost and time-effective technique reported so far seems to be the 
Biocoll gradient centrifugation, which also preserves the naïve condition of the cells (Wada 
et al. 2009). This protocol may still require some improvement in order to increase the MN 
purity above 80%. Also, the viability of the purified cells over long-term in cultures needs 
to be assessed since this method requires full dissociation jeopardizing cell viability, as 
previously mentioned 
 7.5 MODELLING SMA THROUGH iPSC-DERIVED MNS 
One of the main advantages of being able to differentiate iPSC into MN-like cells, 
irrespectively of the limitations previously discussed, is the provision of a human cell type 
which could not be obtained directly from patients. For SMA particularly, where the 
genetic cause is known, but the pathological mechanism is still unclear and no clinical 
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therapy has yet been developed, human iPSC-derived MNs offer an invaluable resource for 
disease modelling and drug screening. The aim of this study was focused on this premise: 
the recreation of the MN developmental process under the genetic background of SMA 
affected and unaffected individuals, a genetic background that predisposed them or 
protected them respectively from the pathology. 
In my study, iPSC clones from two SMA type III siblings (NC, TC), their SMA type 
IV/asymptomatic haploidentical sister (AC) and their unaffected mother (RC, carrier of the 
SMN1 mutation) were differentiated and studied, along with an unrelated unaffected clone 
(4603) and an unrelated clone from a type I SMA patient (SMA1). Given that the affected 
siblings of the Spanish family present a mild form of SMA and the onset of the pathology is 
thought to develop late in these patients (Martinez-Hernandez et al. 2012), more subtle (if 
any) abnormalities were expected to be found in their MNs as compared to SMA1.  
So far, three groups have reported the generation of iPSCs from SMA patients, in all cases 
from SMA type I fibroblasts. Two of these groups have attempted to model the disease in 
differentiated MNs (Ebert et al. 2009; Chang et al. 2011; Sareen et al. 2012), while the 
third one has only produced iPSCs (Luo et al. 2012). Five parameters have been assessed in 
these studies to characterise and distinguish the phenotype of unaffected and diseased 
iPSC-derived MNs:  proportion/number of MNs after differentiation (Ebert et al. 2009; 
Chang et al. 2011; Sareen et al. 2012), neurite outgrowth (Chang et al. 2011), number of 
MN neurites (Sareen et al. 2012), total MN cell body area (Ebert et al. 2009; Sareen et al. 
2012), and MN pre-synaptic defects (Ebert et al. 2009). The latter phenotype will be 
discussed in the next section about functional SMA studies in NMJ models (section 7.6). 
In my study, counting the absolute number of MNs after differentiation was not possible, as 
it turned out to be problematic to identify and count single cells within the three- 
dimensional cluster of differentiating MNs (Figures 5.6 and 5.12). Svendsen’s group 
(University of Wisconsin-Madison, USA) was the first one to find SMA-related differences 
in the proportion of iPSC-derived MNs (Ebert et al. 2009). This group’s main finding at the 
time was that MNs generated from an SMA type I iPSC clone showed selective decline 
(proportionally) in long-term cultures when compared to the MNs derived from a iPSC 
clone of the unaffected carrier mother (4% vs 24% remaining respectively after 2 weeks of 
the beginning of ChAT expression), even though the MN yield was similar at early time 
points (~11%). Nevertheless, certain aspects in this study are not clear, in particular the 
method used for assessing cell number in a three-dimensional cluster. The same is true for 
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the study carried out by Yee’s group (Chang et al. 2011). The second more recent 
publication from Svendsen’s group (Sareen et al. 2012) reported dissociation of the cells 
before plating and counting, while not providing a detailed description of the procedure. 
The attempt at this approach in my study however, impaired the viability of the MNs as 
observed in the p75-NGFR immunopanning trial (data not shown), and could not be used to 
produce a quantitative analysis. An estimation of MN numbers, as assessed by ISL-1 
positive staining, suggests that about 10-15% of the cells within the cultures are MNs 
between days 35-43 (weeks 5 and 6) (Figure 5.6). No obvious differences were observed 
between the clones. A similar proportion of MNs was found when the neurospheres were 
transduced with a LV conferring MN-specific expression of RFP (HB9:RFP H1LVs, 
Figure 5.12). Full cell dissociation prior to plating would be necessary to reliably quantify 
these numbers for each clone. 
The second disease phenotype assessed was the outgrowth of neurites. In order to 
systematically follow the length or area of neurons, they should be plated as single cells and 
at low density, but both requisites affect MN survival significantly (Hu & Zhang 2009). 
Yee’s group measured the length of neurites emerging from neurospheres two and five days 
post-plating and reported retarded neurite outgrowth in SMA type I iPSC-derived cultures 
as compared to matched, rescued control lines (Chang et al. 2011). Unlike Yee’s group (i) I 
measured the average length of the five longest neurites per neurosphere instead of the 
average neurite length, (ii) I compared the average growth rate instead of absolute lengths 
and (iii) I measured one, three, six and eight days post-plating instead of only two and five. 
The reason for measuring only the five longest neurites is derived from the difficulty in 
correctly identifying the smaller neurites without staining, although it is acknowledged that 
with this decision a possible bias is introduced. On the other hand growth rates were 
preferred over absolute lengths in order to avoid the masking effect given by inter clonal 
variation (Hu et al. 2010; Boulting et al. 2011) which will be further addressed within this 
section. Following my adapted protocol, however, I did not find any difference between the 
clones analysed, which included an SMA type I (Figure 5.7). Even though neurite growth 
was heterogeneous between clones, growth rates were not statistically different. It is 
important to mention that the neurites measured by this method may belong to different 
types of cells and not only MNs. For MN-specific measurements, cells would have to be 
fixed and stained for MN markers in order to identify them, but this would not allow time 
course studies on the same sample over several days.  
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Svendsen’s group focused on the number of neurites in SMI-32+ cells over longer time 
intervals instead of general neurite length growth over short intervals. Their study shows 
that the number of neurites in MNs derived from two SMA type I iPSC clones decreases 
over time (ratio at 7-10 weeks over 3-4 weeks), unlike in unaffected iPSC cultures where it 
increases. Similarly, they reported a reduction in total cell body area over time for the SMA 
MNs (Sareen et al. 2012). Here, cells were from independent differentiations, as they had 
been fixed and stained to identify the MNs for the analysis. The lack of a continuous 
assessment introduces bias regarding the intra-clonal variability in the differentiation 
efficiency (which is reflected in the large error bars of their results) and thus, this may not 
necessarily be the ideal method. However, as discussed before, the lack of staining can also 
create bias in these types of measurements. Live expression of MN-specific fluorescent 
reporters such as our HB9:RFP H1LVs (Figure 5.11) will be a more suitable method.  
Three important variables are potentially accounting for much of the differences found 
between Svendsen’s, Yee’s and my own study: the timing of the analysis, the inter 
variability between clones and the technical procedure for MN generation,  
The timing of appearance on the SMA phenotypes in culture reveals a significant 
discrepancy between the results of Yee’s group and Svendsen’s group. Svendsen’s group 
has shown that iPSCs-derived MNs from unaffected individuals and SMA type I patients 
present similar phenotypes (such as MN yield, cell body area and number of processes) 
during the first weeks of culture when the cells are acquiring all the mature MNs markers 
(weeks 4-6) and that phenotypic differences are observed only in long-term cultures (8-10 
weeks) (Ebert et al. 2009; Sareen et al. 2012). These same results regarding the MN yield 
have been obtained by Henderson’s group (Columbia University, USA) in a similar study 
(Henderson Unpublished data). Yee’s group did not provide data about long-term cultures 
of MNs, and the phenotypes reported (lower MN yield and retarded neurite growth) 
correspond only to the 4th-6th week of Svendsen’s MN differentiation protocol. 
Interestingly, the SMA type I iPSCs from Yee’s group are reprogrammed from the same 
patient’s fibroblast used in the second study from Svendsen’s group. Similarly our cultures 
were only kept until D47, when ChAT expression was evident, which also corresponds 
approximately to the 5th week of differentiation in Svendsen’s protocol (in Svendsen’s 
protocol, D0 correspond to the rosettes stage, whereas in mine’s and Yee’s D0 corresponds 
to the formation of EBs). Therefore, this time-point may be too early to observe differences 
in my MN cultures even if the number of MNs could be analysed systematically. 
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A second confounding factor already mentioned before when comparing results is the 
variability between different clones regarding their propensity to terminal differentiation. 
Indeed, it has been shown that each clone has an inherent propensity towards neural and 
terminal differentiation and that this propensity might mask or mislead the true phenotype 
of a given disease (Hu et al. 2010; Boulting et al. 2011). This situation represents a 
particular disadvantage for the first publication of Svendsen’s group where only one 
affected and one unaffected clone were studied (Ebert et al. 2009). Nonetheless, the recent 
second publication from this group (Sareen et al. 2012) employed two different clones 
(from 2 controls and two SMA type I patients). Yee’s group on the other hand, produced 5 
clones of iPSCs from one SMA type I patient, and used two of them to study the phenotype 
of the derived MNs (Chang et al. 2011). In my study I differentiated one clone from each 
patient, which allowed me to study unaffected individuals (RC+4603) versus SMA patients 
(AC, TC, NC, SMA1) taking into account more than one clone. The direct comparison 
between the siblings was nonetheless one clone from each. 
Furthermore, variability is added when the system to generate neurospheres does not 
produce homogeneous clusters of cells, a factor that can dramatically affect the attachment 
of cells and their growth. This issue can be solved by performing a “temporal and 
longitudinal study” were normalized values are compared instead of absolute values. This 
is the case of the measurement of neurite growth in my study, were growth rates were 
compared instead of absolute neurite length values.  In this regard, Svendsen’s group 
reported ratios generated from average measures recorded on last days of data collection 
(weeks 7-10) and the ones recorded on earlier days (weeks 3-4), taking into account four 
different experiments (Sareen et al. 2012).  
The published studies have also attempted to rescue phenotype or restore SMN levels either 
pharmacologically (Ebert et al. 2009; Sareen et al. 2012) or using gene therapeutic LVs 
(Chang et al. 2011). Pharmacological approaches included histone deacetylases (VPA), 
aminoglycosides (tobramycin) and apoptosis inhibitors (a neutralising antibody for Fas-
receptor or a caspase-3 inhibitor). While at least partially successful, the applicability of 
results from these attempts is however limited, as treatments were applied on iPSCs or from 
early differentiation stages and not to mature MNs. Please refer to section 1.1.4 on the 
Introduction for more information about current pharmacological treatment for SMA.  
Among the mentioned treatments it is worth briefly describing the apoptosis inhibition 
approach where Svendsen’s group showed improved MN numbers (SMI-32 positive cells) 
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at 8 weeks of differentiation by applying continuous apoptosis-inhibiting treatments from 
early time points of the differentiation process (week 2) (Sareen et al. 2012). I attempted to 
restore SMN levels in SMA1 iPSC-derived MNs using scAAV9s, but the outcome was 
only evaluated at the molecular level. These results, as well as Yee’s gene therapeutic LV 
approach will be discussed in section 7.7. 
The failure to observe an SMA-related phenotype in my study of MNs was probably due to 
a combination of factors, including the three-dimensional nature of the cultures, the timing 
chosen for the assessment (short-term cultures) and possibly the sensitivity of the analytical 
methods employed. Increased sensitivity may be achieved through more sophisticated 
instrumentation and methods, which may be particularly important when comparing less 
severe forms of SMA. Nonetheless, although the differentiated SMA MNs in my cultures 
did not show a distinct phenotype as described in literature, there was an abnormality 
observed with the SMA1 clone during MN differentiation: Whereas the other five iPSC 
clones efficiently formed rosettes between D10-D15, the differentiating SMA1 iPSC clone 
exhibited a conspicuous reduced capacity to form rosettes and showed features consistent 
with reduced viability, including morphological changes and cell detachment (Figure 5.2). 
Interestingly, this reduced frequency of rosettes has already been pointed out in Yee’s study 
(Supplementary Discussion) of clones SMA-23 and SMA-25 (our SMA1 clone is their 
SMA-19 clone). Furthermore, restoration of SMN expression in clones SMA-23 and SMA-
25 did not improve the rosette-forming efficiency and thus, the behaviour was attributed to 
a different developmental program between iPSCs and hESCs (which were the control cells 
used by this group) (Chang et al. 2011). My study of five iPSC clones with high rosette 
formation efficiency, all of them generated following a similar retroviral infection protocol 
to the one employed by Yee’s group (including VPA treatment), argues against this 
conclusion. Instead, it is tempting to speculate that the reduced rosette formation phenotype 
is specific of severe SMA (with the caveat that all three clones showing phenotype have 
been generated from the same fibroblasts). Unfortunately, the MN differentiation protocol 
of Svendsen’s group did not involved the generation of rosettes and hence is not 
informative in this respect. 
 7.6 FUNCTIONAL SMA STUDIES IN NMJ MODELS  
No functional SMA phenotype has yet been reported in cultured human MNs. One 
observation of relevance has been made: SMI32+ SMA type I iPSC-derived MNs showed 
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diffused synapsin staining after 8 weeks of differentiation, as opposed to the punctuated 
staining in control iPSC-derived MNs, suggesting defective pre-synaptic maturation (Ebert 
et al. 2009). Studies of SMA MNs in a co-culture system, functional or otherwise, have not 
been reported. 
Deficits in the NMJ have consistently been found in several models of SMA (Murray et al. 
2008; usaKariya et al. 2008; Kong et al. 2009; Ling et al. 2010; Ruiz et al. 2010; Lee et al. 
2011) and in post-mortem human tissue (Martinez-Hernandez et al. 2012). From these 
studies, it is now generally accepted that synaptic dysfunction in the NMJ precedes MN cell 
death. Zhangs’s group (University of Wisconsin-Madison, USA) have already shown that 
hESC-derived MNs can establish functional neuro-muscular transmission in co-culture 
systems (Li et al. 2005).  In order to simulate this system in the SMA context, I plated D39 
neurospheres onto differentiated mouse myotubes and cultured them for three days. The 
results suggest that the plating of neurospheres induced the clustering of AChRs and that 
neural terminals were observed in close proximity to these clusters (Figure 5.8). The 
clustering of AChRs in C2C12 myotubes has previously been reported to occur in the 
absence of neurons (aneural cultures) (Kummer et al. 2004). Furthermore, it is thought that 
during human development there are pre-patterned AChRs similar to the ones consistently 
observed in developing mice, rats, chicks and frogs  (see (Sanes & Lichtman 2001) for a 
review on neural induction of AChR aggregates).  In agreement with this, we observed 
some AChR clusters in myotubes cultured aneurally (within the predominantly disperse 
distribution), but they were less abundant and less defined when compared to the pattern 
seen after seeding the neurospheres. Indeed, the disperse AChR expression in myotubes of 
aneural cultures was reorganized upon co-culture with neurospheres into localized 
expression within defined clusters observed in close proximity to the neurites (Figure 5.9). 
No difference was observed between clones, but the system is suitable for 
electrophysiological recordings, which may detect SMA-related differences as part of 
future studies. Recent results from Tizzano’s group (Martinez-Hernandez et al. 2012) 
suggest that defects such as poor clustering of AChRs, axonal swellings and vesicle 
accumulation in the nerve terminal are already present in human SMA type I foetuses. We 
were aiming to observe SV2 (a marker for synaptic vesicles) accumulation in nerve 
terminals of SMA1 iPSC-derived MNs, but it seems that SV2 requires more time in co-
culture to be expressed in the differentiating MNs (Ebert et al. 2009).  
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The study of MNs in co-culture systems would be more relevant with human myoblasts 
instead of mouse cells. The ideal system would include iPSC-derived MNs growing on 
human myotubes, using all possible combinations of control and affected cells to test 
whether the lack of SMN in MN and/or muscle affects the NMJ. A recent study using 
conditional SMA mice with tissue-specific increases in SMN expression seems to suggest 
that NMJ defects are derived specifically from the lack of SMN in the MN (Martinez et al. 
2012). Nonetheless, other studies suggest otherwise (Hayhurst et al. 2012). Short and long 
term co-cultures should both be studied, since it has also been suggested that clustering of 
AChRs in SMA foetuses does occurs early in development (12 weeks), but it is lost 
afterwards (14 weeks) (Martinez-Hernandez et al. 2012).  
 7.7 ORIGIN OF FL-SMN TRANSCRIPTS IN THE CELLS OF 
STUDY 
Parallel to phenotypic studies, several molecular analyses were also performed. As 
described in the Introduction, the main source of FL-SMN mRNA is the SMN1 gene, but a 
smaller percentage is also produced from the SMN2 gene (Lefebvre et al. 1995). In SMA 
patients, no functional SMN protein from the SMN1 gene is produced, but not all SMN1 
mutations are deletions or completely inhibit the transcriptional activity of the defective 
genes (Alias et al. 2009). Our collaborators in Spain have previously described the lack of 
FL-SMN transcripts from the mutated SMN1 gene in fibroblasts from the siblings of study 
(Also-Rallo et al. 2011). I further assessed this event in the seven selected iPSC clones of 
study (SMA1, 4603, RC26, AC28, TC63 and NC32) and their derived cells during the 
iPSC-MN differentiation process (Figure 6.1). As expected, FL-SMN in all SMA1 cell 
cultures originated specifically from SMN2, whereas FL-SMN expressed from SMN1 was 
detected in all 4603 cell cultures (which carry two functional SMN1 alleles) and in all RC26 
cell cultures from the carrier mother (which possess one functional SMN1 allele). In the cell 
cultures derived from the siblings of study (AC, TC and NC), essentially all FL-SMN was 
found to originate from their SMN2 genes. However, in some cases very minor bands of 
FL-SMN mRNA apparently originating from their mutant SMN1 genes could be detected 
(Figure 6.1). These observations suggest that mutant SMN1 transcripts have very low 
stability and are perhaps degraded by the non-sense decay mechanism. The non-sense 
decay is a surveillance mechanism for mRNAs with premature stop codons, such as the 
ones generated by the SMN1 mutation present in the siblings of our study (Silva & Romao 
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2009). The remaining transcripts however, are not expected to be translated into functional 
protein.  
 7.8 SMN AND PLS3 DURING iPSC-MN DIFFERENTIATION 
In addition to the temporal appearance of phenotypic defects in SMA, another important 
question yet to be answered concerns the developmental expression pattern of SMN and 
related proteins. Addressing this issue, the second main focus of my study was to assess the 
variation in the levels of SMN and PLS3 mRNA and protein during the iPSC-MN 
differentiation process in the clones derived from the family of study and my two reference 
clones (SMA1 and 4603).  
7.8.1 SMN 
It has been proposed that even though the lack of SMN preferentially affects MNs, it also 
impacts many other tissues, but with different thresholds of sensitivity (Sleigh et al. 2011). 
According to this view, there is a vulnerability-resistance spectrum and MNs are at the 
sensitive end. Since the regulation of SMN levels in MNs seems to be more critical than in 
other tissues, I anticipated that there should be important variations during the MN 
differentiation process. 
Several lines of study have suggested that SMA pathology begins during the prenatal 
period, at least in the most severe cases (SMA type 1). In less severe cases the results are 
not clear, but a similar process with more subtle manifestations is thought to take place. 
Through the study of severe mouse models of SMA, Sendtner’s group (University of 
Wuerzburg, Germany) have found that in vitro cultures of embryonic MNs have shorter 
axons, smaller growth cones with decreased expression of beta actin and defects in 
spontaneous excitability (Rossoll et al. 2003; Jablonka et al. 2007). On the other hand, in 
vitro cultures of neurospheres from SMA mouse models showed compromised neuronal 
differentiation and neuritogenesis (Shafey et al. 2008). Defects in axon outgrowth and path 
finding have been found in Smn-depleted zefrafish and Xenopus models (McWhorter et al. 
2003; Ymlahi-Ouazzani et al. 2010). Even though most mouse in vivo studies do not 
suggest a developmental defect, there is certainly controversy regarding the appearance and 
development of the disease (Sleigh et al. 2011). Studies on human foetuses have provided 
significant evidence for a developmental defect with prenatal onset. Indeed, it has been 
found that predicted SMA type I foetuses show enhanced neuronal cell death at 12 weeks 
post-conception (Soler-Botija et al. 2002), decreased/delayed expression of antiapoptotic 
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proteins in MNs at 15 weeks post-conception (Soler-Botija et al. 2003) and presynaptic 
retention of vesicles, loss of AChR clustering and aberrant ultrastructure on nerve terminals 
of the NMJ at 14 weeks post-conception (Martinez-Hernandez et al. 2012).  
Very few studies describe human SMN protein levels, but it is known that SMN is high in 
the prenatal period and levels suffer a marked decay in the postnatal period, particularly in 
skeletal muscle, heart and brain tissues (Burlet et al. 1998). In adult tissues, SMN is present 
at particularly high levels in brain, kidney and liver (Coovert et al. 1997). Since iPSC 
differentiation attempts to recapitulate in vivo development, the iPSC-MN differentiation 
system provides a unique model to assess the variation in mRNA and protein levels of 
SMN during human MN development.  
I decided to follow transcript levels of the two more abundant isoforms, FL-SMN and Δ7-
SMN. Total SMN transcript levels (tSMN) were also measured as a reference of 
transcriptional activity. All protein measurements assessed are thought to correspond to FL-
SMN, since a Δ7-SMN isoform has not been reported or detected at the protein level in the 
absence of induced genetic modifications or overexpression, probably due to its low 
stability (Lorson & Androphy 2000).  
The most significant findings from the SMN analyses were: (i) there is a gradual decay in 
SMN protein during iPSC-MN differentiation; (ii) there is a mismatch between FL-SMN 
RNA and protein levels during iPSC-MN differentiation; (iii) unaffected individuals show 
higher FL/Δ7-SMN mRNA ratios than SMA patients; (iv) the severity of SMA phenotypes 
can be distinguished by comparing tSMN mRNA levels. All these findings will be 
discussed in depth in this section. 
In order to try to identify SMA-related cell type-specific differences, clones were grouped 
into two categories: unaffected individuals (4603+RC26) and SMA patients (SMA1, AC28, 
TC63, NC32). AC was included in the SMA group given the patient’s lack of functional 
SMA1 genes (as her SMA type III symptomatic siblings) and the presence of minimal 
electromyography alterations. Statistically significant differences were only found in the 
FL/Δ7-SMN ratio at the rosette and MN stages and in the FL-SMN mRNA at the EB stage 
(Figure 6.2), probably due to the small sample size of the control group. 
From the diversity of results obtained, I formulated a hypothesis describing the molecular 
basis for the onset of SMA. It is plausible to think that the requirement for SMN is more 
crucial in some differentiation stages than in others, for example prior to or during the 
neural specialisation of the cells (EBs/rosette stage) where the main differences in the FL-
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SMN mRNA and protein between control individuals and SMA patients were observed 
(Figure 6.2 A and B). In agreement with this, Yee’s group (Chang et al. 2011) and I have 
observed specific deficits in rosette formation in three iPSC clones derived from the same 
SMA type I patient. If this is true, low levels of SMN like those seen in our SMA cases 
(SMA1, TC63, NC32 and AC28), may predispose the cells to a pathological state without 
necessarily compromising their terminal differentiation potential, as it is the case. A 
continuous relative decreased expression in SMN during the subsequent phases would 
however prompt the appearance of the pathology, whose severity will be subjected to 
narrow variations of SMN. Indeed as it can be seen in the analysis at the MN stage (Figure 
6.6), the cells from the siblings with SMA type III (TC and NC) have very similar values to 
the one seen in SMA1 cells (except in the case of tSMN mRNA), but very different from 
the unaffected 4603 cells. The analysis of more clones from patients with SMA type I and 
II would be needed to confer statistical power to this last statement, but similar narrow 
SMN protein differences have been previously found in SMA type I and type III spinal 
cord samples from human foetuses (showing a 23% and 39% reduction of the normal SMN 
levels, respectively) (Lefebvre et al. 1997). Moreover, the difference in the protein levels 
between the unaffected clone with two functional SMN1 alleles (4603) and the SMA1 clone 
(≥2 fold for both, RNA and protein levels) is in agreement with the significant reduction 
found the in spinal cords from human tissues (Coovert et al. 1997; Soler-Botija et al. 2005). 
Given that all clones, irrespectively of their phenotype suffer a statistically significant 
decline in the SMN protein levels during their MN differentiation, regardless of the 
maintenance or increase in the FL-SMN mRNA expression (Figure 6.4), it seems logical to 
think that there is either (i) a general post-transcriptional mechanism inhibiting the 
translation of the protein; (ii) a general post-translational mechanism producing a faster 
turnover of the protein; or (ii) a combination of the previous two mechanisms. Supporting 
the role of a post-translational regulation, a very recent report has shown that ubiquitin-
specific protease 9x deubiquitinates FL-SMN (but not Δ7-SMN) preventing its degradation 
by the proteasome (Han et al. 2012). Moreover the described mechanism/s might not be 
specific to MN differentiation, since it is also observed in the hepatocyte differentiation 
(Figure 6.3). In this regard, whereas it is true that iPSCs show lower SMN protein values 
than immature and mature hepatocytes, this behaviour can be attributed to an iPSC clone-
specific low SMN expression, given that specifically RC26 iPSCs also show lower values 
than its differentiated EBs, rosettes, neurospheres and MNs (Figure 6.4B). The lack of 
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correlation between transcript and protein levels of FL-SMN has been reported before in the 
study of blood samples (Crawford et al. 2012). Following the adapted threshold theory 
(Sleigh et al. 2011), if cells are able to cope with the protein decay, they will remain 
healthy, but if they level fall beyond a certain point or “threshold”, the cells will be 
affected. The way unaffected MNs (4603 mainly) and mature hepatocytes seem to deal with 
this problem is by up-regulating their FL-SMN mRNA expression, which could be 
compensating for the post-transcriptional/post-translational inhibition (Figures 6.3 and 
6.4). Since SMA cells do not possess functional SMN1 alleles, they can only cope by up-
regulating the transcription from the SMN2 alleles, whose main product is Δ7-SMN 
(Lefebvre et al. 1995). Indeed, Δ7-SMN is maintained at high levels (but not up-regulated) 
in SMA cells during the whole iPSC-MN differentiation process (Figure 6.2 D), as 
opposed to the control unaffected 4603 clone. The expression profile of the clone from the 
carrier (RC26) mother is more similar to the one observed in SMA clones than to the one 
seen in the unaffected control clone. The transcription of other isoforms, particularly of the 
isoform lacking exon 5 and 7 (which is indistinguishable in our assay from the isoform 
lacking only exon 7), are probably also occurring (Gennarelli et al. 1995). It is important to 
mention as well that although the putative Δ7-SMN protein is thought to be less functional 
(with defective self-association and decrease ability to stimulate in vitro splicing) and less 
stable (Lorson et al. 1998; Pellizzoni et al. 1998; Lorson & Androphy 2000), its 
overexpression does ameliorates significantly the SMA phenotype in the severe SMA 
mouse model. It seems that Δ7-SMN is able to oligomerise with the low levels of FL-SMN 
thus becoming stable and functional (Le et al. 2005).  
7.8.2 SMN BIOMARKERS 
Due to the expression profile present in SMA cells by the lack of functional SMA1 alleles, 
the FL/Δ7-SMN mRNA ratio is a very convenient biomarker to distinguish between 
unaffected and affected individuals. Indeed, the FL/Δ7-SMN mRNA ratio is significantly 
higher in cells from 4603 than in cells from all SMA patients (Figure 6.5A). This 
difference is particularly evident in more susceptible cells types such as MNs, where there 
is an average 3.5 fold difference (Fig 6.6).  As mentioned earlier, the carrier mother seems 
to display an SMA-like expression profile. The FL/Δ7-SMN mRNA ratio has been 
suggested before as a biomarker, and indeed the higher difference between SMA and 
control individuals have been found in spinal cord tissues (Soler-Botija et al. 2005). 
Unfortunately, the ratio does not allow to distinguish between SMA types, probably 
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because the level of Δ7-SMN expression is correlated to the number of SMN2 copies 
present in the cell (Crawford et al. 2012), and these values are variable between clones: 
AC28, TC63 and NC32 have 4 copies, RC26 has 3 copies, SMA1 has 2 copies and the 
copy number in 4603 was not determined. Interestingly the tSMN mRNA levels in the 
SMA1 clone are consistently lower than in the rest of the clones, suggesting that this 
parameter could be use to distinguish the type of SMA (Figure 6.5B). The same correlation 
has been found in blood samples from SMA patients in the recent bforSMA study 
(Crawford et al. 2012). 
7.8.3 GENE THERAPY 
It has been suggested that augmenting the MN SMN levels by means of gene therapy could 
rescue the SMA phenotype, and results derived from studies in SMA mouse models are 
indeed promising (Azzouz et al. 2004; Foust et al. 2010; Passini et al. 2010; Valori et al. 
2010; Dominguez et al. 2011). In order to study the expression of SMN mRNA and protein 
isoforms after the restoration of SMN1 in MNs, I transduced SMA1 iPSC-derived MNs 
with a scAAV9 carrying the therapeutic gene (scAAVCaghSMN1F). The transduction 
efficiency in the neurosphere configuration was predicted to be ~25% after 5 days, 
according to a transduction test performed with a reporter sAAV9 (scAAVCageGFP). 
(Figure 5.10). As anticipated, FL-SMN mRNA levels were increased as compared to non-
transduced SMA1 MNs; surprisingly however, Δ7-SMN mRNA levels were decreased 
(Figure 6.6). The expression profile adopted after SMN augmentation is similar to the one 
observed in unaffected control cells (clone 4603) and indeed the FL/Δ7- SMN mRNA ratio 
increases significantly. Although SMN levels could not be assessed at the protein level, 
they are not necessarily expected to be increased into a great extend giving the putative 
post-transcriptional/post translational mechanism previously described. Yee’s group have 
demonstrated that if SMN is restored in SMA type I iPSCs prior to MN differentiation, the 
pathological phenotype is rescued (Chang et al. 2011), but this does not necessarily mean 
that the same is true if SMA is restored after MN generation. 
7.8.4 PLS3 
The fact that AC28 behaves similarly to the rest of the SMA clones shows that the 
influence of modifier factors in the disease severity cannot be anticipated or discriminated 
by any of the previously described measurements. Asymptomatic or less severely affected 
siblings in discordant SMA families have been an important subject of study since they can 
provide insights into modifying factors that bypass or compensate the molecular 
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pathological mechanism caused by the lack of SMN. Moreover, they could provide new 
targets for treating the disease. High PLS3 levels in lymphoblast have been associated with 
a positive modification of the SMA phenotype in females (Oprea et al. 2008; 
Stratigopoulos et al. 2010) (Please refer to section 1.1.3 in the introduction). Plastins are a 
family of actin binding proteins, which in humans have three isoforms: PLS1 or fimbrin, 
lymphocyte cytosolic protein 1 or PLS-L/PLS2, and PLS3 or PLS-T. PLS3 is found in all 
normal cells with a replicative potential, while PLS-L is expressed in hematopoietic cells 
and PLS1 is expressed specifically at high levels in the small intestine (Entrez Gene ID: 
5358). Wirth’s group (University of Cologne) found that PLS3 was expressed in the 
lymphoblasts of some patients, contrary to what was previously thought (Lin et al. 1993; 
Oprea et al. 2008). The level of PLS3 (mRNA) has already been analysed in the 
lymphoblasts of the siblings of study, and it was not found to be a SMA modifier factor in 
the family. Even though the SMA type IV/asymptomatic sister (AC) had higher levels than 
two of her SMA type III siblings (TC and NC), the third SMA type III sibling (CC, from 
whom we could not obtain iPSC clones) showed even higher levels (Bernal et al. 2011) 
(Please refer to Table 4.1). It is intriguing that high levels of PLS3 in lymphoblasts can act 
as a modifier in a MN disease, since they do not necessarily translate into a higher relative 
level at the MN per se. Moreover, no correlation was found in a previous study between the 
PLS3 expression in lympholasts, whole blood and fibroblasts (Bernal et al. 2011). In order 
to determine the PLS3 level at the MN per se, as well as in the preceding cells types, I 
followed its expression through the iPSC-MN differentiation process. Similar to the case of 
SMN, all clones showed a statiscally significant decay in the levels of PLS3 protein along 
the iPSC-MN differentiation process, which in this case was congruent with their mRNA 
levels (Figure 6.7).  A correlation between SMN protein decay and PLS3 protein decay has 
also been recently reported in zebrafish models (Hao le et al. 2012). I found that the PLS3 
mRNA and the protein levels in MNs were significantly lower than in most of the other 
cells types, showing a direct conflict with the opposite behaviour found by Wirth’s group 
during the neural differentiation of PC12 cells (Oprea et al. 2008). All clones showed a 
similar gradual decay (Figure 6.9). Although the unaffected clone 4603 showed lower 
mRNA and protein levels during the whole process of differentiation, the difference 
between unaffected individuals (RC26+4603) and SMA patients 
(AC28+TC63+NC32+SMA1) was in general not statistically significant (data not shown). 
At the MN level, AC28 showed higher protein levels (but not mRNA levels) of PLS3 than 
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her SMA type III siblings (Figure 6.10), partially supporting the results found in 
lymphoblasts (Bernal et al. 2011). Unfortunately, no iPSC clone could be generated from 
the cells of the 4th sibling, CC (who presented the highest PLS3 levels in lymphoblasts) and 
therefore, I cannot determined whether the relative higher PLS3 protein levels in the MNs 
of AC28 could be significant or not. In Wirth’s study, PLS3 mRNA levels were empirically 
categorized as high and low based on the differential expression between the symptomatic 
siblings and the asymptomatic sibling in discordant families; unfortunately we cannot 
identify that threshold without the samples from CC. 
Interestingly, I found what appear to be different forms of PLS3 in fibroblast and in MNs 
(Figure 6.11). At least 3 alternative spliced mRNAs have been reported for the PLS3 gene, 
generating two different protein isoforms (NCBI, Gene ID: 5358). The antibody I used 
recognizes aminoacids 235-456 of PLS3, which is present in both isoforms. Nevertheless, 
the PLS3 size difference observed between MNs and fibroblasts is smaller than the 
difference between the isoforms (21 aminoacids). A post-translational modification such as 
phosphorylation could explain the difference, but this was not studied in this work 
(UnipProtKB P13797). 
 
 
Taken together, the SMN and PLS3 molecular analyses performed in cell cultures derived 
from the iPSC-MN model confirm the findings made from surrogate human cells and foetal 
samples. Furthermore, it expands the array of cell types available to study the SMA 
pathology to include cells from MN progenitor pools and functionally mature MNs, among 
others. The same is true for the study of phenotypic differences; nevertheless, several 
parameters should be improved during future studies: (i) neurospheres should be 
dissociated into single cells, such that markers can be systematically quantified without any 
bias, (ii) MNs should be purified, plated at the same confluence, synchronized in their cell 
cycle and studied over long-term periods, (iii) more than one clone should be studied from 
each patient and each clone must be differentiated several times in order to give consistency 
and statistical significance to the results. Finally, since SMA affects the MN within the 
NMJ context, co-culture systems like the one presented in this work, will provide more 
reliable insights that the ones obtained by study of the MN alone. 
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CHAPTER 8. CONCLUSIONS 
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ü Fibroblasts from four of the five members of the family of study (AC, TC, NC and 
RC, but not CC) were efficiently reprogrammed into iPSCs. One clone from each 
individual was fully characterized passing all quality control standards. 
ü SMA type I iPSCs (reference clone SMA1) showed an impaired ability to form 
rosettes, which may be specific to the severe form of the disease. 
ü The four selected iPSC clones and the two reference clones (SMA1 and 4603) were 
able to efficiently differentiate into ISL-1+/ChAT+ MNs. The MN yield could not be 
determined accurately because of the three-dimensional structure of the cell culture, 
but it was estimated to be between 10-15% for all clones. 
ü rH1LVs and scAAV9 transduced iPSC-derived MN cultures, but their transduction 
efficiencies could not be determined accurately in the three-dimensional structures of 
the cell culture. Increasingly efficient transduction of the developing cultures was 
obtained with a rH1LV where a fluorescent reporter was driven by the MN-specific 
HB9 promoter, confirming the progressive generation of MNs from iPSCs. 
ü The reported SMA iPSC-derived MN phenotypes (proportion of MNs and neurite 
outgrowth) were not observed in my short time cultures (phenotypes evaluated <10 
days after plating of neurospheres). An assay of neurite growth yielded similar results 
in all clones within the first 8 days after the plating of neurospheres. 
ü iPSC-derived MNs promoted clustering of mouse myotube AChRs in co-cultures. 
Close proximity of AChR clusters and TUJ1+ neurites was observed by confocal 
microscopy. 
ü One iPSC clone from the carrier mother (RC26) was efficiently differentiated into 
mature AFP+ hepatocytes able to store lipids and glycogen. 
ü SMN protein and PLS3 mRNA and protein levels showed a progressive decay during 
the iPSC-MN differentiation process in both SMA patients and unaffected individuals. 
The progressive decay was peculiar to  the iPSC-MN differentiation and, the levels 
found in terminal differentiated cells was lower than in the iPSC-hepatocyte 
differentiation.  
ü There seems to be a post-transcriptional/post-translational regulation of FL-SMN 
transcripts. 
ü SMA patients could be distinguished from the unaffected individual carrying two 
functional SMN1 alleles (4603), but not from the unaffected carrier (RC26), by their 
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significantly lower FL/Δ7-SMN mRNA ratios, particularly in the late stages of MN 
differentiation.  
ü The FL-SMN mRNA and protein levels at the MN stage were similar between SMA 
type I (SMA1), III (TC63, NC32) and IV (AC28) patients.  Clone SMA1 could only 
be distinguished from the siblings of the Spanish family of study by its constant lower 
tSMN mRNA levels. 
ü scAAV9-mediated SMN1 restoration in SMA1 iPSC-derived MNs switched the 
expression pattern of SMN transcripts to a profile similar to that observed in the 
unaffected control individual (4603). 
ü The iPSC-derived MNs from the SMA type IV/asymptomatic sibling (AC28) showed 
higher PLS3 protein levels (but not mRNA levels) than the ones from her SMA type 
III siblings (TC63 and NC32), partially confirming the previous findings in 
lymphoblasts. However, it was not possible to determine if PLS3 was a modifier 
factor of the SMA severity in the family of study because of the lack of an iPSC 
clone from CC. 
ü PLS3 protein apparently shows a small difference in PAGE mobility between MNs 
and fibroblasts, which may reflect different isoforms or a post-translational 
modification. 
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 APPENDIX 1: List of reagents and molecules 
GENERAL REAGENTS 
ü 3-[N-morpholino]propanesulfonic acid (MOPS) (Sigma-Aldrich) 
ü 30% Acrylamide/Bis-acrylamide (Merk)  
ü 4’,6-diamino-2’-phenylindole dihydroclhoride (DAPI) (Sigma-Aldrich) 
ü Acetone (Sigma-Aldrich) 
ü Agarose (Sigma-Aldrich) 
ü Alpha amylase from porcine pancreas (Sigma-Aldrich) 
ü Ammonium persulfate (Sigma-Aldrich) 
ü Ampicilin (Sigma-Aldrich) 
ü Bacteriological agar (Sigma-Aldrich) 
ü Bovine serum albumin (BSA) (Sigma-Aldrich) 
ü Bromophenol blue (Sigma-Aldrich) 
ü CaCl2 (Sigma-Aldrich) 
ü Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
ü Dithiothreitol (DTT) (Sigma-Aldrich) 
ü Ethanol (Sigma-Aldrich) 
ü Ethidium bromide (Sigma-Aldrich) 
ü Ethylene Glycol  (Sigma-Aldrich) 
ü Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) 
ü Formaldehyde (Sigma-Aldrich) 
ü Gelatine (Sigma-Aldrich) 
ü Glycerol (Sigma-Aldrich) 
ü Glycine  (Sigma-Aldrich) 
ü HBSS without Ca & Mg with Phenol Red (PAA, Cat. No. H15-010) 
ü HCl (Sigma-Aldrich) 
ü HEPES (Sigma-Aldrich) 
ü HEPES Buffer Solution (Life Technologies) 
ü Isopropanol (Sigma-Aldrich) 
ü KOAc (Sigma-Aldrich) 
ü Luria Broth (Sigma-Aldrich) 
ü Methanol (Sigma-Aldrich) 
ü MgCl2 (Sigma-Aldrich) 
ü MnC12 (Sigma-Aldrich) 
ü Na2HPO4 (Sigma-Aldrich) 
ü NaCl (Sigma-Aldrich) 
ü NaOH (Sigma-Aldrich) 
ü PBS (PAA) 
ü PEG8000 (Sigma-Aldrich) 
ü PFA (Sigma-Aldrich) 
ü Phenol Red solution (Sigma-Aldrich) 
ü RbC12 (Sigma-Aldrich) 
ü Sodium acetate (Sigma-Aldrich) 
ü Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich) 
ü Sudan III (Sigma-Aldrich) 
ü Sudan IV (Sigma-Aldrich) 
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ü TEMED (Sigma-Aldrich) 
ü Tissue culture grade water (PAA) 
ü Trehalosa (Sigma-Aldrich) 
ü Tris (Sigma-Aldrich) 
ü Triton X-100 (Sigma-Aldrich) 
ü Trypan blue (Sigma-Aldrich) 
ü Tween-20 (Sigma-Aldrich) 
 
SPECIAL REAGENTS AND MEDIA COMPONENTS 
ü β- mercaptoetanol  (Gibco, Cat. No. 31350010) 
ü 25:24:1 phenol/chloroform/isoamyl alcohol (Invitrogen, Cat No. 15593-031) 
ü Amersham Hybond™ ECL™ membrane 0.45 µM (GE Healthcare, Cat. No. 
RPN303D) 
ü Aqua-Poly/Mount (Polysciences, Cat. No 18606-20) 
ü b-Mercaptoethanol (Gibco, cat. no. 31350010)  
ü B27 supplement without vitamin A 50X (Gibco, Cat. No. 12587-010) 
ü Benzonase (Sigma-Aldrich, Cat. No. E8263) 
ü Colchicine (Sigma-Aldrich, Cat No. C 3915) 
ü cOmplete ULTRA Tablets, Mini, EDTA-free (Roche, Cat No. 05892791001) 
ü CryoStem freezing medium (Stemgent, Cat. No. 130-095-847) 
ü CryoStem™ Freezing Medium (Stemgent Cat. No. 01-0013) 
ü Cyclic AMP (Sigma-Aldrich, cat. no. D-0260) 
ü Dexamethasone (Sigma-Aldrich, Cat. No. D4902) 
ü Dispase (Gibco-BRL, cat. no. 17105-041) 
ü DMEM high glucose with stable glutamine (PAA, Cat. No. E15-883) 
ü DMEM Nutrient mix F12 (DMEM/F12) (Gibco, Cat. No 11330032) 
ü DMEM, high glucose with glutamax (Gibco Cat. No. 31965023) 
ü DNAse I (Promega, Cat. No. M6101) 
ü FACs Flow solution (BD Biosciences, Cat. No. 342003) 
ü FACs Rinse solution (BD Biosciences, Cat. No. 3403346) 
ü FACS shutdown solution (BD Biosciences, Cat. No. 334224) 
ü Fetal Bovine serum (FBS) (Gibco, Cat. No. 10099-141) 
ü Fetal Bovine serum (FBS) (PAA, Cat. No. H15-101) 
ü Fugene HG Transfection Reagent (Roche, Cat. No. 04709705001) 
ü Gentamicine (Gibco, Cat. No. 15710-049) 
ü Glutamax (Gibco, Cat. No. 35050038) 
ü Glycogen (Invitrogen, Cat No. 10814-010) 
ü HCM bullet kit (Lonza, Cat. No. cc3198) 
ü Heparin (Sigma-Aldrich, cat. no. H3149) 
ü Horse serum (Gibco, Cat. No. 16050-130) 
ü Hybond N+ hybridisation membrane (GE healthcare, Cat. No RPN203B) 
ü Insulin-Transferrin-Selenium-X (Gibco, Cat. No 51500-056) 
ü Knockout D-MEM (Gibco, Cat. No 10829018) 
ü Knockout Serum Replacement (Gibco-BRL, cat. no. 10828) 
ü Knockout serum replacement (Gibco, Cat. No. 10828010) 
ü L-Ascorbic acid (Sigma-Aldrich cat. no. A4403) 
ü L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich cat. no. 
A8960) 
 229 
ü L-Glutamine solution (Gibco-BRL, cat. no. 25030) 
ü Medium 199 with Earle's BSS, with L-glutamine, HEPES and 2.2 g/L NaHCO3 
(Lonza, Cat. No. 12117F) 
ü MEM Alpha Modification Liquid with Ribonucleosides L-glutamine (PAA, Cat. No. 
E15-862) 
ü MEM non-essential amino acids  (Gibco-BRL, cat. no. 11140035 ) 
ü Mitomycin C (Sigma-Aldrich, Cat. No. M4287) 
ü Mouse Laminin (Sigma-Aldrich cat. no. L2020) 
ü N2 supplement 100X (Gibco, Cat. No. 17502-048) 
ü Non essential amino acids 100X (Gibco, Cat. No. 11140035) 
ü Oncostatin-M (R&D Systems, Cat. No. 295-OM-010) 
ü Optiprep Density  Gradient Medium (60% (w/v) solution of iodixanol in water 
(Sigma-Aldrich, Cat. No. D1556). 
ü Penicillin and streptomycin (Pen&Strep) (PAA, Cat. No. P11-010) 
ü Poly-L-Ornithine solution (Sigma-Aldrich cat. no. P4957) 
ü Polybrene (Sigma-Aldrich, Cat. No H-9268) 
ü Proteinase K (Ambion, Cat No. AM2546) 
ü Purmorphamine (CALBIOCHEM, cat. no. 540220) 
ü Recombinant  BDNF (PeproTech, cat. no. 450-02) 
ü Recombinant  BMP2 (PeproTech, Cat. No 120-02) 
ü Recombinant  EGF (Miltenyi, Cat. No. 130-093-825) 
ü Recombinant  FGF2 (Miltenyi, Cat. No. 130-093-837) 
ü Recombinant  FGF4 (PeproTech, Cat. No 100-31) 
ü Recombinant  GDNF (PeproTech, cat. no. 450-10) 
ü Recombinant  HGF (PeproTech, Cat. No 100-39) 
ü Recombinant  Human Activin A (PeproTech, Cat. No 120-14E) 
ü Recombinant  IGF-1 (PeproTech, cat. no. 100-11) 
ü Recombinant  KGF (PeproTech, Cat. No 100-19) 
ü Retinoic Acid (Sigma-Aldrich, cat. no. R2625) 
ü Rock Inhibitor (Calbiochem, Cat. No. 688000) 
ü RPMI 1640 medium (Gibco, Cat. No. A10491-01) 
ü SensiMixPlus SYBR 1X (Quantance, Cat. No. QT605-02) 
ü SIGMAFAST™ BCIP®/NBT (5-bromo-4-chloro-3-indolylphosphate/nitro blue 
tetrazolium. Sigma-Aldrich. Cat No. B5655). 
ü Sodium pyruvate MEM (Gibco, Cat. No. 11360-039) 
ü Stemedia NutriStem XF/FF Culture Medium (Stemgent, Cat. No. 130-095-543) 
ü Stempro accutase (Gibco, Cat. No. A1110501) 
ü TaqMan® Universal PCR Master Mix (Applied Byosystems, Cat. No. 4324018) 
ü Thiazovivin (Stemgent, Cat. No. 130-095-568) 
ü Tris-EDTA endotoxin-free. Taken from Qiagen Endotoxin-free kits (12381, 12362, 
12391) 
ü TRIZOL® Reagent (Invitrogen, Cat. No. 15596-018) 
ü TrypLE Express (1X), Phenol Red (Gibco, Cat. No. 12605028) 
ü Trypsin/EDTA (PAA , Cat. No. L11-004) 
ü Valproic acid (Sigma-Aldrich, Cat. No., P4543) 
ü Vitro PBS (VitroLife, Cat. No. 10506) 
ü X-tremeGENE 9 DNA Transfection Reagent (Roche, Cat No. 06365779001). 
ü α-Amylase (Sigma-Aldrich Cat. No. A 3176) 
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APPENDIX 2: Primers. Description, characteristics and sequences 
      
 
 
 
 
 
Name Use Target
Product 
size 
(bp)
Sequence 
designation Sequence (5' to 3')
Flag hSMN1 Cloning 937 Forward
GCACGTACCGGTATGGATTACAAGGA
TGACGACGATAAGATGGCGATGAGCA
GCGG
hSMN1 Cloning 910 Forward GCACGTACCGGTATGGCGATGAGCAGCGG 
F/NoF hSMN1 Cloning Reverse GCTTGCCTGCAGGTTAATTTAAGGAATGTGAGCACCTTCC
Cag promoter Sequencing
Cytomegalovirus enhancer/ 
chicken beta actin promoter  
in scAAV9CaghSMN1NoF 
and scAAV9CaghSMN1F 
(Designed by me)
NA Forward CCTATAAAAAGCGAAGCGCG
Poly A Sequencing
Poly A in 
scAAV9CaghSMN1NoF and 
scAAV9CaghSMN1F 
(Designed by me)
NA Reverse CCCCCTGAACCTGAAACATAAAATG
Forward CCAAGCTGACCTGACTCGATGC
Reverse CCCCCTGAACCTGAAACATAAAATG
Forward GCGTTGACATTGATTATTGACTA
Reverse CATAAGGTCATGTACTGGGC
Forward TGTGTGCCCGTCTGTTGTGT
Reverse GAGTCCTGCGTCGAGAGAGC
Forward TCACCCACACTGTGCCCATCTACGA
Reverse CAGCGGAACCGCTCATTGCCAATGG
Forward TGCCTCAAATTGGACTTTGG
Reverse GATTGAAATTCTGTGTAACTGC
Forward ACTCTGAGGAGGAACAAGAA
Reverse TGGAGACGTGGCACCTCTT
Forward CCTCACTTCACTGCACTGTA
Reverse CAGGTTTTCTTTCCCTAGCT
Forward AGCGAACCAGTATCGAGAAC
Reverse TTACAGAACCACACTCGGAC
Forward GATGAACTGACCAGGCACTA
Reverse GTGGGTCATATCCACTGTCT
Forward TCTCAAGGCACACCTGCGAA
Reverse TAGTGCCTGGTCAGTTCATC
Forward CCCAGCAGACTTCACATGT
Reverse CCTCCCATTTCCCTCGTTTT
Forward AGCTACAGCATGATGCAGGA
Reverse GGTCATGGAGTTGTACTGCA
Forward CTACGACAAGAAAAAGCGGA
Reverse GCCCCAGATAGGCAAAC
Forward GAGGATGAGGTGGAACGTGT
Reverse TCTTCAGTCGCTCCAGGTCT
103
CMV probe Dot blot. AAV titter Cytomegalovirus enhancer in scAAV (Designed by me) 333
Poly A qPCR qPCR. AAV titter Poly A sequence in scAAV (Designed by me)
LRT qPCR.  lentiviral titter 
Lonf terminal repeat sequence 
in lentiviral backbone (Butlet 
et al., 2001)
140
qPCR.  lentiviral 
titter ß-actin lenti
159
Endogenous expression of 
OCT4 (Park et al., 2008) 154
mRNA of human ß-actin 
(Designed by Dr Klaus 
Wanish) 
294
Kfl4 endo
KFL4 total
SOX2 endo
RPL13A
18S
142
Endogenous expression of 
KFL4 (Park et al., 2008) 145
SOX2 total 
Total expression of KFL4 
(Park et al., 2008) 105
Endogenous expression of 
SOX2  (Park et al., 2008) 151
Total expression of SOX2 
(Park et al., 2008) 126q
-R
T-
PC
R
. Q
ua
lit
y 
co
nt
ro
l o
f i
PS
C
s
192
c-MYC total
OCT4 endo
OCT4 total
c-MYC endo
86
166
Human Survival Motor 
Neuron 1  cDNA (Designed by 
me)
cDNA of 18S ribosomal RNA 
(Designed in iSTEM)
cDNA of ribosomal protein 
L13a (Designed by me)
Total expression of OCT4 
(Park et al., 2008)
Endogenous expression of c-
MYC (Park et al., 2008)
Total expression of c-MYC 
(Park et al., 2008)
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Name Use Target
Product 
size 
(bp)
Sequence 
designation Sequence (5' to 3')
Forward CCTCACTTCACTGCACTGTA
Reverse CCTTGAGGTACCAGAGATCT
Forward CCCAGCAGACTTCACATGT
Reverse CCTTGAGGTACCAGAGATCT
Forward  TGCCTCAAATTGGACTTTGG
Reverse CGCTCGAGGTTAACGAATT
Forward GATGAACTGACCAGGCACTA
Reverse CCTTGAGGTACCAGAGATCT
FL-SMN Forward  GCT GAT GCT TTG GGA AGT ATG TTA
Reverse CAC CTT CCT TCT TTT TGA TTT TGT C
Taqman probe
5’FAM-TTT CAT GGT ACA TGA GTG 
GCT ATC ATA CTG GCT ATT AT-
MGBNFQ
D7-SMN Forward TGG ACC ACC AAT AAT TCC CC
Reverse ATG CCA GCA TTT CCA TAT AAT AGC C
Taqman probe FAM-ACC ACC TCC CAT ATG TCC AGA TTC TCT TGA TG-MGBNFQ
SMN total
cDNA of  human survival of 
motor neuron 1, telomeric and 
survival of motor neuron 2, 
centromeric   
(SMN). (Applied Biosystems 
Cat No. Hs00165806_m1)
126 NA Exon junction 1-2
PLS3
cDNA of plastin  3. (Applied 
Biosystems Cat No. 
Hs00192406_m1) 
85 NA Exon junction 8-9
GAPDH 
cDNA of glyceraldehyde-3-
phosphate dehydrogenase. 
(Applied Biosystems Cat No 
Hs02758991_g1)
93 NA Exon junction 7-8
PPIA
cDNA of peptidylprolyl 
isomerase A (cyclophilin A) 
(Applied Biosystems 
Hs99999904_m1) !
98 NA Exon 4
ß-actin qPCR
cDNA of beta actin (Applied 
Biosystems Cat 
Hs99999903_m1)
171 NA Exon 1
Forward CTCCCATATGTCCAGATTCTCTTG
Reverse CTACAACACCCTTCTCACAG
SMN Qualitative 
RT-PCR and 
spliced isoform 
dection   
cDNA of full length human 
survival motor neuron (Also-
Rallo et al., 2011)
cDNA of delta 7 human 
survival motor neuron (Also-
Rallo et al., 2011)
cDNA of full length and delta 
7 human survival motorn 
neuron (Soler-Botija et al., 
2005)
q 
RT
-P
C
R
 in
 c
el
ls
 d
ur
in
g 
M
N
 d
iff
er
en
tia
tio
n
Transgene 
OCT4
Trangene SOX2
Trangene c-
MYC
Transgene 
KFL4
Transgene expression of 
OCT4 (Park et al., 2008)
Transgene expression of 
SOX2 (Park et al., 2008)
Transgene expression of c-
MYC (Park et al., 2008)
Transgene expression of 
KFL4 (Park et al., 2008)RT
-P
C
R
. Q
ua
lit
y 
co
nt
ro
l o
f i
PS
C
s
1000
~100
~120
~180
~150
SMN Exon 6-8
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 APPENDIX 3: Quality control of the primers used for qRT-
PCR/qPCR experiments. 
 
 
*Not all the data of the primers that were validated in another laboratory are available. QC: quality control. 
 
 
 
  
Target
QC 
performed 
Melting 
curve
Minimum linear 
dilution Efficiency R2 Slope Gel Signal in gel
RPL13A good tested: 1:1000 1.01 0.997 "-3.307" 1 product intermediate
18S good tested: 1:1000 1.01 0.998 "-3.294" 1 product strong
SOX2 endo good tested: 1 in 1000 0.98 0.999 "-3.373" 1 product strong
SOX2 total good tested: 1 in 1000 0.98 0.993 "-3.376" 1 product strong 
OCT4 endo good tested: 1 in 1000 1.03 0.990 "-3.247"
1 product with  
faint primer 
dimers strong
OCT4 total good tested: 1 in 1000 1.03 0.990 "-3.250" 1 product strong
KFL4 endo good 1 in 100 0.98 0.970 "-3.366" 1 product intermediate
KFL4 total good 1 in 10 1.02 0.990 "3.323" 1 product dim
c-MYC endo good 1 in 10 1.07 1.0 "-3,162" 1 product very dim
c-MYC total good 1 in 10 1.15 0.960 "-3.241" 1 product very strong
Poly A qPCR good 100 copies 1.07 0.998 "-3.169" 1 product very strong
FL-SMN 1 in 1000 0.9926
D7-SMN 1 in 100 0.976
SMN total 1 in 10,000 0.9997
PLS3 1 in 10,000 0.9991
ACTB 1 in 10,000 0.9995
GADPH 1 in 10,000 0.9988
PPIA 1 in 10,000 0.9988
R
H
U
L 
(m
e)
S
pa
in
 (D
r S
ar
a 
B
er
na
l)
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 APPENDIX 4: iPSC clones selected from each family member  
Fibroblasts AC
Cryovials frozen Clones Passage number at the time of freezing
4 25 p5
7 28 p6
4 29 p6
4 30 p6
3 59 p5
Fibroblasts CC
Cryovials frozen Clones Passage number at the time of freezing
NONE
Fibroblasts NC
Cryovials frozen Clones Passage number at the time of freezing
7 21 p6
4 32 p5
4 42 p5
3 43 p6
2 61 p5
Fibroblasts RC
Cryovials frozen Clones Passage number at the time of freezing
4 + 7 26 p12
Fibroblasts TC
Cryovials frozen Clones Passage number at the time of freezing
4 63 p6
4 + 4 64 p6
First clone selected for quality control
Second selection for quality control
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 APPENDIX 5:  List of plastic ware and culture surfaces 
ü BD Falcon™ round-bottom tubes for flow cytometry (BD Biosciences) 
ü Cell strainers (BD Biosciences) 
ü Centre well organ culture dish 60 x 15 mm (BD Biosciences) 
ü Centrifugal filters Amicon Ultra -15 PL100 (Millipore) 
ü Conical polystyrene tubes 15 and 50ml (Corning) 
ü Cryovials 1.5, and 2 ml (Nalgene) 
ü Eppendorfs tubes 2, 1.5 and 0.5 ml (Eppendorf) 
ü Freezing container (Nalgene) 
ü Glass coverslips 10 mm No 1.5 (Marienfeld GmbH) 
ü Hidrocell 6 multidish (Thermo Fisher) 
ü Inoculation loop (Greiner bio-one) 
ü Multidish 4 well Nuclon Delta (Nunc) 
ü Needles  23 G X 1’ 0.6x25 mm (Terumo) 
ü Pipettes polystyrene 5, 10 and 25 ml (Corning) 
ü qPCR tubes 0.1ml (Qiagen) 
ü Stericup & Steritop filtration system 250 and 500 ml (Millipore) 
ü Sterile Syringes (BD Biosciences) 
ü Syringe SFCA Filters 0.2 um and 0.45 um (Nalgene) 
ü Syringes 1, 5, 20 and 50 ml (BD biosciences) 
ü TC chamber slide 4 well gamma radiation sterilised Permanox 1.8cm2/well 0.33mm x 
0.28mm x 0.2mm Lab Tek (Thermo Scientific Nunc) 
ü Tips and filter tips (StartLab) 
ü Tissue culture dish 35 mm with 4 inner rings (Cellstart, Greiner bio-one) 
ü Tissue culture flat tubes 10 cm2 with screw cap (TPP) 
ü Tissue culture treated polystyrene Flasks 25, 75 and 175 cm2 (Corning) 
ü Tissue culture treated polystyrene petri dishes 30, 60, 100 and 150 mm (Corning)  
ü Tissue culture treated polystyrene plates 6, 12, 24 and 96 wells (Corning) 
ü Tube, QuickSeal®, Polyallomer, 39 mL, 25 x 89 mm (Beckman Coulter) 
ü Tube, Thinwall, Polyallomer, 17 mL, 16 x 102 mm (Beckman Coulter) 
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 APPENDIX 6: LIST OF INSTRUMENTS AND SOFTWARE 
 
INSTRUMENTS 
ü Balance EK-610i (A&D Company Limited) 
ü BD FACSCanto™ II (BD Biosciences) 
ü Biophotometer 613101139 (Eppendorf) 
ü Biosafety cabinet Class II (Esco) 
ü Centrifuge tube sealer, 50 Hz (Beckman Coulter) 
ü Digital Block Heater D110 (Jencons-PLS) 
ü Electrophoresis Power Pac Basic (BIORAD) power source 
ü Flowgen Bioscience chamber (Model No MH1070B)  
ü GLOMAX 96 microplate Luminometer (Promega) 
ü Gyro Rocket SSL3 (Stuart) 
ü Heraeus Multifuge 3S Plus Series Benchtop Centrifuges. Rotor 75006441 (Thermo 
Scientific) 
ü Hot plate and stirrer PC-620D (Corning) 
ü Humidified tissue culture incubator CB150 (E3) (Binder. 37 ◦C, 5% CO2) 
ü Hybridisation Incubator (Techne, Cat No., HB-1D) with Hybridisation Tubes (Techne, 
Cat No. FHB12) 
ü Incubator INCOmed (Memmert) (*for bacteria) 
ü Incubator Shaker Excella E25 (New Brunswick Scientific) (*for bacteria)  
ü InGenius gel documentation and analysis system (Syngene) 
ü Inverted microscope Axio observer.A1 (Zeiss). Filter sets: 43 HE [Red. Excitation BP 
550/25 (HE), emission BP 605/70 (HE)], 38 [Green. Excitation BP 470/40, emission 
BP 525/50],  49 [blue. Excitation G 365, emission BP 445/50] (Zeiss).  
ü Lynx Stereo Dynascopic microscope (Vision Engineering) 
ü Microcentrifuge (Thermo Scientific Heraeus Fresco 17) 
ü Microcope Leica DM IRB, (Leica Microsystems) 
ü Microscope Olympus LX81, confocal Fluoview FV1000 (Olympus). Lasers: 440 
(cyan channel), argon (green channel), helium/neon (red channel),  633 (far red 
channel). 
ü Mini Trans-Blot Cell (Biorad) 
ü Mini-PROTEAN Tetra Electrophoresis System (Biorad) 
ü Minifold (96 well dot blotter) SRC-96/1 (Schleicher & Schuell). Vacuum source – 
Capex L2C (Charles Austen Pumps). 
ü NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific) 
ü Odyssey Infrared Imaging System (Li-cor Bioscience)  
ü Orbital Shaker SSL1 (Stuart) 
ü PCR gradient Thermal cycler TC-512 (TECHME) 
ü Pipette Controller Bibbyjet Pro, PC2000 (Stuart) 
ü Pipettes LM10, LM100, LM1000 (Labmate) 
ü PowerWave HT microplate spectrophotometer (BioTek) 
ü Refrigerated Superspeed Centrifuge Sorvall RC 5B. Rotors GSA, GS-3, SS34 
(Sorvall) 
ü Rotor-Gene ™ 6000 real-time rotary analyzer (Corbett Life Science). 
ü Ultracentrifuge  Beckman Optima L7. Rotor SW32.1Ti (Beckman Coulter) 
ü Ultracentrifuge optima L-100XP. Rotor Type 70Ti (Beckman Coulter) 
ü UV transiluminator Gel doc 2000 (Biorad) 
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ü Vortex mixer classic (Velp Scientific) 
ü Waterbath SUBAQUA12 (Grant) 
 
SOFTWARES 
ü Adobe Photoshop CS4  
ü Axio Vision 4.8.1 (Carl Zeiss Image solution)  
ü BD FACSDiva™ Software (BD Biosciences) 
ü Gen5 Data Analysis Software (BioTek) 
ü GeneFlash syngene Bio Imaging software (Syngene) 
ü geNorm VBA applet for Microsoft Excel 
ü GraphPah Prism (GraphPah) 
ü GloMax® 96 software (Promega) 
ü Image J 1.45 S (NIH) 
ü Leica application Suite (Leica) 
ü Statistical Package for the Social Sciences (SPSS) (IBM) 
ü Odyssey Infrared Imaging System application software V1 (Li-cor Bioscience) 
ü Olympus FV10 –ASW Vs 3 (Olympus) 
ü Rotor Gene Software 1.7 (Corbett Life Science). 
ü Vector NTI (Invitrogen) 
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